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 Ever tried? 
Ever failed? 
No matter. 
Try again. 
Fail again. 
Fail better. 
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Abstract. 
Sialic acid binding immunoglobulin-like lectins (Siglecs) play an important role in the 
mediation of cell-cell interactions as well as in the regulation of signaling pathways. 
They are mainly expressed in the haematopoietic and immune system, with exception 
of Siglec-4, also called myelin-associated glycoprotein (MAG). It was identified as 
one of neurite outgrowth inhibitors, playing a crucial role in paraplegia, which is 
caused by injuries of the central nervous system (CNS) and especially young people 
suffer from these severe consequences as, for example, the loss of motor functions. 
The lack of repair of the injured nerve strands originates from the inhibitory 
environment for axon regeneration in the CNS. Specific inhibitory proteins, such as 
MAG block the regrowth of nerve roots. We identified potent small molecule MAG 
antagonists modifies in the 2- and 5-position. Furthermore, we investigated new 
neuraminic acid derivatives modified in the 4-position, and the influence of various 
structural modifications on their kinetic and thermodynamic binding properties. In a 
next step we presented high affinity ligands, which were identified in second-site 
screenings and optimized them according to medicinal chemistry aspects. All ligands 
were elucidated with respect to their binding affinity as well as their kinetic and 
thermodynamic profile.  
Siglec-2, also known as CD22, is involved in the regulation and survival of B-cells 
and has been successfully targeted in cell depletion therapies with antibody-based 
approaches. Sialic acid derivatives, already known to bind with high affinity to 
myelin-associated glycoprotein (MAG, Siglec-4), were screened for their binding 
affinity for CD22 by surface plasmon resonance. The best compound identified was 
further modified with various hydrophobic substituents at the 2-, 5-, and 9-positions 
of the sialic acid scaffold, leading to nanomolar derivatives. Furthermore, initial tests 
regarding drug-like properties of these antagonists demonstrate the required high 
plasma protein binding yet a lack of oral availability, although its distribution 
coefficient (log D) is in the required range.  
Finally, we investigated a library of sialic acid mimetics with respect to binding 
towards another member of the Siglec family, namely Sialadhesin and discuss the 
influence of various structural moieties with regard to the arising selectivity towards 
these three proteins. 
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1. Introduction 
1.1 Carbohydrate-binding proteins. 
Carbohydrates are involved in numerous physiological processes. Complex carbohydrates, so 
called glycans, are located on cell surfaces and serve as ligands for protein-carbohydrate 
interactions, e.g. they act as regulatory elements in the immune and nervous system or 
regulate metabolic processes.
1
 For many of these functions, sialic acid, which is found as 
terminal carbohydrate moiety of glycan structures on glycoproteins or glycolipids, plays an 
important role.
2
 Until recently, the modulation of carbohydrate-protein interactions has rarely 
been exploited in medicinal chemistry. However, in the last decade, the interest steadily 
increased and nowadays, intensive research is focusing on the pharmaceutical potential of 
carbohydrate-protein interactions.  
The focus of our investigations are members of the Siglec family. Three members of this 
family of sialic acid binding lectins will be discussed with respect to their physiological 
functions and the current status of antagonist research. 
 
1.2 Siglecs.  
The immunoglobulin (Ig) superfamily comprises a distinct subgroup of proteins, which share 
structural and functional similarities and bind to sialic acid by definition. They were 
classified as sialic acid binding immunoglobulin-like lectins (Siglecs).
3-5
 Siglecs are type 1 
membrane proteins which have an N-terminal V-set immunoglobulin domain, responsible for 
sialic acid binding and a variable number of C2-set immunoglobulin domains.
6
 According to 
their structural similarity, they are divided into two subsets: Sialoadhesin (Siglec-1), CD22 
(Siglec-2), Myelin-associated glycoprotein (MAG, Siglec-4) and Siglec-15 are highly 
conserved proteins in mammalian species and show some structural similarities (25-30%) in 
their sequences, whereas the CD33-related Siglecs (Siglec 3, 5-14) show similarities of about 
50-90%.
4,5  
Up to now, detailed structural information is available for Sialoadhesin
7,8
 and 
Siglec-7.
9,10
 The binding site for sialic acid was found to be highly conserved, however the 
different members display specificities for a distinct sialic acid linkage to the residual glycan 
structure. Furthermore, they are expressed in a highly constrained manner, suggesting that the 
proteins fulfill distinct functions. With exception of MAG and Siglec-6, Siglecs are mainly 
expressed in the haematopoietic and immune system. In general, they are involved in the 
mediation of cell-cell interactions as well as in the regulation of signaling pathways. Some of 
them have immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytosolic part 
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(e.g. CD22), enabling them to suppress activation signals by recruitment of tyrosine and 
inositol phosphatases.
4
 
 
 
Figure 1. Schematic representation of the structure of Sialoadhesin, CD22 and MAG; GRB2: growth-factor-
receptor bound protein 2; ITIM: immunoreceptor tyrosine-based inhibitory motif; adapted from Crocker et al, 
2007.
4
 
 
Here, only the first subgroup will be discussed in more detail. For CD33-related Siglecs von 
Gunten et al. recently published a review.
11
 
 
Sialoadhesin (Siglec-1) is the largest member within the Siglec-family, having 17 
extracellular domains, and is expressed on macrophages. As it lacks the ITIM motif, it is 
predominantly involved in cell-cell interactions.
12,13
 Furthermore, the interspace between the 
binding site of Sialoadhesin and cell surfaces excludes masking by cis ligands, a phenomena 
observed with all other Siglecs.  
Whereas the expression of Sialoadhesin is normally restricted to subpopulations of 
macrophages in lymphoid tissues,
13
 Sialoadhesin is highly up-regulated on inflammatory 
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macrophages, which act as effectors in inflammation associated with autoimmune diseases.
13
 
Moreover, tumor cells secrete macrophage-activating factors, stimulating inflammation and 
facilitating tumor spread.
14
 First, modulation of macrophages expressing Sialoadhesin might 
be an interesting approach for the treatment of inflammation related to tumor spread. But 
more importantly, Sialoadhesin-mediated interactions were shown to be important for 
effective killing of tumor cells by CTLs.
15
 In addition, increasing interest evolved in 
Sialoadhesin, as it was observed to play an important role in HIV and bacterial infection. 
Sialoadhesin binds to HIV-1 directly and is responsible for trans-infection.
16
 Furthermore, 
Sialoadhesin is overexpressed on CD14+ monocytes correlating with HIV-1 viral load.
17
 
Remarkably, it was found that interactions occur in a sialic acid dependent as well as 
independent manner. In the first case, interactions are mediated by sialomucins (e.g. CD43,
18
 
mucin-1
19
), which contain high densities of sialylated O-linked glycans with terminal (!2-3) 
linked sialic acids.
20
 CD43, considered as putative counter-receptor of T-cells for 
Sialoadhesin, enables initial physical contacts between macrophages and T-cells.
18
 In 
contrast, sialic acid independent pathways may involve e.g. binding to mannose receptor.
4
 
 
Figure 2. Sialoadhesin is involved in cell-cell interaction and recognition, Crocker et al., 2008.
6
 
 
CD22 (Siglec-2) is expressed on the surface of B-cells and B-cell lymphomas. It is involved 
in the regulation of B-cell activity,
21-23
 homeostasis
24
 and survival.
25
 CD22 was identified as 
inhibitory co-receptor for B-cell receptors (BCR), being therefore responsible for a threshold 
for B-cell activation and thereby preventing autoimmune responses.
22,26
 Upon antigen-
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induced stimulation, BCR-ligated CD22 is phosphorylated at its ITIM motifs, initiating a 
cascade, which finally leads to a dampening of the BCR-induced signal. The inhibitory 
activity of CD22 depends on binding to BCR and on the interaction with glycans on the cell 
surface (= cis ligands). This has been demonstrated with CD22-deficient mice, showing 
hyperinflammation,
27-29
 whereas mice lacking cis ligands of CD22 showed the adverse effect, 
namely hypoinflammation.
30
 In the latter case, it was also found that the allocation of BCR 
was changed, being more clustered with CD22 than in the wild-type
4,31
 and consequently 
being faster internalized by endocytosis. CD22 has several ITIM motifs in its cytosolic part, 
but also an activating GBR2-motif. The ITIM motifs are crucial for initiating the inhibitory 
cascade and are also required for clathrin-dependent endocytosis.
26
 Consistently, CD22 is 
primarily located in clathrin-coated pits, and undergoes constitutive endocytosis.
31,32
  
 
 
Figure 3. Regulation of B-cell activity by CD22, from Nitschke et al, 2009.
26
 
 
CD22 has a specificity for Neu5Ac!2-6Gal, binding with an affinity of 100-200 !M.
20,33
 
Since the glycan concentration on B-cell surfaces is estimated to be around 25-30 mM, CD22 
is constitutively masked,
34
 i.e. its binding site is blocked by sialylated ligands located on the 
cell surface. This “masking” by cis interactions exhibits a threshold for CD22, which can be 
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competed by trans ligands with sufficient high affinity and avidity. Collins et al. reported that 
upon binding to cells bearing CD22 ligands, CD22 clusters at the site of contact and thereby 
increases its local concentration.
34
 Interestingly, Razi et al. reported that CD22 gets 
unmasked upon activation of B-cells, e.g. using protein kinase C activation.
35
 Furthermore, 
certain sub-populations of B-cells bear constitutively un-capped CD22 which interacts with 
ligands expressed on the sinusoidal endothelium leading to subsequent homing of B-cells to 
the bone marrow.
36,37
 
CD22 has become a target for cell depletion therapies as it was proven to be a marker for B 
cell malignancies
38-40
. Moreover, it plays an important role in lymphoma, AML (leukemia) 
and non-Hodgkins lymphoma (NHL)
41
. Clinical trials with anti-CD22 antibodies are 
ongoing, two of them being immunotoxins
42,43
, and one being a native antibody, called 
epratuzumab
44
. The immunotoxin approach is based on antibody-triggered endocytosis, 
leading to selective internalization of antibody-coupled toxins. BL22 is an anti-CD22 
conjugated exotoxin, being in clinical phase I/II
42
 and CMC-544 is a humanized IgG4 anti-
CD22 antibody conjugated to the chemotoxin calicheamicin
43
, and is in clinical trials phase 
II/III. Epratuzumab alone shows only modest reduction of B-cells, however in combination 
with the anti-CD20 antibody rituximab promising results have been reported
44
. Furthermore, 
it was observed that blocking the binding sites of CD22 effects the half-life time and turnover 
of B-cells
45
. Recently, the concept of targeting CD22 for triggering endocytosis is an arising 
field using synthetic sialosides. Finally, CD22 is regarded as a promising target for 
modulation antigen-induced responses.  
 
Myelin associated glycoprotein (MAG, Siglec-4) is expressed on oligodentrocytes in the 
central nervous system (CNS) and plays a crucial role in myelin stabilization as well as in the 
inhibition of nerve strand outgrowth in adults after injury
46-49
, causing paraplegia. The lack of 
regeneration originates from the inhibitory environment in the CNS, i.e. specific inhibitor 
proteins on residual myelin and on astrocytes, which are recruited to the site of injury. A 
therapy for full regeneration of injured nerve strands is not yet available. However, in the last 
decade, several of these inhibitor proteins have been identified, one of them being the 
myelin-associated glycoprotein (MAG). Other inhibitory proteins are Nogo-66
50
 and 
oligodentrocyte myelin-associated glycoprotein (OMgp)
51
. They all bind to the same Nogo-
66 receptor (NgR), followed by complex formation with the transmembrane neurotrophin 
receptor p75 (p75
NTR
)
52
. Although the exact mechanism of the signaling pathway remains to 
be determined, it has been demonstrated that Nogo, MAG and OMgp activate the small 
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GTPase Rho-A in a p75-dependent manner, inducing subsequent growth cone collapse
53,54
. 
Interaction of MAG with NgR has been reported to be sialic acid independent, however, 
Venkatesh et al. have recently shown that the Nogo receptor homolog NgR2 is a sialic acid 
dependent receptor for MAG
55
. As a second pathway, it was proposed that MAG interacts 
with gangliosides, e.g. GD1a, GT1b and GQ1b!, which are predominantly found on neuron 
cell surfaces in the CNS
56-58
. These gangliosides were proposed to be function-mediating 
binding partners of MAG. By clustering of GT1b with a multivalent IgM antibody, the 
inhibitory effects of MAG via signaling to the intracellular mediator Rho-A was 
mimicked
59,60
.  
 
 
Figure 4. Signaling cascades of MAG, involving interaction with NgR or gangliosides, adapted from Filbin et 
al.
61
 by A. Vögtli. 
 
Although the relative role of Nogo receptors and gangliosides as MAG ligands has yet to be 
resolved, in some systems, neurite outgrowth can be initiated by sialidase treatment, 
suggesting that the sialic acid-mediated interactions of MAG, i.e. the interaction with 
gangliosides, predominantly contributes to the inhibitory process. Furthermore, the ability to 
reverse MAG-mediated inhibition in an affinity-dependent manner was shown for a partial 
structure of GQ1b!
62,63
. Therefore, blocking MAG with potent glycomimetic antagonists 
offers a valuable therapeutic approach for the enhancement of axon regeneration. 
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1.3 Gangliosides. 
Gangliosides, glycosphingolipids with terminal sialic acids, are the natural ligands of Siglecs. 
They are expressed on all vertebral cells, most abundantly on the surface of nerve cells and in 
the hematopoietic lineage
1
. They are fixed to the plasma membrane by a ceramide lipid 
anchor, and based on the core of four uncharged sugar residues attached to ceramide they are 
divided into different sub-classes
64
. As they are located on the cell surface, they mediate cell-
cell recognition and are involved in pathogen internalization. Moreover, they regulate 
signaling and response cascades in the immune system, influencing NK-cell cytotoxicity
65
 
and B-cell activity
3
. In the CNS, they are important receptors for Siglec-4 (MAG), stabilizing 
myelin-axon interactions and controlling the neurite outgrowth after injury
46
. As gangliosides 
play a critical role in immune regulation and signaling, they are an interesting target for 
therapeutic applications and, even more important, can serve as starting point for the 
development of therapeutic carbohydrate-antagonists and mimics thereof
66
. 
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Figure 5. Structures of GD1a and GQ1b!, which are natural ligands for MAG,
67
 but also bind to Sialoadhesin.
20
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Depending on the linkage of the terminal sialic acid, preferences for different Siglecs are 
established. Sialoadhesin (Siglec-1) and MAG (Siglec-4) prefer !2,3-linked sialic acid, 
whereas CD22 binds to !2,6-linked sialosides. Consistently, the glycans in the central 
nervous system bear predominantly !2,3- and on B-cells !2,6-linked sialic acids
20
.  
 
             Table 1. Siglecs specificities and exemplary natural ligands. 
Siglec Preferred linkage Physiological ligand 
Siglec-1 !2,3    GQ1b!, GD1a 
Siglec-2 !2,6 CD45
*
 
Siglec-4 !2,3  GQ1b!, GD1a 
*Glycoprotein, bearing !2-6-linked sialic acid 
 
Nevertheless, the amino acids responsible for sialic acid binding were found to be conserved 
throughout the Siglec family. It was observed that the carboxylic acid is crucial for binding, 
as well as the glycerol side chain contributes strongly to the overall binding affinity
68,69
. 
Furthermore, different substituents at the 5-position of Neu5Ac are proposed to influence 
selectivity
8,70
.  
 
Sialoadhesin (Siglec-1) and Siglec-7 were co-crystallized with the trisaccharide Sia!2-
3Galß1-4Glu (sialyllactose)
71
 and a ganglioside analog DSLc4, 2-(trimethylsilyl)ethyl 
NeuAc!2,3Gal"1,3GlcNAc"-[NeuAc!2,6]lactose,
72
 respectively. Although these two 
proteins belong to different subgroups of the Siglec family, in both cases the most crucial 
interaction is a salt bridge formed between the carboxylic acid of Neu5Ac and Arg97 
(Arg124 in Siglec-7, respectively). This observation was also confirmed by mutation studies, 
where complete abrogation of binding was observed, when Arg97 was mutated to Ala97.
73
 In 
the Sialoadhesin-sialoside complex, a further contribution to the overall binding affinity is 
related to hydrogen bonding of 5-NH to the backbone carbonyl of Ser103, the interaction of 
the 8-hydroxy with NH of Leu107 and the formation of a hydrogen bond of the 9-hydroxy to 
the backbone carbonyl of Leu107. Moreover, Trp106 establishes a lipophilic contact with C-
9. All these interactions were also found in the complex of Siglec-7 with DSLc4. It is 
noteworthy that Arg97, Trp2 and Trp106 are conserved in all Siglecs. 
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 Important interactions for sialic acid 
binding are indicated. Conserved interactions within the Siglec-family are highlighted in yellow. 
 
Differences in the binding site of Siglec-1 and Siglec-7 were observed with regard to the 
hydrophobic cleft when substituents are introduced in the 9-position (e.g. Figure 7). 
Additionally, in the case of Sialoadhesin, hydrophobic interactions are established between 
Trp2 and the NHAc residue in 5-position
8
, an interaction which is not observed with Siglec-
7. Also the impact of the 4- and 7-hydroxy to the binding affinity seems to be different 
among the Siglecs.  
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Figure 7. left: Siglec-7 in complex with Me!-9-oxamido-Neu5Ac (1).
10
 The oxamido-substituent was reported 
to form hydrogen-bonds with Lys131. right: Sialoadhesin co-crystallized with 9-biphenyl-Neu5Ac (2).
7
 The 
biphenyl is nicely aligned within a hydrophobic pocket. Overlay with the oxamido-compound reveals a steric 
clash with Val109 as the reason for non-binding of 1 to Sialoadhesin.  
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Amongst others, Sialoadhesin was co-crystallized with 9-naphtyl !-methyl sialoside, 
providing further insight into the binding mode of siglec-sialoside interactions.
7
 Derivatives 
modified in the 5- and 9-position show identical binding modes for the sialic acid core.  
Additional hydrophobic interactions of 5-NHAc with Trp2 and the aromatic carboxamide in 
the 9-position with the hydrophobic groove formed by Val109, Tyr44, Leu107, Ser45 and 
Asn95, respectively, led to improved affinities.
7
 As Sialoadhesin is most closely related to the 
yet not crystallized MAG and CD22, homology models were generated on the basis of these 
crystallographic data. 
 
1.4 Synthetic ligands for Siglecs. 
Sialoadhesin. Interest in targeting Sialoadhesin is evolving, although up to now only a 
limited number of antagonists have been reported (Figure 8).
7,8,68,71,74
 Sialoadhesin was co-
crystallized with either the trisaccharide 3’-sialyllactose
71
 or synthetic sialosides, modified in 
2-, 5- and 9-position.
7,8
 Detailed studies of the required functional groups for binding 
revealed that beside the carboxy group the hydrogen bonds of 8- and 9-OH are crucial. 
Modifications where these hydrogen-bond donors were abolished, led to drastically decreased 
binding affinities or even complete loss of affinity.
68
 In contrast, 4- and 7-deoxy neuraminic 
acid were tolerated without drastically affecting affinity.
75
 As analysis of sialyllactose 
binding to Sialoadhesin revealed that the main contribution results from the sialic acid 
moiety
71
 and that the replacement of the disaccharide could be accomplished by a peptidic 
substitute ("6)
74
 or benzyl aglycon  ("3).
68
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With a benzyl aglycon, binding affinity could be increased in comparison to !-methyl 
Neu5Ac by a factor of 8. Introduction of a benzyl carboxamide in the 9-position ("2) led to  
a further increase in binding affinity. This effect was even more pronounced in the case of 
biphenyl and naphtyl carboxamide
7,76
. X-ray analysis revealed favorable hydrophobic 
contacts, however introduction of 3,5-dinitro benzoyl or 4-acetoxy-biphenoyl was not 
tolerated, presumably due to a steric clash with the protein. As the acetamide in the 5-position 
is engaged in hydrophobic contacts with Trp2, synthetic sialosides, bearing halogenated or 
extended hydrophobic substituents were investigated
68
. Whereas binding affinities were only 
slightly increased in the case of FH2CC(=O) and F3CC(=O), propionamide and butyramide 
improved affinity by a factor of 2. However with N-benzoyl in 5-position, affinity was almost 
completely lost
8
. This indicates the spatial limitation of the hydrophobic groove. Currently, 
the best antagonists exhibit affinities in the range of 70-200 !M. 
 
CD22 exhibits a strong preference for glycans bearing !2,6-linked sialic acids. Powell et al. 
identified the minimal structural motif required for recognition, namely Neu5Ac!2,6Hex or 
Neu5Gc!2,6Hex, whereas Hex being Gal, GalNAc or GlcNAc
33
. The minimal binding motif 
was further reduced to sialic acid by Rossenberg et al.
77
 Furthermore, Kelm et al. showed 
that sialoside 2, modified in the 9-position (Figure 7 and 9) with biphenyl carboxamide 
exhibits !M CD22 affinity.  
Using a cellular signaling assay, specificity towards CD22 was checked and the influence on 
BCR inhibition was investigated. When 2 was added to B-cells, Ca
2+
 influx induced by BCR-
antigen-binding was decreased and revealed that binding of 2 leads to incomplete activation 
of the intracellular inhibitory domain of CD22. Hence, a reduced association of CD22 with 
BCR leads to reduced phosphorylation
76
. These results validated CD22 as a pharmaceutical 
target and reveal the potential of synthetic sialosides for therapeutic applications. 
Recently, Kiso et al. introduced substituted biphenyl carboxamide-substituents into the 9’-
position of 4-methoxy-phenyl Neu5Gc!2-6Gal,
78
 and among the various tested substituents, 
4-(4-hydroxyphenyl) benzamide ("9, Figure 9) yielded the most potent antagonist.
78
 
Furthermore, amines instead of amides in 9’-position were identified as affinity enhancers. 
Finally, for murine CD22 a replacement of the galactose moiety by a benzyl substituent was 
reported
79
. 
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 -- 1 
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Figure 9. Overview on sialic acid based ligands for hCD22. Compounds 7, 8 and 11 were also investigated as 
multivalent ligands. 
80,77
 
 
Several groups reported increased affinity of multivalent ligands compared to monovalent 
sialosides
77,81
 (Figure 10). A similar observation was reported for sialosides coupled to 
several “supporter” such as polymers, proteins or gold nanoparticles. Collins et al. observed 
that compound 7 (9-biphenylcarboxamide-Neu5Ac!2-6Galß1-4GlcNAcß-ethylamine) 
showed an 18-fold improved affinity compared to sialoside 2 (Figure 10).
80
 Interestingly, 
with a multivalent presentation, cis interactions could be abolished without precedent 
removal of masking. Moreover, the introduction of a more potent sialoside into the glycan 
structure present on B-cells led to a “masking” that could not be overcome.
80
 Therefore, the 
crucial point for competition with cis ligands is an antagonist with sufficient high potency 
and avidity. 
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Figure 10. Multivalent display was achieved with different approaches, one example is based on self-assembly 
of bifunctional sialoside 8, triggered by an antibody.
82
 
 
Siglec-2 (CD22) has been successfully targeted by anti-CD22 antibodies, which were applied 
as conjugates with different toxins.
43
 The toxins were selectively transported to B-cells and 
internalized by antibody-triggered endocytosis. This approach of toxin-delivery was also 
applied for synthetic sialosides. Hence, Collins et al. coupled the toxin saporin to a 
polyacrylamide carrier, loaded with sialoside 7 (Figure 10) and observed B-cell killing.
80
 
Another approach is based on the design of bifunctional molecules (Figure 9), presenting a 
sialoside and an antigen. Upon addition of an antigen-specific antibody this led to in situ 
complex formation, providing a multivalent ligand that could overcome cis interaction, 
accompanied with an increase of the apparent KD by a factor of 100. It is noteworthy that also 
a dimer binds to CD22, although higher concentrations were needed in comparison to the 
decavalent complex.
83
  
 
MAG. Based on the most potent natural ligand of MAG, the ganglioside GQ1b!, antagonists 
with improved affinity and drug-like properties were developed.
84
 Extensive structure–
affinity relationship (SAR) studies led to the identification of tetrasaccharide 13
85
 as the 
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minimal binding epitope of GQ1b!.
67,86
 A first generation of antagonists consisting of 
modified tetrasaccharides, e.g. 14
20
 were synthesized (Figure 11).  
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Figure 11. Overview on synthetic antagonists for MAG. Salt bridge and hydrogen bonds are indicaited in blue; 
Green represents hydrophobic interactions with MAG.
85
 Relative inhibitory potencies (rIP) for 3 and 18 were 
measured against Me!Neu5Ac.
68 
 
Further investigations of the binding event by STD NMR revealed that both, the Gal and 
GalNAc moiety form hydrophobic contacts with the lectin and can therefore successfully be 
replaced by hydrophobic moieties such as biphenyl ("16).
88
 Furthermore, it was found that 
the carboxylic function of the terminal sialic acid is crucial for binding as well as the 
hydrogen bond capacity of 9-hydroxy and should therefore not be altered.
68,87
 
In a second approach, the 2,6-linked sialic acid was substituted by hydrophilic and 
hydrophobic moieties. It is noteworthy that biphenyl in derivative 15 yielded a notably 
improved binding affinity. Combination with modifications in the 9-position of sialic acid 
further improved affinity to the low !M range.
89
  
Finally, Kelm et al. and our lab reported a pivotal simplification, where sialic acid modified 
in 2, 5 or 9-position showed !M binding.
68,87
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1.5 Goal of the thesis. 
The topic of my thesis is centered around the synthesis and biological evaluation of sialic 
acid based antagonists of Siglecs. Although ligands for Siglec-1, and -2 are presented, the 
main part is dedicated to the optimization of antagonists for Siglec-4 (MAG). Here, small-
molecule antagonists modified in the 2- and 5-position were synthesized and evaluated. 
Furthermore, the kinetic and physicochemical properties were elucidated. For this purpose, a 
series of 4-modified ligands was synthesized with the attempt to influence the kinetic 
behavior. As found earlier in our lab, the combination of small fragments to a first site 
yielded highly active antagonists
90
. Based on these results, optimization and evaluation of a 
series of ligands was performed. Finally, the synthesized antagonists were also tested for 
selectivity for Siglec-1, -2 and -4. 
 
 
2. Results and Discussion 
 16 
From the Ganglioside GQ1b! to Glycomimetic Antagonists of the Myelin-Associated 
Glycoprotein (MAG) 
 
This review summarizes the progresses made in the development of MAG-antagonists. 
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Low Molecular Weight Antagonists of the Myelin-Associated Glycoprotein: Synthesis, 
Docking, and Biological Evaluation 
 
Small-molecule antagonists for MAG, based on sialic acid, were synthesized and evaluated 
regarding their affinity.  
 
This part was published in the Journal of Medicinal Chemistry: 
S. Mesch, D. Moser, D. Strasser, A. Kelm, B. Cutting, G. Rossato, A. Vedani, H. Koliwer-
Brandl, M. Wittwer, S. Rabbani, O. Schwardt, S. Kelm, B. Ernst, J. Med. Chem. 2010, 1597-
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Kinetic and thermodynamic properties of MAG antagonists 
 
The influence of 4- and 5-substituents on the kinetic behaviour of MAG antagonists was 
investigated. Furthermore, the thermodynamic properties of the most promising compound 
were elucidated. 
 
This part was accepted by the Journal of Carbohydrate Research: 
S. Mesch, K. Lemme, H. Koliwer-Brandl, D. S. Strasser, O. Schwardt, S. Kelm, B. Ernst, in 
press. 
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MAG-antagonists: Approach towards high-affinity ligands by click-chemistry 
 
This report comprises the optimization approach applied to a novel generation of MAG-
antagonists. 
 
The article is a draft version and supposed to be submitted to ChemMedChem. 
Stefanie Mesch, Beatrice Wagner, Xiaohua Jiang, Gianluca Rossato, Hendrik Koliwer-
Brandl, Katrin Lemme, Daniel Schwizer, Angelo Vedan, Matthias Wittwer, Oliver Schwardt, 
Soerge Kelm, Beat Ernst. 
 
 
Work performed by Stefanie Mesch: 
Synthesis of ligand 9, performance and evaluation of Biacore assay. 
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 Introduction. The central nervous system (CNS) is an inhibitory environment for axon 
regeneration.
[1,2]
 After injury, nerve strands lack the ability of adhesion due to the presence of 
several inhibitory proteins.
[3]
 In the last decade, three inhibitors have been identified, one of 
them being the myelin-associated glycoprotein (MAG)
[4]
. MAG interacts with several 
neuronal receptors, such as proteins of the Nogo receptor family and gangliosides, primarily 
GD1a, GT1b and GQ1b!.
[5-8]
 Although the relative role of Nogo receptors and gangliosides 
as MAG ligands has yet to be resolved, it is supposed that binding to MAG leads in all cases 
to the activation of the small kinase RhoA and finally to growth cone collapse.
[9]
  
We focus on the ganglioside mediated cascade, as in certain systems, sialidase treatment 
resulted in enhanced neural outgrowth.
[10]
 Taking this one step further, blocking MAG with 
potent glycomimetic antagonists offers a valuable therapeutic approach to enhance axon 
regeneration. Extensive SAR studies resulted in mimetics with simplified structures and high 
potency.
[11-14]
 For further affinity enhancement and with respect to selectivity issues, the 
concept of “fragment assembly” was applied. Here, fragments binding in proximity are 
linked and benefit results from the multiplied affinities.
[15]
 Shelke et al. used a NMR based 
approach for the identification of second site fragments.
[16]
 The fragments were linked in situ 
applying Cu
I
-catalyzed Huisgen [3+2] cycloaddition, also known as click-chemistry, yielded 
a lead compound providing a KD in the low nanomolar range
[17]
 (Figure 1). In this report we 
present the optimization of the identified lead by means of medicinal chemistry and the 
biological evaluation thereof.  
 
Results and Discussion. The influence of a radical on the relaxation-behavior of protons 
located in close proximity is used by NMR-based screenings to identify weak binders around 
any ligand’s binding site.
[18]
 In the case of MAG, Shelke et al. found that 5’-nitroindole is 
binding near the binding site of sialic acid. After evaluation of the optimal spacer length by in 
situ click experiments, antagonist 1 was synthesized and its affinity was determined (see also 
Table 1).
[17]
 In a next step this lead was considered for further optimization. As the 
attachment of the linker on the indole nitrogen led to a decrease in affinity (data not shown), 
attachment of the linker at 3’-C was maintained. 
 
  Chapter 2.1.3 
 
58 
 
Figure 1. Lead identification by NMR based approach and further optimization. 
 
Here, we examine the influence of various modifications on the indole such as alkylation of 
the indole nitrogen and alteration of the 5’-, 6’- and 7’-substituents respectively. Apart from 
elucidating the effects of the electron density on binding affinity, the hydrophobic surface of 
the indole was enlarged by amides in 6’-position. During the optimization process, lead 
compound 1 was modified in 5-position of neuraminic acid by inserting fluoroacetate, which 
was found earlier to improve binding affinity and p-chlorobenzamide in 9-position.
[14,19]
 Final 
combination with miscellaneous substituted indole moieties yielded a library of antagonists 
2-20. The binding affinity of the final compounds was elucidated using a surface plasmon 
resonance based assay, hapten binding assay and ITC. Furthermore, molecular mechanic 
studies were conducted to rationalize the binding process and the effect of the different 
substituents was scrutinized by testing the ligands towards a MAG mutant. Finally, the 
thermodynamic profile of the most potent antagonists was investigated. 
 
Synthesis. The antagonists 2 - 20 (Figure 1) were obtained by click-chemistry as the final 
key step. Sialoside 21 (Scheme 4) was synthesized according to a reported procedure
[17]
 and 
the synthesis of the various indole substituents was accomplished by following different 
approaches (Scheme 1 - 3). In more detail, 3- and 3,5-substituted indoles were synthesized by 
reacting hydrazine derivatives 22a - 22k with 3,4-dihydro-2H-pyran under modified Fisher 
indolization conditions (!23a - k).
[20]
 Following, the primary alcohols were converted into 
the corresponding azides by applying the Appel-reaction.
[21,22]
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N
H
NH2
HCl
N
H
R1
R1
22a - k
a: R1, R2, R3 = H
b: R1 = OMe, R2, R3 = H
c: R1 = Cl, R2, R3 = H
d: R1 = F, R2, R3 = H
e: R1, R2 = H, R3 = Me
f:  R1 = H, R2 = Cl, R3 = H
g: R1 = isopropyl, R2, R3 = H
h: R1, R2 = -(CH2)3-, R
3 = H
i:  R1, R2 = H, R3 = Cl
j: R1 = CN, R2, R3 = H
k: R1 = SO2Me, R
2, R3 = H
R2
R3
R2
R3
OH
N
H
R1
R2
R3
N3
23a - k 25a - k
a) b,c)
 
Scheme 1. a) 3,4-Dihydro-2H-pyran, DMAc, 4% aq. H2SO4, 100 °C (11–90%); (b) PPh3, CBr4, CH3CN (!24a 
- k); (c) NaN3, DMF (16-85%, 2 steps). 
 
Starting from intermediate 23a, 3,6-disubstituted indoles were obtained after protection of the 
free alcohol and the indole-amine by performing Friedel-Crafts acylation (!23l, m). 
Subsequent deprotection and conversion of the primary alcohol into the azide yielded the 
desired indole derivatives (!25l, m) for click-chemistry.  
 
23a
a,b)
N
OAc
Ts
c)
N
H
OH
R
O
d,e)
N
H
N3
R
O
28 23l,m 25l:   R = cyclopropyl
25m: R = 4-chlorophenyl  
Scheme 2. a) Ac2O, DMAP, pyridine (!27: 92%); b) TsCl, NaH, THF (70%); c) (i) RCOCl, AlCl3, CH3NO2, 
(ii) 6 M NaOH, MeOH (23l: 61%; 23m: 47%). Yields refer to inseparable mixture of 5- and 6- substituted 
indoles); d) PPh3, CBr4, CH3CN, rt, (!24l, m); e) DMF, NaN3, rt (25l: 36%; 25m: 37%)  
 
In the case of 1,3,5- and 3,5-substituted indoles, having electron-withdrawing substituents in 
5’-position (Scheme 3), they were synthesized by reacting 2-iodo-aniline derivatives 29n, o 
with 30 under Larock indole conditions
[22,23]
 (!31n, o). After removal of the silyl protecting 
group, the alcohol (!23n, o) was converted into the desired azide (!25n, o).
[17]
 Starting 
from 25n N-alkylation was performed using the corresponding alkyl iodides and potassium 
hydroxide as base to receive 32 and 33.  
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I
NH2
R1
+
N
H
Si
N
H
R1 R1
NR2
R1a) b) c,d)
25n: R1 = NO2, R2 = H
25o: R1 = CF3,  R2 = H
30 31n,o 23n,o
32: R1 = NO2, R
2 = Me
33: R1 = NO2, R
2 = Et
OTBS OH N3
29n,o
OTBS
SiMe3
 
Scheme 3. a) Pd(OAc)2, LiCl, KOAc, DMF, 70 °C; b) 48% HF, CH3CN, rt (23n: 62%; 23o: 69%, 2 steps); c) 
PPh3, CBr4, CH3CN (24n, o); d) DMF, NaN3, rt (25n: 85%; 25o: 80%, 2 steps); e) R
2I, KOH, DMF (32: 94%; 
33: 92%). 
 
Finally, with sialoside 21 and the various substituted indole derivatives in hand, the final 
compounds were synthesized applying Cu
I
-catalyzed click-conditions as shown in scheme 4.  
 
a)
21 25a,b,l,m,o
32
33
NR1
R3
R2
2 - 8
N3O
COONa
O
HO
AcHN
OH
OHH
N
O
O
COONa
O
HO
AcHN
OH
OHH
N
O
N N
N
NR1
R3
R2
+
 
Scheme 4. a) CuSO4·5H2O, sodium ascorbate, H2O/t-BuOH 1:1, rt (2 - 8: 47-80%); for R
1, R2 and R3 see Table. 
 
Earlier SAR studies showed that introduction of fluoro acetamide in 5-position leads to a 
distinct improvement of the binding affinity
[14,19]
 and therefore we decided to incorporate this 
modification into compound 1 (Scheme 5). Intermediate 35 was obtained by cleavage of the 
N-acetate in 5-position followed by Boc-protection to give 36. After deprotection, selective 
acylation was performed (!37). Afterwards, the azide was transformed into benzylamide or 
p-chlorobenzylamide, respectively, under modified Staudinger conditions (!38a, b). After 
deprotection (!39a, b) the test compounds 9 - 20 were obtained by click-reaction with 
indole derivatives 25b –k, n.  
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OHH
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N N
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H
R4
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COOMe
O
AcO
AcHN
OAc
OAc
N3 b)
34 35
a)
f)
36: R = H
9 - 20
c)
37: R = FAc
38a: R1 = Ac, R2 = Me, R3 = H
38b: R1 = Ac, R2 = Me, R3 = Cl
39a: R1 = H,  R2 = Li, R3 =H
39b: R1 = H, R2 = Li, R3 = Cl
e)
d)
O
COOMe
O
AcO
BocHN
OAc
OAc
N3
O
COOMe
O
AcO
RHN
OAc
OAc
N3
O
COOR2
O
R1O
FAcHN
OR1
OR1H
N
R3
O
R3
R2
R1
NH
R3
R2
N3
R1
25 b - k, n
 
Scheme 5. a) i. Boc2O, DMAP, THF; ii. N2H4!H2O, MeOH; iii. Ac2O, DMAP, pyridine (50%); b) PhOH, 
TMSCl, DCM, rt (70%); c) FCH2COCl, NEt3, DMAP, THF (43%); d) PPh3, RCOCl, DCE, rt (38a: 52%; 38b: 
65%); e) 10% aq. LiOH, THF/H2O (39a: 80%); 39b: 50%); f) i. (25b – k, n), CuSO4·5H2O, sodium ascorbate, 
H2O/
tBuOH 1:1, rt; ii. Dowex 50 X 8 Na+ form (9-20: 16-80%). for R1, R2, R3 and R4 see Table. 
 
Biological evaluation. To evaluate the binding properties of the sialosides the following 
formats were applied: a surface plasmon resonance (SPR) based assay (Biacore) and a hapten 
inhibition assay. The affinities of 1 and 2-20 were determined by the SPR based assay and in 
addition, the inhibitory potencies of 1 and 4 were determined by hapten inhibition assay 
(details see below). 
For SPR assays, recombinant protein, consisting of the three N-terminal domains of MAG 
and the Fc part of human IgG (MAGd1-3-Fc) was captured on polyclonal anti-Fc antibody, 
which was covalently bound to the surface. A reference cell, providing only antibody was 
used for compensation of unspecific binding to the matrix. The test compounds were 
dissolved in running buffer and injected over the surface. The obtained sensorgrams were 
fitted according to a 1:1 binding model. Concerns that our test compounds might form 
micelles in aqueous solution or show surface activity were vanished by determining the 
critical micelle concentration (CMC) with high-precision microbalances and wire probes.  
 
CMC determination. The device is measuring the energy that needs to be expended to pull 
the wire probes out of the solution. This energy corresponds to the surface pressure (mN/m), 
which is inversely proportional to the surface tension. Due to the fact that the energy is 
decreasing with higher surface activity and stays constant as soon as micelles are being 
formed, the CMC and/or surface activity of a compound can be detected with a dilution 
series. In the case of compound 1 no activity up to 1 mM was observed. 
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The determination of the affinities (Table 1) revealed that N-alkylation of 5’-nitroindole with 
methyl (!2) or ethyl (!3) led to a slight decrease in affinity. Therefore we led the focus on 
the investigation of various substituents in 5’-position (! 4-8). We replaced the nitro group 
by electron with-drawing as well as electron-donating groups to elucidate whether this 
substituents influence the affinity. 
 
O
COONa
O
HO
R5HN
OH
OHH
N
O
N
N
N
N
R1
R4
R3
R
2
R6
 
 
Table 1. Overview on affinities of antagonists 1 - 20, determined by Biacore. 
Compound R
1 
R
2
 R
3 
R
4 
R
5
 R
6
 KD [nM] 
1 H H H NO2 Ac H 190 
2 Me H H NO2 Ac H 445 
3 Et H H NO2 Ac H 333 
4 H H H H Ac H 167 
5 H H H OMe Ac H 322 
9 H H H CF3 Ac H 354 
7 H 
H  
H Ac 
H 
300 
8 H 
H  
H Ac H 75 
9 H H H NO2 FAc H 50 
10 H H H NO2 FAc Cl 53 
11 H H H Cl FAc Cl 48 
12 H H Cl H FAc Cl 57 
13 H Cl H H FAc Cl 92 
14 H CH3 H H FAc Cl 96 
O
O
Cl
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15 H H H F FAc Cl 67 
16 H H H OCH3 FAc Cl 79 
17 H H H CH(CH3)2 FAc Cl 101 
18 H H H CN FAc Cl 66 
19 H H H SO2Me FAc Cl 113 
20 H H cyclopentane FAc Cl 98 
 
The replacement of the nitro-group by trifluoromethyl (!6) or by the electron-donating 
methoxy-group (!5) yielded in a decreased affinity. In contrast, the unsubstituted indole 
(!4) showed a similar potency as the reference compound. These observations suggest on 
the one hand that the nitro-group might be interacting beneficially with the protein, whereas 
the other 5’-substituents are sterically too demanding. In the next step, we introduced 
substituents with increased lipophilic surface at 6’-position of the indole (!7, 8). 
Unfortunately, cyclopropylacyl did not show any effect, however when 4-chlorobenzylacyl 
was introduced a gain in affinities by a factor of 3 was achieved. Here, the amelioration 
might result from additional favorable hydrophobic interactions. However, the compound 
was not soluble in aqueous buffer solution and therefore we returned our focus onto the initial 
lead 1.  
As mentioned above, we expected an improvement in binding affinity upon insertion of 
fluoroacetate in 5-position of 1, and indeed this yielded an antagonist with a KD of 50 nM 
(!9).  
 
Molecular modeling studies. For an improved understanding of the biological data, 
compounds 4 and 9 and were docked to a homology model of MAG
[13,14]
 and a molecular-
dynamics simulation in aqueous solution was performed (4 ns at 300 K) using Desmond.
[24]
 
In both antagonist-protein complexes, the sialic acid core established the crucial interactions 
responsible for recognition and binding e.g. the salt bridge between Arg118 and the 
carboxylate.
[19]
 Moreover, hydrogen bonds between 5-NH and the carbonyl of Gln126, 8-OH 
and Thr128 and 9-NH and Tyr125 were formed in both cases.  
In the case of 9, the 5’-nitroindole is embedded in a hydrophobic pocket lined by residues 
Tyr60, Tyr69 and Tyr116. Here, the indole-moiety is sandwiched by Tyr69 and 116, 
displaying an angle to Tyr69 of 17° and to Tyr116 an angle of 39° (Figure 2). It is 
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noteworthy that the !-! interactions are maintained during the whole simulation. 
Furthermore, the nitro-substituent interacts with Lys67 by dipolar interactions and seems to 
stabilize the position of the indole. The nitro-group is in the distance range of about 2.6 to 5.0 
Å also found in other protein-ligand complexes.[25] In order to elucidate the role of the nitro-
group experimentally, compounds 1 and 4 were tested with a MAG mutant K67A, where 
Lys67 is replaced, in a hapten inhibition assay as described below. 
Simulations of ligand–protein complexes aim to understand details of the binding mode and to 
estimate the associated binding affinity. When comparing the binding of two similar ligands to 
a target protein, the difference in their free energy of binding (!!G) can be calculated using 
free-energy perturbation (FEP).[26] Here, the calculation of the relative-free energy difference 
by using the free energy perturbation method (FEP, 1 ns) of the protein-ligand (ligand: 9) 
complex and the complex with a virtual abolishment of the nitro-group in the ligand 9 led to a 
positive free energy difference, meaning that the abolishment of the nitro decreases the 
stability of the complex.  
The linker contributes only marginally to the overall binding affinity but enables the 
alignment of the indole. Surprisingly, the linker seems to be in a rather locked conformation 
after binding (Figure 2, up). Finally, the FAc-substituent in 5-position of sialic acid 
contributes via hydrophobic interactions with Trp22. 
 
a. 
 
b. 
O
OHFAcHN
HN
HO
OH
O
O
O
O
NN
N
NH
O2N
69Tyr
HO
Tyr116
HO
!"! interactions
Lys67
H2N
 
  Chapter 2.1.3 
 
65 
c. 
 
d. 
 
 
Figure 2. a. Conformations of antagonist 9 and the position of Tyr69 and Tyr116 during the dynamic simulation 
were clustered. 5’-Nitroindole interacts via !-! interactions with Tyr69 and Tyr116 resulting in a locked 
conformation of the linker. b. 2D-representation of 9 and its interactions with Tyr69 and 116. The dipolar 
interactions with Lys67 are depicted in pink. c. Plot of the frequency against the angle between Tyr69 and 5’-
nitroindole. d. 2D-plot of angles between Tyr69/5’-nitroindole and Tyr116/5’-nitroindole shows that both 
tyrosine maintain a distinct angle during the simulation. 
 
In the case of the unsubstituted indole no !-! interactions were observed. The angles of both 
tyrosines are around 70°-90° and the dispersion is clearly higher. Furthermore, the mobility 
of the linker was strikingly increased during the dynamic simulation (Figure 3). The 
nevertheless good binding affinity might be explained that no constraints raise from the linker 
positioning and that the core interactions might be slightly better established. 
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c. 
 
d. 
 
 
Figure 3. a. Conformations of antagonist 4 and position of Tyr69 and Tyr116 occurring during the dynamic 
simulation were clustered. Antagonist 4, lacking the 5’-nitro substituent, seems not to be sandwiched and 
consequently shows increased mobility of the linker. b. 2D representation of 4, Tyr69 and Tyr116. c. Plot of the 
frequency vs. the angle between Tyr69 and indole shows that no !-! interactions occur. d. 2D-plot of angles 
between Tyr69/indole and Tyr116/indole shows a higher dispersion and that the indole is almost perpendicular 
to both tyrosins. 
 
In general, the findings discussed above are in agreement with the observation that 
replacement of nitro by other substituents decreases the affinity (!6), as no interaction with 
Lys67 is possible. Finally, modifications in 6’-position could be aligned in the hydrophobic 
cleft and additional hydrophobic interactions (!8) contribute to the binding affinity. 
 
Hapten inhibition assay.  
The molecular docking experiments of sialoside 9 described above suggested an interaction 
of the nitro residue of 5’-nitroindole with Lys67. To elucidate this interaction, two sialosides 
1 and 4 were used in hapten inhibition assays with MAGd1-3-Fc wt and a MAG mutant K67A. 
Using hapten inhibition assays, for each compound tested the concentrations required for 50 
% inhibition (IC50) were determined in microtiter plates coated with fetuin as the binding 
target for MAGd1-3 Fc-chimeras
[27]
. Relative inhibitory potencies (rIP) were calculated from 
its IC50 (IC50sample) and the IC50 of a reference compound (IC50ref): rIP = IC50ref/IC50sample. 
At least three independent titrations were performed for each compound tested with seven or 
eight concentrations in triplicates. Relative inhibitory potencies (rIP) were calculated using 
compound 4 as reference (rIP of 1, Figure 5, Table 2).  
Both substances lead to IC50-values in the low nanomolar range (Figure 4 a, Table 1). The 
presence of the nitro group in sialoside 1 leads to a 4.25-fold stronger inhibition compared to 
4 for MAGd1-3-Fc wt, whereas for MAGd1-3-Fc K67A this increase is only 2.14-fold. 
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This supports the hypothesis that Lys67 contributes to binding via a hydrogen bond with the 
nitro group of compound 1, as suggested in figure 4b. However, other interactions of the nitro 
group are likely to support binding to some extend, since its introduction also enhances 
inhibiton of the K67A mutant. 
 
a. 
 
b. 
 
Figure 4. a. Inhibition curves of MAGd1-3-Fc wild type (wt) and mutant K67A for the determination of IC50-
values by hapten inhibition assay. b. rIP of sialosides 1 and 4 for both Fc-chimeras MAG wt and K67A. 
Sialoside 4 without nitro residue was calculated relative to sialoside 1 to obtain a factor of enhanced inhibition 
in consequence of the additional nitro group of 4. 
 
Table 2. Comparison of the half maximal inhibitory concentrations (IC50) and relative inhibitory potencies 
(rIP) for MAGd1-3-Fc wild type (wt) and mutant K67A inhibited by sialosides 1 and 4 determined by hapten 
inhibition assay. 
Compound MAGd1-3-Fc wt MAGd1-3-Fc K67A 
 IC50 [nM] rIP [-] IC50 [nM] rIP [-] 
1 13 ± 2 4.25 ± 0.19 41 ± 5 2.14 ± 0.21 
4 53 ± 9 1.00 ± 0.00 88 ± 4 1.00 ± 0.00 
 
Optimization with respect to medicinal chemistry aspects. 
The new lead compound 4 showed improved binding affinity, however, there are two 
metabolic soft spots present in the molecule. At first we replaced the benzylamide by p-
chlorobenzylamide, which showed an equivalent binding affinity (!10) and examined a 
series of ligands (11-20) where the nitro group was replaced by either halogen-, sulfonyl- or 
cynanide-substituents. Considering our findings with the MAG-mutant discussed above, we 
predicted interactions of the latter substituents with Lys67.  
Antagonists 11 and 15 (Table 1) showed equivalent binding affinity of 48 nM and 57 nM 
respectively, and we demonstrated that the nitro group can be replaced by a chorine or 
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fluorine. In the case of 18 (5’-CN) we observed again a comparable binding affinity to 10, 
unfortunately 19 (5’-SO2Me) was less active. Furthermore, compound 12 with a chlorine 
substituent in the 6’ position showed a comparable affinity. The introduction of substituents 
in 7’- position or larger substituents in 5’- position led to a decreased binding affinity. 
 
Isothermal titration calorimetry (ITC). 
Using our most potent compounds (9-11, 13, 15 and 18) and our initial lead 1, we performed 
thermodynamic measurements in order to gain further insight into the different contributions 
to the overall binding affinity and determined the thermodynamic parameters !H, !S and 
!G.
[28]
 For the experiments, MAGd1-3-Fc was used. A solution of the ligands in HBS-E buffer 
was injected into a solution of MAGd1-3-Fc (HBS-E buffer) at 25 °C. The experimental data 
were fitted to a theoretical titration curve (one site binding model) using Origin version 7 
software (MicroCal). The thermodynamic parameters !H, !S and !G were calculated 
according to equation 1 (Figure 5). The ITC experiments confirmed the high affinity of the 
antagonists, in the case of compounds 1 and 9 however, the obtained affinities were higher 
compared to the ones determined by Biacore. Nevertheless, we consider these results to be in 
good agreement as two different assays are compared and the trend is maintained.  
Having now a closer look to the separate thermodynamic parameters, in all cases ligand 
binding is enthalpy driven.
[29,30]
 As the enthalpy term highlights the difference of the ligands’ 
interactions with the solvent compared to those with the protein,
[31]
 this led to the conclusion 
that the antagonists exhibit directed interactions e.g. salt bridge, hydrogen bonds and van der 
Waals interactions and is in good agreement with our molecular modeling studies. 
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!G = !H - T!S = - RTlnKD     (1) 
 
 
Figure 5. Enthalpogram of 9 (left). !G, !H and !S were calculated according to equation 1, enthalpy-entropy 
compensation plot (right). 
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Table 3. Thermodynamic profile of selected MAG antagonists.* 
 1 9 10 11 12 15 18 
!G [kJ/mol] -35.5 -39.2 -41.1 -42.5 -42.0 -42.4 -40.9 
!H [kJ/mol] -39.0 -32.1 -48.8 -38.8 -42.8 -39.0 -51.0 
-T!S [kJ/mol] 3.5 -7.1 7.7 -3.8 0.8 -3.4 10.1 
KD [nM] 588 136 64 35 44 37 69 
*The stoichiometry N was in all measurements 1.01±0.03. 
 
We observed, that the difference in the total binding energy results from the entropy term. 
Substitution by a halogen (!11, 15) in 5’-position leads to an enhanced entropy, whereas the 
compounds with the 5’-nitro (!10) or 5’-cyanide (!18) suffer from a loss in entropy. We 
also observed this effect in the case of compound 19 (data not shown). This could be the 
result, at least partial, from the enforced orientation upon interaction with Lys 67, which is 
not as pronounced with the chlorine or fluorine substituents. An enthalpy-entropy plot 
revealed that we faced an enthalpy-entropy compensation effect (Figure 5), which has been 
already observed in the case of CD22.
[33] 
 
Conclusion. A small library of high affinity ligands was synthesized following medicinal 
chemistry approaches and investigated by Biacore and ITC. The effects of various 
modifications on the indole moiety were elucidated. Here, N-alkylation as well as substitution 
with sterically demanding substituents decreased binding slightly. Substitution with halogens 
or cyanide instead yielded an increase in binding affinity. Also the insertion of the 4-
chlorobenzyl acyl in 6’-position yielded an improvement in affinity. With respect to the 
binding mode, 5’-nitro seems to be required for stabilizing the geometric orientation of the 
indole. Furthermore, we showed that the binding is enthalpy driven, however, the ligands 
entropy makes the difference with respect to the total binding affinity. Finally, compounds 11 
and 15, having a fluoroacetate substiuent at 5-position of neuraminic acid, a p-
chlorobenzamide in 9-position and a chloro or fluoro substituent in 5’-position of the indole 
moiety were identified as the most potent antagonist for MAG to date, binding in the low 
nanomolar range. 
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Experimental part. 
Chemistry. NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, TOCSY). Chemical shifts are expressed in ppm using residual CHCl3, 
CHD2OD and HDO as references. Optical rotations were measured using Perkin-Elmer 
Polarimeters 241 and 341. MS analyses were carried out using a Waters Micromass ZQ 
Detector system. The spectra were recorded in positive or negative ESI mode. The 
HPLC/HRMS analyses were carried out using an Agilent 1100 equipped with a photodiode 
array detector and a Micromass QTOF I equipped with a 4 GHz digital-time converter. All 
target compounds exhibit a purity of ! 95%. Reactions were monitored by TLC using glass 
plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
charring with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate 
and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column chromatography 
was performed on silica gel (Uetikon, 40-60 mesh). Methanol was dried by refluxing with 
sodium methoxide and distilled immediately before use. Pyridine was freshly distilled under 
argon over CaH2. Dichloromethane (DCM), dichloroethane (DCE), acetonitrile (ACN), 
nitromethane, toluene, and benzene were dried by filtration over Al2O3 (Fluka, type 5016 A 
basic). Molecular sieves (3 Å) were activated under vacuum at 500 °C for 2 h immediately 
before use. If not stated otherwise, all starting materials were commercially available. 
 
General procedure A: (23f – i) 
To a solution of hydrazine-HCl (2.5 mmol) in aq. 4% H2SO4 (4 mL) and N,N-
dimethylacetamide (DMAc, 10 mL), 3,4 dihydro-2H-pyran (2.5 mmol) was added dropwise. 
The reaction was aged for 2 h, then cooled to rt, extracted with ethylacetate (20 mL) and 
washed with water (3 x 20 mL). The aqueous layers were extracted with ethylacetate (20 mL) 
and the combined organic layers were dried over Na2SO4, filtered and evaporated. The crude 
product was purified by chromatography. 
 
General procedure B: Appel-reaction (25a - o). 
The alcohol (1.0 eq) was dissolved in dry MeCN and cooled to 0 °C. Afterwards, 
triphenylphosphine (1.2-1.5 eq) was added, followed by successive addition of CBr4 (1.2-1.5 
eq). The mixture was stirred at rt for 2 h and then diluted with ethyl acetate, washed with 
H2O, brine and dried over Na2SO4. The solvent was removed under vacuum and the residue 
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was purified by chromatography (PE/ ethyl acetate) to yield the corresponding bromide. 
Afterwards, to a solution of bromide (1.0 eq) in dry DMF, NaN3 (2.0-5.0 eq) was added at rt 
and stirring was continued overnight. Afterwards, the solvent was removed under vacuum 
and the residue was purified by chromatography (petroleum ether/ ethyl acetate) to afford the 
desired azides.  
 
General procedure C: click-reaction (2 - 20).  
To a mixture of acetylene (1.0 eq) in degassed 
t
BuOH:H2O (v/v, 1:1), azide (1.2-1.5 eq), 
CuSO4·5H2O (0.25 eq) and sodium ascorbate (0.5 eq) were added under argon atmosphere. 
The reaction mixture was stirred at rt overnight. Afterwards, the solvent was removed under 
reduced pressure and the residue was purified by reverse phase chromatography (Merck 
LiChroprep RP-18, 5% gradient of MeOH in water), Dowex 50x8 (Na
+
 type) ion exchange 
chromatography and P2 size exclusion chromatography to afford the pure test compounds. 
 
3-(6-chloro-1H-indol-3-yl)propan-1-ol (23f). Prepared from 22f (400 mg, 2.234 mmol) 
according to general procedure A to afford 23f (53 mg, 11%). 1H NMR (500 MHz, CDCl3) ! 
1.94 – 2.03 (m, 2H, CH2), 3.01 – 3.09 (m, 2H, CH2), 3.73 (t, J = 6.5 Hz, 2H, CH2), 6.95 (s, 
1H, CHar), 7.00 – 7.08 (m, 2H, CHar), 7.16 – 7.23 (m, 1H, CHar), 8.27 (s, 1H, NH); 
13C NMR 
(126 MHz, CDCl3) ! 22.73, 34.61, 62.73 (CH2), 110.14, 116.53, 120.45, 122.56, 123.12, 
124.33, 126.57, 138.14 (C-Ar); ESI-MS m/z calcd for C11H12ClNO [M]
+: 209.06; found: 
209.89. 
 
3-(5-isopropyl-1H-indol-3-yl)propan-1-ol (23g). Prepared from 22g (300 mg, 1.6069 mmol) 
according to general procedure A to afford 23g (152 mg, 43%). 1H NMR (500 MHz, CDCl3) 
! 1.34 (d, J = 6.9 Hz, 6H, 2 CH3), 1.94 – 2.07 (m, 2H, CH2), 2.88 (t, J = 7.5 Hz, 2H, CH2), 
3.05 (hept, J = 6.9 Hz, 1H, CH), 3.77 (t, J = 6.4 Hz, 2H, CH2), 6.98 (s, 1H, CHar), 7.12 (dd, J 
= 1.4, 8.4 Hz, 1H, CHar), 7.30 (d, J = 8.4 Hz, 1H, CHar), 7.46 (s, 1H, CHar); 
13C NMR (126 
MHz, CDCl3) ! 21.58 (CH2), 24.94 (2C, CH3), 33.06 (CH2), 34.49 (CH), 62.97 (CH2), 
111.09, 115.93, 115.95, 121.37, 121.63, 127.70, 135.18, 140.17 (C-Ar); ESI-MS m/z calcd 
for C14H19NO [M]
+: 217.14; found: 217.94; 
 
3-(5,6-cyclopropyl-1H-indol-3-yl)propan-1-ol (23h). Prepared from 22h (200 mg, 1.0831 
mmol) according to general procedure A to afford 23h (140 mg, 60%).1H NMR (500 MHz, 
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CDCl3) ! 1.86 – 1.94 (m, 2H, CH2), 2.04 (p, J = 7.3 Hz, 2H, CH2
cyc), 2.74 (t, J = 7.4 Hz, 2H, 
CH2), 2.90 (t, J = 7.3 Hz, 4H, 2 CH2
cyc), 3.64 (t, J = 6.4 Hz, 2H, CH2), 6.82 (d, J = 2.0 Hz, 
1H, CHar), 7.09 (s, 1H, CHar), 7.34 (s, 1H, CHar), 7.70 (s, 1H, NH); 
13C NMR (126 MHz, 
CDCl3) ! 22.73 (CH2), 26.86, 32.57, 32.67 (CH2
cyc), 33.05 (CH2), 62.96 (CH2), 106.68, 
113.85, 118.87, 120.95, 126.82, 136.05, 136.08, 139.36 (C-Ar); ESI-MS m/z calcd for 
C14H17NO [M]
+: 215.13; found: 215.92. 
 
3-(7-chloro-1H-indol-3-yl)propan-1-ol (23i). Prepared from 22i (300 mg, 1.6755 mmol) 
according to general procedure A to afford 23i (80 mg, 22%).1H NMR (500 MHz, CDCl3) ! 
1.91 – 2.02 (m, 2H, CH2), 2.84 (t, J = 7.4 Hz, 2H, CH2), 3.71 (t, J = 6.4 Hz, 2H, CH2), 6.92 – 
7.13 (m, 2H, CHar), 7.17 (d, J = 7.3 Hz, 1H, CHar), 7.50 (d, J = 7.9 Hz, 1H, CHar), 8.16 (s, 1H, 
NH); 13C NMR (126 MHz, CDCl3) ! 21.63, 33.12, 62.71 (CH2), 116.83, 117.42, 117.78, 
120.22, 121.55, 122.11, 129.20, 133.84 (C-Ar); ESI-MS m/z calcd for C11H12ClNO [M]
+: 
209.06; found: 209.85. 
 
3-(3-Azidopropyl)-1H-indole (25a). Prepared from 23a (494 mg, 2.82 mmol) according to 
general procedure B to afford 25a (277 mg, two steps 50%) after chromatography as yellow 
oil. 
1
H NMR (CDCl3, 500 MHz): ! 2.02 (m, 2H, CH2), 2.88 (t, J = 7.5 Hz, 2H, CH2), 3.34 (t, 
J = 7.0 Hz, 2H, CH2), 7.01 (s, 1H, CHar), 7.15 (t, J = 7.0 Hz, 1H, CHar), 7.22 (t, J = 7.0 Hz, 
1H, CHar), 7.37 (d, J = 8.0 Hz, 1H, CHar), 7.61 (d, J = 7.5 Hz, 1H, CHar), 7.99 (s, 1H, NH); 
13
C NMR (CDCl3, 125 MHz): ! 22.1, 29.2, 50.9 (3 CH2), 111.1, 115.0, 118.8, 119.3, 121.5, 
122.1, 127.3, 136.3 (8 C-Ar); IR (film): ! 3415, 2929, 2097, 1456, 742 cm
-1
.  
 
3-(3-Azidopropyl)-5-methoxy-1H-indole (25b). Prepared from 23b (523 mg, 2.548 mmol) 
according to general procedure B to afford 25b (396 mg, two steps 68%) after 
chromatography as yellow oil. 
1
H NMR (CDCl3, 500 MHz): ! 2.01 (m, 2H, CH2), 2.85 (t, J = 
7.0 Hz, 2H, CH2), 3.36 (t, J = 7.0 Hz, 2H, CH2), 3.89 (s, 3H, OMe), 6.88 (dd, J = 9.0, 2.5 Hz, 
1H, CHar), 7.00 (d, J = 2.5 Hz, 1H, CHar), 7.05 (d, J = 2.0 Hz, 1H, CHar), 7.27 (d, J = 3.5 Hz, 
1H, CHar), 7.87 (s, 1H, NH); 
13
C NMR (CDCl3, 125 MHz): ! 22.1, 29.1, 50.8 (3 CH2), 55.9 
(OMe), 100.6, 111.8, 112.2, 114.7, 122.3, 127.7, 131.5, 153.9 (8 C-Ar); IR (film): ! 3415, 
2938, 2097, 1485, 1214 cm
-1
. 
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3-(3-Azidopropyl)-5-chloro-1H-indole (25c). Prepared from 23c (99.4 mg, 0.4741 mmol) 
according to general procedure B to afford 25c (86 mg, two steps 77%). 1H NMR (500 MHz, 
CDCl3) ! 1.94 (p, J = 7.0 Hz, 2H, CH2), 2.78 (t, J = 7.4 Hz, 2H, CH2), 3.28 (t, J = 6.7 Hz, 2H, 
CH2), 6.99 (d, J = 1.9 Hz, 1H, CHar), 7.12 (m, 1H, CHar), 7.22 (d, J = 3.8 Hz, 1H, CHar), 7.51 
(d, J = 1.6 Hz, 1H, CHar), 7.95 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3) ! 22.20, 29.36, 
51.03 (CH2), 112.36, 115.13, 118.57, 122.62, 123.15, 125.36, 128.67, 134.92 (C-Ar); ESI-
MS m/z calcd for C11H11ClN4 [M]
+: 234.08; found: 234.82; IR (film): ! 3435, 2929, 2098, 
1463 cm-1. 
 
3-(3-Azidopropyl)-5-fluoro-1H-indole (25d). Prepared from 23d (65.7 mg, 0.3395 mmol) 
according to general procedure B to afford 25d (54 mg, two steps 73%) after 
chromatography. 1H NMR (500 MHz, CDCl3) ! 1.83 – 1.94 (m, 2H, CH2), 2.70 (t, J = 7.4 
Hz, 2H, CH2), 3.21 (t, J = 6.7 Hz, 2H, CH2), 6.85 (td, 
3
J1,2 = 2.5 Hz, 
3
JH,F 9.0 Hz, 1H, CHar), 
6.92 (s, 1H, CHar), 7.14 (m, 2H, CHar), 7.85 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3) ! 
22.20, 29.24, 50.98 (CH2), 103.85 (d, 
2
JC,F = 23.29 Hz, C-4indole), 110.57 (d, 
2
JC,F = 26.35, C-
6indole), 111.95 (d, 
3
JC,F = 9.68 Hz, C-7indole), 115.36 (d, 
4
JC,F = 4.79 Hz, C-8indole), 123.57 
(indole), 127.86 (d, 3JC,F = 9.54 Hz, C-3indole), 133.03 (indole), 157.88 (d, 
1
JC,F = 234.40 Hz, C-
5indole); ESI-MS m/z calcd for C11H11FN4 [M]
+: 218.23; found: 218.88; IR (film): ! 3429, 
2927, 2098, 1485 cm-1. 
 
3-(3-Azidopropyl)-7-methyl-1H-indole (25e). Prepared from 23e (82 mg, 0.4333 mmol) 
according to general procedure B to afford 25e (64 mg, two steps 70%) after 
chromatography. 1H NMR (500 MHz, CDCl3) ! 1.96 – 2.08 (m, 2H, CH2), 2.49 (s, 3H, CH3), 
2.88 (t, J = 7.3 Hz, 2H, CH2), 3.33 (t, J = 6.7 Hz, 2H, CH2), 6.97 – 7.05 (m, 2H, CHar), 7.08 
(td, J = 2.0, 7.4 Hz, 1H, CHar), 7.47 (d, J = 7.8 Hz, 1H, CHar), 7.86 (s, 1H, NH); 
13C NMR 
(126 MHz, CDCl3) ! 16.74 (CH3), 22.44, 29.45, 51.09 (CH2), 115.72, 116.72, 119.77, 
120.54, 121.49, 122.79, 127.04, 136.16 (C-Ar); ESI-MS m/z calcd for C12H14N4 [M]
+: 214.12; 
found: 214.88; IR (film): ! 3418, 2930, 2097 cm-1. 
 
3-(3-Azidopropyl)-6-chloro-1H-indole (25f). Prepared from 23f (43 mg, 0.2051 mmol) 
according to general procedure B to afford 25f (35 mg, two steps 75%) after chromatography. 
1H NMR (500 MHz, CDCl3) ! 2.00 – 2.14 (m, 2H, CH2), 3.10 (t, J = 7.5 Hz, 2H, CH2), 3.37 
(t, J = 6.8 Hz, 2H, CH2), 7.03 (d, J = 1.9 Hz, 1H, CHar), 7.09 – 7.15 (m, 2H, CHar), 7.24 – 
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7.31 (m, 1H, CHar), 8.07 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3) ! 23.53, 30.86, 51.06 
(CH2), 110.13, 115.82, 120.66, 122.80, 123.31, 124.27, 126.56, 138.11 (C-Ar); ESI-MS m/z 
calcd for C11H11ClN4 [M]
+: 234.08; found: 234.81; IR (film): ! 3429, 2929, 2097, 1437 cm-1. 
 
3-(3-Azidopropyl)-5-isopropyl-1H-indole (25g). Prepared from 23g (152 mg, 0.6995 mmol) 
according to general procedure B to afford 25g (144 mg, two steps 85%) after 
chromatography. 1H NMR (500 MHz, CDCl3) ! 1.32 (d, J = 6.9 Hz, 6H, CH3), 2.01 (p, J = 
6.9 Hz, 2H, CH2), 2.86 (t, J = 7.3 Hz, 2H, CH2), 3.03 (hept, J = 6.9 Hz, 1H, CH), 3.34 (t, J = 
6.8 Hz, 2H, CH2), 6.95 (s, 1H, CHar), 7.11 (dd, J = 1.5, 8.4 Hz, 1H, CHar), 7.28 (d, J = 8.4 Hz, 
1H, CHar), 7.42 (s, 1H, Indole), 7.83 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3) ! 22.31 
(CH2), 24.92 (2C, CH3), 29.41 (CH2), 34.49 (CH), 51.14 (CH2), 111.14, 115.03, 115.87, 
121.47, 121.91, 127.57, 135.17, 140.31 (C-Ar); ESI-MS m/z calcd for C14H18N4 [M]
+: 242.15; 
found: 242.07; IR (film): ! 3412, 2957, 2096 cm-1. 
 
3-(3-Azidopropyl)-5,6-cyclopropyl-1H-indole (25h). Prepared from 23h (36 mg, 0.1672 
mmol) according to general procedure B to afford 25h (10 mg, two steps 25%) after 
chromatography. 1H NMR (500 MHz, CDCl3) ! 1.98 (p, J = 7.0 Hz, 2H, CH2), 2.12 (dq, J = 
7.3, 14.6 Hz, 2H, CH2
cyc), 2.82 (t, J = 7.3 Hz, 2H, CH2), 2.98 (td, J = 2.1, 7.2 Hz, 4H, 2 
CH2
cyc), 3.31 (t, J = 6.8 Hz, 2H, CH2), 6.90 (d, J = 2.1 Hz, 1H, CHar), 7.18 (s, 1H, CHar), 7.40 
(s, 1H, CHar), 7.75 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3) ! 22.44 (CH2), 26.86 (CH2
cyc), 
29.44 (CH2), 32.67, 33.05 (CH2
cyc), 51.12 (CH2), 106.73, 113.76, 114.70, 121.25, 126.67, 
136.19, 136.25, 139.48 (C-Ar); ESI-MS m/z calcd for C14H16N4 [M]
+: 240.13; found: 240.96; 
IR (film): ! 3401, 2934, 2094, 1646 cm-1. 
 
3-(3-Azidopropyl)-7-chloro-1H-indole (25i). Prepared from 23i (80 mg, 0.3816 mmol) 
according to general procedure B to afford 25i (10 mg, two steps 16%) after chromatography. 
1H NMR (500 MHz, CDCl3) ! 1.91 – 2.02 (m, 2H, CH2), 2.84 (t, J = 7.4 Hz, 2H, CH2), 3.31 
(t, J = 6.7 Hz, 2H, CH2), 7.04 (t, J = 7.8 Hz, 2H, CHar), 7.18 (d, J = 7.6 Hz, 1H, CHar), 7.48 
(d, J = 7.9 Hz, 1H, CHar), 8.17 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3) ! 22.40, 29.44, 
51.01 (CH2), 116.46, 116.91, 117.67, 120.36, 121.66, 122.38, 129.02, 133.85 (C-Ar); ESI-
MS m/z calcd for C11H12ClN4 [M+H]
+: 235.08; found: 235.82; IR (film): ! 3427, 2925, 2098, 
1437 cm-1. 
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3-(5-cyano-1H-indol-3-yl)propyl acetate (26j). To a mixture of  3,4 dihydro-2H-pyran (242 
µL, 2.65 mmol) in AcOH (6 mL) and HCl conc. (2 mL) at rt 22j (150 mg, 0.8833 mmol) was 
added and the reaction mixture was stirred for 3 h at 100°C. After cooling to rt the reaction 
mixture was diluted in ethyl acetate (50 mL) and washed with water (40 mL) and brine (40 
mL). The aqueous layers were extracted with ethyl acetate (40 mL) and the combined organic 
layers were dried over Na2SO4, filtered and evaporated to dryness. Chromatography 
(petroleum ether/ ethyl acetate 2:1) of the residue gave pure 26j (66 mg, 32%). 1H NMR (500 
MHz, CDCl3) ! 1.97 – 2.10 (m, 2H, CH2), 2.06 (s, 3H, CH3), 2.82 (t, J = 7.4 Hz, 2H, CH2), 
4.11 (t, J = 6.5 Hz, 2H, CH2), 7.11 (m, 1H, CHar), 7.39 (s, 2H, CHar), 7.92 (s, 1H, CHar), 8.40 
(s, 1H, NH); 13C NMR (126 MHz, CDCl3) ! 21.14, 21.17 (CH2, CH3), 44.34 (CH2), 63.92 
(CH2), 102.54, 112.22, 116.56, 121.00, 123,73, 124.73, 125.12, 127.48, 138.21 (C-Ar, CN) 
171.39 (C=O); ESI-MS m/z calcd for C14H14NaN2O2 [M+Na]
+: 265.09; found: 264.92; IR 
(film): ! 3343, 2924, 2219, 1734, 1246 cm-1. 
 
3-(5-methylsulfonyl-1H-indol-3-yl)propyl acetate (26k). Prepared from 22k (150 mg, 
0.5926 mmol) according to procedure for compound 26j to afford 26k (65 mg, 37%). 1H 
NMR (500 MHz, CD3OD) ! 2.00 – 2.09 (m, 2H, CH2), 2.05 (s, 3H, CH3), 2.90 (t, J = 7.4 Hz, 
2H, CH2), 3.11 (s, 3H, CH3), 4.10 (t, J = 6.4 Hz, 2H, CH2), 7.27 (s, 1H, CHar), 7.54 (d, J = 8.5 
Hz, 1H, CHar), 7.65 (dd, J = 1.8, 8.6 Hz, 1H, CHar), 8.17 (d, J = 1.5 Hz, 1H, CHar). 
13C NMR 
(126 MHz, CD3OD) ! 21.00 (CH3), 22.14, 30.66 (CH2), 45.46 (CH3), 65.17 (CH2), 113.19, 
117.57, 120.36, 120.83, 126.31, 128.60, 131.77, 140.62 (C-Ar), 173.31 (C=O). ESI-MS m/z 
calcd for C14H17NaNO4S [M+Na]
+: 318.08; found: 318.02. 
 
3-(5-cyano-1H-indol-3-yl)propan-1-ol (23j). To a mixture of 26j (80 mg, 0.3302 mmol) in 
MeOH (2 mL)  an equivalent freshly prepared NaOMe was added. After 2 h the reaction 
mixture was neutralized with AcOH and evaporated to dryness. Chromatography (petroleum 
ether/ethyl acetate 3:2) of the residue gave 23j (18 mg, 27%). 1H NMR (500 MHz, CDCl3) ! 
1.92 – 1.99 (m, 2H, CH2), 2.84 (t, J = 7.5 Hz, 2H, CH2), 3.71 (t, J = 6.3 Hz, 2H, CH2), 7.10 
(s, 1H, CHar), 7.38 (d, J = 0.8 Hz, 2H, CHar), 7.93 (s, 1H, CHar), 8.49 (s, 1H, NH); 
13C NMR 
(126 MHz, CDCl3) ! 21.22, 33.01, 62.45 (CH2), 102.39, 112.19, 117.24, 121.11, 123.64, 
124.89, 125.07, 127.62, 138.22 (CN, C-Ar); ESI-MS m/z calcd for C12H12NaN2O [M+Na]
+: 
223.08; found: 222.81; IR (film): ! 3339, 2932, 2220, 1472, 1056 cm-1. 
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3-(5-methylsulfonyl-1H-indol-3-yl)propan-1-ol (23k). Prepared from 26k (102 mg, 0.3454 
mmol) according to procedure for compound 23j to afford 23k (37 mg, 42%). 1H NMR (500 
MHz, CDCl3) ! 1.90 – 2.01 (m, 2H, CH2), 2.88 (t, J = 7.5 Hz, 2H, CH2), 3.07 (s, 3H, CH3), 
3.72 (t, J = 6.3 Hz, 2H, CH2), 7.15 (s, 1H, CHar), 7.46 (d, J = 8.5 Hz, 1H, CHar), 7.70 (dd, J = 
1.7, 8.5 Hz, 1H, CHar), 8.24 (d, J = 1.6 Hz, 1H, CHar), 8.35 (s, 1H, NH); 
13C NMR (126 MHz, 
CDCl3) ! 21.05, 32.92 (CH2), 45.24 (CH3), 61.78 (CH2), 112.06, 117.26, 119.61, 119.74, 
124.47, 127.24, 130.08, 138.97 (C-Ar); ESI-MS m/z calcd for C12H15NaNO3S [M+Na]
+: 
276.06; found: 275.93.  
 
3-(3-Azidopropyl)-5-cyano-1H-indole (25j). Prepared from 23j (30 mg, 0.1498 mmol) 
according to general procedure B to afford 25j (25 mg, two steps 70%) after chromatography. 
1H NMR (500 MHz, CDCl3) ! 1.90 – 2.01 (m, 2H, CH2), 2.84 (t, J = 7.4 Hz, 2H, CH2), 3.32 
(t, J = 6.7 Hz, 2H, CH2), 7.12 (d, J = 2.0 Hz, 1H, CHar), 7.33 – 7.56 (m, 2H, CHar), 7.92 (s, 
1H, CHar), 8.47 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3) ! 22.00, 29.34, 50.92 (CH2), 
102.51, 112.30, 116.21, 121.03, 123.93, 124.72, 125.16, 127.42, 138.23 (CN, C-Ar); ESI-MS 
m/z calcd for C12H11NaN5 [M+Na]
+: 248.09; found: 247.89; IR (film): ! 3333, 2926, 2217, 
2093 cm-1. 
 
3-(3-Azidopropyl)-5-methylsulfonyl-1H-indole (25k). Prepared from 23k (37 mg, 0.1462 
mmol) according to general procedure B to afford 25k (22 mg, two steps 55%) after 
chromatography. 1H NMR (500 MHz, CDCl3) ! 1.91 – 2.02 (m, 2H, CH2), 2.85 (t, J = 7.4 
Hz, 2H, CH2), 3.08 (s, 3H, CH3), 3.30 (t, J = 6.7 Hz, 2H, CH2), 7.14 (d, J = 2.1 Hz, 1H, 
Indole), 7.46 (d, J = 8.6 Hz, 1H, CHar), 7.68 (dd, J = 1.7, 8.6 Hz, 1H, CHar), 8.20 (d, J = 1.5 
Hz, 1H, CHar), 8.68 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3) ! 22.02, 29.36 (CH2), 45.47 
(CH3), 50.93 (CH2), 112.21, 116.89, 119.82, 120.57, 124.43, 127.25, 131.30, 138.89 (C-Ar); 
ESI-MS m/z calcd for C12H14NaN4O2S [M+Na]
+: 301.07; found: 300.99; IR (film): ! 3351, 
2925, 2098, 1293, 1142 cm-1. 
 
3-(1H-indol-3-yl)propyl acetate (27). To a solution of 23a  (3.90 g, 22.3 mmol) and DMAP 
(133 mg, 1.1 mmol) in pyridine (30 mL), Ac2O (20 mL) was added and the reaction mixture 
was stirred at rt overnight. The solvent was co-evaporated with toluene and the residue 
purified by chromatography (petroleum ether/ethyl acetate, 6:1 to 4:1) to yield 27 (4.44 g, 
92%) as a colourless solid. Analytic data were in accordance with published data. 
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3-(1-Tosyl-1H-indol-3-yl)propyl acetate (28). To an ice-cold slurry of NaH (60%, 1.31 g, 
32.7 mmol) in THF (5 mL) a solution of 27 (2.34 g, 10.8 mmol) in THF (15 mL) was added. 
After stirring for 1 h at 0 °C, tosyl chloride (6.15 g, 32.3 mmol) was added over a period of 1 
h in three portions and the reaction mixture was stirred for another 2 h at 0 °C. After 
quenching by adding aq. NH4Cl (10 mL) the mixture was transferred into a separation funnel, 
diluted with ethyl acetate (100 mL) and washed with aq. NH4Cl (100 mL) and water (100 
mL). The aqueous layers were extracted with ethyl acetate (100 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified 
by chromatography (toluene/ethyl acetate, 1:0 to 2:1) to yield 28 (2.81 g, 70 %) as colourless 
oil. 
1
H NMR (CDCl3, 500 MHz): ! 2.01 (m, 2H, CH2), 2.05 (s, 3H, OAc), 2.33 (s, 3H, CH3), 
2.74 (t, J = 7.5 Hz, 2H, CH2), 4.10 (t, J = 6.4 Hz, 2H, CH2), 7.20 - 7.26 (m, 3H, CHar), 7.29-
7.34 (m, 2H, CHar), 7.46 (m, 1H, CHar), 7.74 (m, 1H, CHar), 7.98 (m, 1H, CHar); 
13
C-NMR 
(CDCl3, 125 MHz): ! 20.9 (OAc), 21.4 (CH2), 21.5 (CH3), 27.9 (CH2), 63.7 (CH2), 113.8, 
119.3, 122.0 (C-3), 122.9 (C-2), 123.0, 124.6, 126.7, 129.8, 130.8, 135.3, 135.4, 144.7 (C-
Ar), 171.1 (CO).  
 
3-((6-Cyclopropanecarbonyl)-1H-indol-3-yl)propan-1-ol (23l). To an ice-cold solution of 
28 (302 mg, 0.80 mmol) in nitromethane (6 mL), cyclopropanecarbonyl chloride (340 !L, 3.7 
mmol) and AlCl3 (545 mg, 4.1 mmol) were added. After stirring for 1.5 h at 0 °C, the 
reaction mixture was quenched by addition of water (10 mL). The mixture was transferred 
into a separation funnel, diluted with ethyl acetate (40 mL) and subsequently washed with 
water (40 mL) and brine (40 mL). The aqueous layers were extracted with ethyl acetate (40 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was redissolved in methanol (5 mL) and treated with aqueous 
solution of NaOH (6 M, 5 mL). After refluxing for 1 h, the mixture was transferred into a 
separation funnel with CH2Cl2 (40 mL), neutralized with aq. HCl and extracted with water (2 
" 40 mL). The organic layers were extracted with CH2Cl2 (2 " 40 mL). The combined 
organic layers were dried over Na2SO4, filtered and evaporated to dryness. The residue was 
purified by chromatography (toluene/ethyl acetate, 2:1 to 1:2) to yield a inseparable mixture 
of 3-((5-cyclopropanecarbonyl)-1H-indol-3-yl)propan-1-ol and 23l (121.2 mg, 61%) as a 
white solid. The mixture was reacted further and separation was accomplished in the next 
step. 
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3-((6-(4-Chlorophenylcarbonyl))-1H-indol-3-yl)propan-1-ol (23m). To an ice-cold 
solution of 28 (408 mg, 1.10 mmol) in nitromethane (12 mL), 4-chlorobenzoyl chloride (560 
!L, 4.40 mmol) and AlCl3 (732 mg, 5.50 mmol) were added. After stirring for 2 h at 0 °C, 
the reaction mixture was quenched by addition of water (10 mL). The mixture was 
transferred into a separation funnel, diluted with ethyl acetate (40 mL) and subsequently 
washed with water (40 mL) and brine (40 mL). The aqueous layers were extracted with ethyl 
acetate (40 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was redissolved in methanol (8 mL) and 
treated with aq. NaOH (6 M, 8 mL). After stirring for 1.5 h at rt, the mixture was neutralized 
with aq. HCl, transferred into a separation funnel with CH2Cl2 (40 mL), and extracted with 
water (2 ! 40 mL). The organic layers were extracted with CH2Cl2 (40 mL). The combined 
organic layers were dried over Na2SO4, filtered and evaporated to dryness. The residue was 
purified by chromatography (toluene/CH2Cl2/i-propanol, 25:5:1 to 4:5:1) to yield a 
inseparable mixture of 3-((5-(4-chlorophenylcarbonyl))-1H-indol-3-yl)propan-1-ol and 23m 
(163 mg, 47%). The mixture was reacted further and separation was accomplished in the next 
step. 
 
3-(3-Azidopropyl)-6-cyclopropanecarbonyl-1H-indole (25l). The mixture of 23l and 3-((5-
cyclopropanecarbonyl)-1H-indol-3-yl)propan-1-ol (112.0 mg, 0.460 mmol), CBr4 (231 mg, 
0.70 mmol) and triphenylphosphine (145 mg, 0.55 mmol) in dry DMF (1 mL) was shaking in 
an eppendorf tube (2 mL) at 50 °C and 900 rpm for 30 min. NaN3 (60.0 mg, 0.923 mmol) 
was added and the reaction mixture was allowed to be shaken overnight at 50 °C. The 
reaction was quenched by addition of a few drops of water and directly purified by LC-MS to 
yield 25l (44.4 mg, 36%) and 3-(3-azidopropyl)-5-cyclopropanecarbonyl-1H-indole (15 mg, 
12%) as colourless solids. 
1
H NMR (500 MHz, CDCl3): " 0.93 – 1.10 (m, 2H, CH2) 1.21 – 
1.32 (m, 2H, CH2), 2.01 (p, J = 7.0 Hz, 2H, CH2), 2.72 – 2.80 (m, 1H, CH), 2.89 (t, J = 7.4 
Hz, 2H, CH2), 3.34 (t, J = 6.7 Hz, 2H, CH2), 7.20 (d, J = 1.9 Hz, 1H, CHar), 7.65 (d, J = 8.4 
Hz, 1H CHar), 7.75 – 7.90 (m, 1H CHar), 8.10 (s, 1H, CHar), 8.25 (s, 1H, NH); 
13
C NMR (125 
MHz, CDCl3): " 11.3 (CH2), 17.1 (CH), 22.0, 29.3, 50.8 (3 CH2), 111.9, 115.5, 118.4, 119.5, 
125.3, 130.8, 132.4, 135.9 (8 C-Ar), 200.6 (CO).  
 
3-(3-Azidopropyl)-6-(4-chlorophenylcarbonyl)-1H-indole (25m). The mixture of 23m and 
3-((5-(4-chlorophenylcarbonyl))-1H-indol-3-yl)propan-1-ol (104 mg, 0.33 mmol), CBr4 (165 
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mg, 0.50 mmol) and triphenylphosphine (106 mg, 0.40 mmol) in dry DMF (1 mL) was 
shaken in an eppendorf tube (2 mL) at 50 °C and 900 rpm for 15 min. NaN3 (44 mg, 0.68 
mmol) was added and the reaction mixture was allowed to be shaken overnight at 50 °C. The 
reaction was quenched by addition of a few drops of water and directly purified by LC-MS to 
yield 3-(3-azidopropyl)-6-(4-chlorophenylcarbonyl)-1H-indole (4.5 mg, 4%) and 25m (42 
mg, 37%) as yellow solids.  
 
3-(3-(tButyldimethylsilyl)oxy)propyl-5-trifluoromethyl-2-trimethylsilyl-1H-indole (31o). 
A mixture of 29o (1.2 g, 4.2 mmol), 30[17] (2.3 g, 8.4 mmol), potassium acetate (2.1 g, 21.0 
mmol), lithium chloride (178 mg, 4.2 mmol) and palladium(II) acetate (77 mg, 0.42 mmol) in 
dry DMF ( 10 mL) was heated at 70 - 75 °C under argon for 2.5 h. After cooling to rt, the 
reaction mixture was diluted with ether and ice-water, the aqueous layer was separated and 
extracted with ethyl acetate (50 mL). The combined organic layers were washed with water 
(50 mL) and brine (50 mL), dried over Na2SO4 and evaporated. The residue was purified by 
chromatography (petroleum ether/ethyl acetate 8:1) to give 31o (1.7 g, 89%) after 
chromatography as a yellow oil.1 H NMR (CDCl3, 500 MHz): ! 0.12 (s, 6H, 2CH3), 0.43 (s, 
9H, 3CH3), 0.97 (s, 9H, C(CH3)3), 1.89 (m, 2H, CH2), 2.95 (m, 2H, CH2), 3.77 (t, J = 6.0 Hz, 
2H, CH2), 7.42 (m, 2H, CHar), 7.92 (s, 1H, CHar), 8.06 (s, 1H, NH); 
13C NMR (CDCl3, 125 
MHz): ! -5.3 (CH3), -0.7 (CH3), 18.4 (C(CH3)), 22.4 (CH2)?, 35.2 (), 62.9 (CH2), 107.1, 
111.0, 116.7 (q, J = 4.25 Hz), 118.9 (q, J = 3.25 Hz), 126.4, 128.2, 135.1, 139.4. 
 
3-(5-Trifluoromethyl-1H-indol-3-yl)propan-1-ol (23o). To a solution of 31o (1.7 g, 4.0 
mmol) in MeCN (20 mL) was added sequentially 48% HF (2 mL) and stirred at rt. for 48 h. 
The mixture was then cautiously basified with satd aq. Na2CO3 and extracted with ethyl 
acetate. The organic extract was washed with brine, dried over Na2SO4 and evaporated to 
give a viscous solid. Purification by chromatography (petroleum ether/ ethyl acetate 1:1) gave 
23o (671 mg, 65%) after chromatography as yellow oil.1 H NMR (CDCl3, 500 MHz): ! 2.01 
(m, 2H, CH2),
 2.89 (t, J = 7.5 Hz, 2H, CH2), 3.75 (t, J = 6.5 Hz, 2H, CH2), 7.11 (t, J = 1.0 Hz, 
1H, CHar), 7.42 (d, J = 1.5 Hz, 2H, CHar), 7.90 (s, 1H, CHar), 8.17 (s, 1H, NH);
 13C NMR 
(CDCl3, 125 MHz): ! 21.1, 32.8, 62.4 (3 CH2), 111.3, 116.6 (q, J = 4.3 Hz), 117.1, 118.8 (q, 
J = 3.5 Hz), 121.7 (q, J = 31.8 Hz), 122.9, 126.5, 126.9, 137.6.  
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3-(3-Azidopropyl)-5-trifluoromethyl-1H-indole (25o). Prepared from 23o (607 mg, 2.50 
mmol) according to general procedure B to afford 25o (533 mg, two steps 80%) after 
chromatography as yellow oil. 
1 
H NMR (CDCl3, 500 MHz): ! 2.02 (m, 2H, CH2), 2.90 (t, J = 
7.5 Hz, 2H, CH2), 3.36 (t, J = 6.5 Hz, 2H, CH2), 7.12 (d, J = 2.0 Hz, 1H, CHar), 7.44 (m, 2H, 
CHar), 7.89 (s, 1H, CHar), 8.17 (s, 1H, NH); 
13
C NMR (CDCl3, 125 MHz): ! 21.9, 29.1, 50.8 
(3 CH2), 111.4, 116.1, 116.5 (q, J = 4.3 Hz), 118.9 (q, J = 3.5 Hz), 121.9 (q, J = 31.5 Hz), 
123.1, 124.3, 126.7, 137.6. IR (film): ! 3440, 2940, 2101, 1432, 1329, 1111 cm
-1
. 
 
3-(3-Azidopropyl)-1-methyl-5-nitro-1H-indole (32). To a stirred solution of 25n[
17] (48.5 
mg, 198 "mol) in DMF (2 mL), powdered KOH (112 mg, 2.00 mmol) was added. 
Iodomethane (125 "L, 2.00 mmol) was added drop-wise and the reaction was stirred at rt for 
2 h. The reaction mixture was quenched by addition of water (2 mL), transferred into a 
separation funnel with CH2Cl2 (20 mL) and extracted with water (2 " 20 mL). The aqueous 
layers were extracted with CH2Cl2 (20 mL). The combined organic layers were dried over 
Na2SO4, filtered and co-evaporated with toluene to dryness. The residue was purified by 
chromatography (petroleum ether/ethyl acetate, 9:1 to 1:1) to yield 32 (48 mg, 94%) as an 
yellow oil. 
1
H NMR (500 MHz, CDCl3) ! 1.87 – 2.08 (m, 2H, CH2), 2.88 (t, J = 7.4 Hz, 2H, 
CH2), 3.35 (t, J = 6.7 Hz, 2H, CH2), 3.81 (s, 3H, CH3), 7.01 (s, 1H, CHar), 7.31 (t, J = 9.5 Hz, 
1H, CHar), 8.13 (dd, J = 2.2, 9.0 Hz, 1H, CHar), 8.55 (d, J = 2.1 Hz, 1H, CHar). 
13
C NMR 
(125 MHz, CDCl3) ! 21.8, 29.4, 33.2 (3 CH2), 50.7 (CH3), 109.2, 116.4, 117.5, 129.5 (8C, C-
Ar).  
 
3-(3-Azidopropyl)-1-ethyl-5-nitro-1H-indole (33). To a stirred solution of 25n (56.0 mg, 
0.23 mmol) in DMF (2 mL), powdered KOH (129 mg, 2.30 mmol) was added. Iodoethane 
(185 "L, 2.30 mmol) was added drop-wise and the reaction mixture was stirred at rt for 2 h. 
The reaction was quenched by addition of water (2 mL), transferred into a separation funnel 
with CH2Cl2 (20 mL) and extracted with water (2 " 20 mL). The aqueous layers were 
extracted with CH2Cl2 (20 mL). The combined organic layers were dried over Na2SO4, 
filtered and co-evaporated with toluene to dryness. The residue was purified by 
chromatography (petroleum ether/ethyl acetate, 1:0 to 3:1) to yield 33 (57 mg, 92%) as an 
yellow oil. 
1
H NMR (500 MHz, CDCl3): # 1.48 (t, J = 7.3 Hz, 3H, CH3), 1.96 – 2.04 (m, 2H, 
CH2), 2.88 (t, J = 7.5 Hz, 2H, CH2), 3.35 (t, J = 6.7 Hz, 2H, CH2), 4.18 (q, J = 7.3 Hz, 2H, 
CH2), 7.07 (s, 1H, CHar), 7.32 (d, J = 9.1 Hz, 1H, CHar), 8.11 (dd, J = 2.2, 9.1 Hz, 1H, CHar), 
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8.54 (d, J = 2.1 Hz, 1H, CHar); 
13
C NMR (125 MHz, CDCl3): ! 15.4 (CH3), 21.9, 29.4, 41.4, 
50.8 (4 CH2), 109.1, 116.5, 117.3, 127.7 (8C, C-Ar).  
 
Methyl [2-propynyl 4,7,8-tri-O-acetyl-9-azido-5-
t
butyrylcarbamat-3,5,9-trideoxy-D-
glycero-"-D-galacto-2-nonulo-pyranosid]onate (35). Compound 34[
17] (39.0 mg, 80 !mol) 
was reacted with Boc-anhydride (33 mg, 0.15 mmol) and DMAP (2.5 mg, 20 !mol) at 50 °C 
for 5 h. After addition of N2H4#H2O (24 !L, 0.49 mmol), stirring was continued for 16 h. The 
mixture was diluted with CHCl3 (20 mL) and washed successively with 1 M aq. HCl (5.0 
mL), 0.5 M aq. CuSO4 (5.0 mL) and satd aq. NaHCO3 (3 $ 10 mL). The organic layer was 
dried over Na2SO4, filtererd and concentrated under reduced pressure to give an yellow oil. 
The crude product was reacted further in dry pyridine (1.0 mL) with acetic anhydride (0.5 
mL) for 3 h at rt. The reaction mixture was diluted with CHCl3 (10.0 mL) and washed with 
0.5 M aq CuSO4 (3 $ 3 mL) and sat. aq. NaHCO3 (3 $ 5 mL). The organic layer was dried 
over Na2SO4, filtered and the solvent was evaporated. The crude product was purified by 
chromatography (petroleum ether/ethyl acetate 1:1) to yield 35 (14 mg, 34%) as a white 
foam. 
1
H NMR (500 MHz, CD3OD): ! 1.40 (s, 9H, C(CH3)3), 1.77 (t, J = 12.4 Hz, 1H, H-3a), 
2.00, 2.13, 2.16 (3s, 9H, 3OAc), 2.67 (dd, J = 4.7, 12.6 Hz, 1H, H-3b), 2.86 (t, J = 2.4 Hz, 
1H, C%CH), 3.35 (dd, J = 6.0, 13.5 Hz, 1H, H-9a), 3.56 – 3.70 (m, 2H, H-5, H-9b), 3.83 (s, 
3H, OMe), 4.03 (dd, J = 2.0, 10.7 Hz, 1H, H-6), 4.19, 4.35 (A, B of AB, J = 2.5, 15.8 Hz, 2H, 
H-1’), 4.79 (ddd, J = 4.7, 10.4, 12.0 Hz, 1H, H-4), 5.30 – 5.41 (m, 2H, H-7, H-8). 
13
C NMR 
(CD3OD, 125 MHz): ! 20.8, 20.9, 21.2 (3 OAc), 28.7 (C(CH3)3), 39.0 (C-3), 51.4 (C-5), 52.2 
(C-9), 53.4 (OMe), 53.5 (C-1’), 69.5 (C-7), 70.8 (2C, C-4, C-8), 73.8 (C-6), 75.8 (C%CH), 
80.1 (C%CH), 80.6 (C(CH3)3), 99.4 (C-2), 157.7 (CONH), 169.1, 171.5, 171.7, 171.8 (4 CO). 
ESI-MS calcd. for C29H33Cl2F2NaN2O9 [M+Na]
+
: 593.21; Found 593.26. 
 
Methyl [2-propynyl 4,7,8-tri-O-acetyl-5-amino-9-azido-3,5,9-trideoxy-D-glycero-"-D-
galacto-2-nonulo-pyranosid] onate (36). Compound 35 (177 mg, 0.31 mmol) was dissolved 
in 4 M PhOH (5 mL, in dry DCM). After addition of 4 M TMSCl (5 mL, in dry DCM), the 
reaction mixture was stirred at rt for 2 h. After completion of the reaction, CHCl3 was added 
and the organic layer was washed with satd aq. NaHCO3 (3 $ 10 mL) and water (1 $ 10 mL). 
The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude product was purified by chromatography (ethyl acetate/petroleum ether 1:2 then 
ethyl acetate/acetone 9:1) to yield 36 as a colourless oil (98 mg, 67%). 
1
H NMR (500 MHz, 
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CD2Cl2): ! 1.63 (t, J = 12.2 Hz, 1H, H-3a), 1.97, 2.08, 2.10 (3s, 9H, 3OAc), 2.42 (t, J = 2.4 
Hz, 1H, C"CH), 2.49 (dd, J = 8.3, 10.9 Hz, 1H, H-5), 2.58 (dd, J = 4.5, 12.6 Hz, 1H, H-3b), 
3.26 (dd, J = 5.0, 13.6 Hz, 1H, H-9a), 3.57 (dd, J = 2.8, 13.6 Hz, 1H, H-9b), 3.63 (dd, J = 1.0, 
10.1 Hz, 1H, H-6), 4.04, 4.27 (dd, J = 2.5, 15.5 Hz, 1H, H-1’), 4.53 (ddd, J = 4.6, 10.0, 11.9 
Hz, 1H, H-4), 5.29 (m, 1H, H-8), 5.42 (dd, J = 1.1, 8.5 Hz, 1H, H-7); 
13
C NMR (CD2Cl2, 125 
MHz): ! 21.1, 21.3, 21.4 (3 OAc), 37.2 (C-3), 52.3 (C-9), 52.9 (C-1’), 53.2 (C-5), 53.4 
(OMe), 69.6 (2C, C-7, C-8), 71.8 (C-4), 72.1 (C"CH), 74.8 (C"CH), 75.9 (C-6), 117.2 (C-2), 
170.4, 170.8, 170.9, 171.0 (4C, CO); ESI-MS calcd. for C19H26N4NaO10 [M+Na]
+
: 493.15; 
found 493.21.  
 
Methyl [2-propynyl -4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-5-fluoroacetamido -D-
glycero-#-D-galacto-2-nonulopyranosid]onate (37). Compound 36 (130 mg, 0.27 mmol) 
was dissolved in dry THF (3 mL) and cooled to 0 °C. Fluoroacetyl chloride (60 !L, 0.83 
mmol) was added, followed by the addition of NEt3 (190 !L, 1.35 mmol). The reaction 
mixture was allowed to come to rt and stirring was continued for 24 h. DCM (10 mL) was 
added and the organic layer was washed with satd aq. NaHCO3 (3 $ 2 mL) and water (1 $ 2 
mL). The organic layer was dried over Na2SO4, filtered and the solvent removed under 
reduced pressure. The crude product was purified by chromatography (petroleum ether/ethyl 
acetate 1:1) to yield 37 (63 mg, 43%). 
1
H NMR (500 MHz, CDCl3): ! 1.98 (t, J = 12.5 Hz, 
1H, H-3a), 2.03, 2.15, 2.19 (3s, 9H, 3OAc), 2.46 (t, J = 2.1 Hz, 1H, C"CH), 2.69 (dd, J = 4.5, 
12.8 Hz, 1H, H-3b), 3.26 (dd, J = 5.4, 13.5 Hz, 1H, H-9a), 3.56 (dd, J = 2.6, 13.5 Hz, 1H, H-
9b), 3.83 (s, 3H, OMe), 4.08 – 4.20 (m, 3H, H-5, H-6, H-1’a), 4.40 (B of AB, J = 2.3, 15.6 
Hz, 1H, H-1’b), 4.57 – 4.86 (m, 2H, CH2F), 4.93 (m, 1H, H-4), 5.25 – 5.40 (m, 2H, H-7, H-
8), 6.19 (d, J = 8.6 Hz, 1H, NH); 
13
C NMR (CDCl3, 125 MHz): ! 21.0, 21.1, 21.2 (3 OAc), 
38.1 (C-3), 48.7 (C-5), 51.1 (C-9), 53.3 (2C, OMe, C-1’), 67.9 (C-4), 68.7 (C-7), 69.4 (C-8), 
72.7 (C-6), 74.8 (C"CH), 79.0 (C"CH), 79.5, 81.0 (d, J = 186 Hz, CH2F), 98.3 (C-2), 168.3, 
168.4, 170.3, 170.4, 170.9 (5 CO); ESI-MS calcd. for C21H27FNaN4O11 [M+Na]
+
: 553.15; 
found m/z 553.12.  
 
Methyl [2-propynyl 4,7,8-tri-O-acetyl-9-benzamido -3,5,9-trideoxy-5-fluoroacetamido-
D-glycero-#-D-galacto-2-nonulopyranosid]onate (38a). Compound 37 (63 mg, 0.12 mmol) 
was dissolved in dry DCE (2 mL). Benzoyl chloride (55 µL, 0.47 mmol) and 
triphenylphosphine (70 mg, 0.26 mmol) were added successively and stirring was continued 
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for 24 h. DCM (5 mL) was added and the organic layer was washed with satd aq. NaHCO3 (3 
! 2 mL) and water (1 ! 2 mL). The organic layer was dried over Na2SO4, filtered and the 
solvent removed under reduced pressure. The crude product was purified by chromatography 
(0.5% gradient of MeOH in DCM) to yield 38a (37 mg, 52%). 
1
H NMR (500 MHz, CD2Cl2): 
" 1.97 (m, 1H, H-3a) 2.08, 2.15, 2.21 (3s, 9H, 3OAc), 2.53 (t, J = 2.4 Hz, 1H, C#CH), 2.75 
(dd, J = 4.7, 12.7 Hz, 1H, H-3b), 3.08 (td, J = 4.3, 15.2 Hz, 1H, H-9a), 3.79 (s, 3H, OMe), 
4.14 – 4.33 (m, 4H, H-5, H-6, H-9b, H-1’a), 4.43 (dd, J = 2.5, 15.6 Hz, 1H, H-1’b), 4.75 (m, 
2H, CH2F), 4.99 (ddd, J = 4.7, 10.4, 12.1 Hz, 1H, H-4), 5.24 (d, J = 9.5 Hz, 1H, H-7), 5.33 
(m, 1H, H-8), 6.64 (d, J = 9.9 Hz, 1H, 5-NH), 7.04 (dd, J = 4.4, 7.4 Hz, 1H, 9-NH), 7.48 (m, 
2H, CHar), 7.58 (m, 1H, CHar), 7.69 (m, 2H, CHar); 
13
C NMR (CD2Cl2, 125 MHz): " 21.0, 
21.3, 21.4 (3 OAc), 38.2 (C-3), 38.5 (C-9), 48.9 (C-5), 53.1 (OMe), 53.3 (C-1’), 68.3 (C-7), 
68.9 (C-8), 69.1 (C-4), 72.4 (C-6), 72.8 (C#CH), 74.8 (C#CH), 79.9 (CH2F), 98.5 (C-2), 
128.9, 129.0, 132.4, 134.8 (6C, C-Ar), 167.9, 168.4, 168.6, 168.9, 170.8, 172.3 (6 CO); ESI-
MS calcd. for C28H33FNaN2O12 [M+Na]
+
: 631.19; found m/z 631.18.  
 
Methyl [2-propynyl 4,7,8-tri-O-acetyl-9-(4-chlorobenzamido) -3,5,9-trideoxy-5-
fluoroacetamido-D-glycero-$-D-galacto-2-nonulopyranosid]onate (38b) Prepared from 
37 (400 mg, 0.7531 mmol) and 4-chlorobenzoyl chloride (385 µL, 3.0124 mmol) according 
to procedure for compound 38a to afford 38b (313mg, 65%) after chromatography. [$]D
20 -
11.52 (c 1.41, DCM); 1H NMR (500 MHz, CDCl3) ! 1.96 (m, 1H, H-3a), 2.01, 2.11, 2.21 (3s, 
9H, OAc), 2.42 (t, J = 2.4 Hz, 1H, C#CH), 2.68 (dd, J = 4.6, 12.8 Hz, 1H, H-3b), 2.97 (dt, J 
= 4.0, 15.1 Hz, 1H, H-9a), 3.78 (s, 3H, OMe), 4.08 (m, 1H, H-6), 4.14 (dd, J = 2.4, 15.6 Hz, 
1H, H-1’a), 4.17 – 4.30 (m, 2H, H-9b, H-5), 4.39 (dd, J = 2.5, 15.6 Hz, 1H, H-1’b), 4.58 – 
4.79 (m, 2H, CH2F), 4.86 (m, 1H, H-4), 5.13 (dd, J = 2.2, 9.8 Hz, 1H, H-7), 5.29 (m, 1H, H-
8), 6.12 (dd, J = 3.2, 10.2 Hz, 1H, 5-NH), 6.89 (dd, J = 4.4, 8.0 Hz, 1H, 9-NH), 7.38 (d, J = 
8.5 Hz, 2H, C6H4), 7.71 (d, J = 8.5 Hz, 2H, C6H4); 
13C NMR (126 MHz, CDCl3) ! 20.98, 
21.32, 21.34 (3 OAc), 38.11 (C-3), 38.86 (C-9), 48.89 (C-5), 53.13, 53.14 (C-1’, OMe), 
67.92 (C-7), 68.37 (C-8), 68.80 (C-4), 72.26 (C-6), 74.80 (C#CH), 79.01 (C#CH), 80.21 (d, 
2
JC,F = 186 Hz, CH2F), 98.24 (C-2), 128.61, 129.04, 132.87, 137.95 (6C, C6H4), 166.58, 
167.68, 170.63, 170.86, 172.47 (6C, C=O); ESI-MS m/z calcd for C28H32ClFNaN2NaO12 
[M+Na]+: 665.14; found: 665.15.  
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Lithium [2-propynyl 9-benzamido -3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-
galacto-2-nonulopyranosid]onate (39a). Compound 38a (25 mg, 41 !mol) was dissolved in 
THF (4.5 mL) and LiOH (6.0 mg, 0.25 mmol in 0.5 mL water) was added. The reaction 
mixture was stirred at rt for 7 h. After neutralization with 7% aq. HCl the solvents were 
removed under reduced pressure and the crude product was purified by chromatography (1% 
gradient of water in DCM/MeOH 5:1) to yield 39a (15 mg, 80%). 
1
H NMR (500 MHz, 
CD3OD): " 1.59 (t, J = 11.6 Hz, 1H, H-3a), 2.70 (s, 1H, C#CH), 2.80 (dd, J = 3.6, 11.9 Hz, 
1H, H-3b), 3.42 (d, J = 8.7 Hz, 1H, H-7), 3.65 (m, 1H, H-9a), 3.68 – 3.85 (m, 4H, H-4, H-5, 
H-6, H-9b), 4.00 (m, 1H, H-8), 4.13, 4.40 (A, B of AB, J = 14.1 Hz, 2H, H-1’), 4.78 (m, 2H, 
CH2F), 7.41 (t, J = 7.3 Hz, 2H, CHar), 7.48 (t, J = 7.1 Hz, 1H, CHar), 7.80 (d, J = 7.6 Hz, 2H, 
CHar); 
13
C NMR (CD3OD, 125 MHz): " 42.2 (C-3), 44.3 (C-9), 53.2 (C-1’), 53.7 (C-5), 69.2 
(C-4), 71.6 (C-8), 72.1 (C-7), 73.8 (C-6), 75.0 (C#CH), 80.2, 81.7 (d, J = 181 Hz, CH2F), 
81.0 (C#CH), 101.7 (C-2), 128.4, 129.6, 132.7, 135.6 (6C, C-Ar), 172.0, 178.5 (2 CO); ESI-
MS calcd. for C21H24FN2O9 [M-H]
-
: 467.15; found m/z 467.23.  
 
Lithium [2-propynyl 9-(4-chlorobenzamido) -3,5,9-trideoxy-5-fluoroacetamido -D-
glycero-!-D-galacto-2-nonulopyranosid]onate (39b) Prepared from 38b (313mg, 0.4868) 
according to procedure for compound 39a to afford 39b (123 mg, 50%) as a white solid. 
[!]D
20 -17.43 (c 1.100, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.64 (t, J = 11.8 Hz, 1H, H-
3a), 2.72 (t, J = 2.4 Hz, 1H, C#CH), 2.85 (dd, J = 4.5, 12.3 Hz, 1H, H-3b), 3.45 (dd, J = 1.4, 
8.9 Hz, 1H, H-7), 3.52 (m, 1H, H-9a), 3.73 – 3.92 (m, 4H, H-9b, H-4, H-5, H-6), 4.04 (td, J = 
3.0, 8.4 Hz, 1H, H-8), 4.18 (dd, J = 2.3, 15.0 Hz, 1H, H-1’a), 4.44 (dd, J = 2.4, 15.0 Hz, 1H, 
H-1’b), 4.83 (d, J = 46.9 Hz, 2H, CH2F), 7.46 (d, J = 8.5 Hz, 2H, C6H4), 7.82 (d, J = 8.5 Hz, 
2H, C6H4), 8.35 (d, J = 5.1 Hz, 1H, NH); 
13C NMR (126 MHz, CD3OD) ! 42.42 (C-3), 44.63 
(C-9), 53.33 (C-1’), 53.73 (C-5), 69.45 (C-4), 71.56 (C-8), 72.33 (C-7), 73.95 (C-6), 75.09 
(C#CH), 81.09 (d, 2JC,F = 183.3 Hz, CH2F), 81.14 (C#CH), 129.82, 130.23, 134.56, 138.78 
(6C, C6H4), 169.53, 172.18, 172.32 (C=O); ESI-MS m/z calcd for C21H24ClFNaN2NaO9 
[M+Na]+: 525.10; found: 525.04. 
 
Sodium [3-(1-methyl-5-nitro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 5-
acetamido -9-benzamido-3,5,9-trideoxy-D-glycero-!-D-galacto-2-nonulopyranosid]onate 
(2). Prepared from 21[
17]  (10 mg, 20 !mol) and 32 (6.5 mg, 30 !mol) according to general 
procedure C to afford 2 (12.3 mg, 80%) after chromatography as a yellow solid. [!]D
20
 –19.8 
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(c 0.30, MeOH); 
1
H NMR (CD3OD, 500 MHz): ! 1.62 (t, J = 11.5 Hz, 1H, H-3a), 2.0 (s, 3H, 
NHAc), 2.30 (m, 2H, H-2”), 2.80 (t, J = 7.0 Hz, 2H, H-3”), 2.88 (dd, J = 11.5, 3.0 Hz, 1H, H-
3b), 3.43 (d, J = 9.0 Hz, 1H, H-7), 3.48 (dd, 1H, J = 13.5, 8.0 Hz, H-9a), 3.66 (d, J = 9.0 Hz, 
1H, H-6), 3.82 (s, 3H, NCH3), 3.81 - 3.71 (m, 3H, H-4, H-5, H-9b), 4.03 (dt, J = 8.5, 2.5 Hz, 
1H, H-8), 4.43 (t, J = 7.0 Hz, 2H, H-1”), 4.67, 4.94 (d, J = 12.5 Hz, 2H, H-1’), 7.20 (s, 1H, 
CHar), 7.50 - 7.40 (m, 4H, CHar), 7.80 (d, J = 8.0 Hz, 2H, CHar), 7.96 (s, 1H, triazole-H), 8.06 
(dd, J = 4.0, 1.5 Hz, 1H, CHar), 8.48 (d, J = 1.5 Hz, 1H, CHar); 
13
C NMR (CD3OD, 125 
MHz): ! 22.5 (OAc), 22.6 (C-3”), 31.6 (C-2”), 33.2 (NCH3), 42.6 (C-3), 44.6 (C-9), 50.8 (C-
1”), 54.0 (C-5), 59.0 (C-1’), 69.6 (C-4), 71.3 (C-8), 72.5 (C-7), 74.4 (C-6), 102.0 (C-2), 
110.6, 116.8, 117.3, 117.9, 125.4, 128.3, 131.6, 132.1, 135.8, 141.3, 142.2, 146.9 (16C, C-
Ar), 170.3, 174.1, 175.4 (3 CO). HRMS calcd. for C33H38N7Na2O11 [M+Na]
+
: 754.2419; 
Found 754.2419. 
 
Sodium [3-(1-ethyl-5-nitro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 5-acetamido 
-9-benzamido-3,5,9-trideoxy-D-glycero-!-D-galacto-2-nonulopyranosid]onate (3). 
Prepared from 21 (10 mg, 20 "mol) and 33 (6.8 mg, 30 "mol) according to general procedure 
C to afford 3 (11 mg, 71%) after chromatography as a yellow solid. [!]D
20
 –18.94 (c 0.27, 
MeOH); 
1
H NMR (CD3OD, 500 MHz): ! 1.43 (t, J = 7.5 Hz, 3H, NCH2CH3),
 
1.62 (t, J = 
11.5 Hz, 1H, H-3a), 2.0 (s, 3H, NHAc), 2.32 (m, 2H, H-2”), 2.81 (t, J = 7.5 Hz, 2H, H-3”), 
2.88 (dd, J = 12.5, 4.0 Hz, 1H, H-3b), 3.43 (d, J = 9.0 Hz, 1H, H-7), 3.48 (dd, 1H, J = 13.5, 
8.0 Hz, H-9a), 3.66 (m, 1H, H-6), 3.74 - 3.71 (m, 2H, H-5, H-4), 3.81 (dd, J = 13.5, 3.0 Hz, 
1H, H-9b), 4.04 (td, J = 8.0, 3.0 Hz, 1H, H-8), 4.23 (q, J = 7.0 Hz, 2H, NCH2), 4.44 (t, J = 
7.0 Hz, 2H, H-1”), 4.67, 4.94 (d, J = 12.5 Hz, 2H, H-1’), 7.28 (s, 1H, CHar), 7.49 - 7.40 (m, 
4H, CHar), 7.81 (d, J = 7.5 Hz, 2H, CHar), 7.96 (s, 1H, triazole-H), 8.06 (dd, J = 9.0, 2.0 Hz, 
1H, CHar), 8.49 (d, J = 1.5 Hz, 1H, CHar); 
13
C NMR (CD3OD, 125 MHz): ! 15.8 (NCH2CH3), 
22.6 (C-3”), 22.6 (NHAc), 31.6 (C-2”), 42.2 (NCH2), 42.6 (C-3), 44.6 (C-9), 50.8 (C-1”), 
54.1 (C-5), 59.0 (C-1’), 69.6 (C-4), 71.2 (C-8), 72.6 (C-7), 74.4 (C-6), 102.0 (C-2), 110.6, 
116.9, 117.5, 117.8, 125.3, 128.3, 128.4, 129.5, 129.9, 132.5, 135.8, 140.4, 142.2, 146.9 
(16C, C-Ar), 170.3, 174.1, 175.4 (3 CO); HRMS calcd. for C34H40N7Na2O11 [M+Na]
+
: 
768.2576; Found 768.2580. 
 
Sodium [3-(5-nitro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 5-acetamido -9-
benzamido -3,5,9-trideoxy-D-glycero-!-D-galacto-2-nonulopyranosid]onate (4) Prepared 
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from 21 (8.0 mg, 20 !mol) and 25a (4.1 mg, 20 !mol) according to general procedure C to 
afford 4 (7.7 mg, 68%) after chromatography as a white solid. [!]D
20
 –15.9 (c 0.2, MeOH); 
1
H NMR (CD3OD, 500 MHz): " 1.62 (t, J = 11.5 Hz, 1H, H-3a), 1.99 (s, 3H, NHAc), 2.28 
(m, 2H, H-2”), 2.75 (t, J = 7.0 Hz, 2H, H-3”), 2.88 (dd, J = 12.5, 4.5 Hz, 1H, H-3b), 3.44 (d, 
J = 9.0 Hz, 1H, H-7), 3.51 (dd, 1H, J = 13.5, 8.0 Hz, H-9a), 3.67 (d, J = 9.0 Hz, 1H, H-6), 
3.75-3.69 (m, 2H, H-4, H-5), 3.79 (dd, J = 13.5, 3.0 Hz, 1H, H-9b), 4.05 (dt, J = 8.0, 3.0 Hz, 
1H, H-8), 4.38 (t, J = 7.0 Hz, 2H, H-1”), 4.68, 4.95 (d, J = 12.5 Hz, 2H, H-1’), 6.98 (t, J = 7.5 
Hz, 1H, CHar), 7.08 - 7.04 (m, 2H, CHar), 7.32 (d, J = 8.0 Hz, 1H, CHar), 7.49 - 7.41 (m, 4H, 
CHar), 7.81 (d, J = 7.5 Hz, 2H, CHar), 7.94 (s, 1H, triazole-H); 
13
C NMR (CD3OD, 125 
MHz): " 22.6 (NHAc), 22.9 (C-3”), 31.8 (C-2”), 42.6 (C-3), 44.6 (C-9), 50.9 (C-1”), 54.1 (C-
5), 58.9 (C-1’), 69.7 (C-4), 71.2 (C-8), 72.6 (C-7), 74.4 (C-6), 102.0 (C-2), 112.2, 112.8, 
114.6, 119.2, 119.5, 122.3, 123.3, 125.3, 128.3, 129.5, 132.5, 135.9, 146.7 (16C, C-Ar), 
170.3, 174.1, 175.4 (3 CO); HRMS calcd. for C32H37N6Na2O9 [M+Na]
+
: 695.2412; Found 
695.2413. 
 
Sodium [3-(5-methoxy-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 5-acetamido -9-
benzamido-3,5,9-trideoxy-D-glycero-!-D-galacto-2-nonulopyranosid]onate (5). Prepared 
from 21 (10 mg, 20 !mol) and 25b (5.8 mg, 30 !mol) according to general procedure C to 
afford 5 (8.2 mg, 70%) after chromatography as white solid. [!]D
20
 –24.30 (c 0.23, MeOH); 
1
H NMR (CD3OD, 500 MHz): " 1.63 (t, J = 11.5 Hz, 1H, H-3a), 2.0 (s, 3H, NHAc), 2.27 (m, 
2H, H-2”), 2.72 (t, J = 7.0 Hz, 2H, H-3”), 2.88 (dd, J = 13.5, 4.0 Hz, 1H, H-3b), 3.44 (d, J = 
9.0 Hz, 1H, H-7), 3.52 (dd, 1H, J = 13.5, 8.0 Hz, H-9a), 3.66 (d, J = 9.0 Hz, 1H, H-6), 3.80 
(s, 3H, OMe), 3.80 - 3.73 (m, 3H, H-4, H-5, H-9b), 4.05 (m, 1H, H-8), 4.39 (t, J = 7.0 Hz, 
2H, H-1”), 4.68, 4.95 (d, J = 12.5 Hz, 2H, H-1’), 6.73 (d, J = 8.5 Hz, 1H, CHar), 6.95 (s, 1H, 
CHar), 7.02 (s, 1H, CHar), 7.20 (d, J = 8.5 Hz, 1H, CHar), 7.50 - 7.42 (m, 3H, CHar), 7.81 (d, J 
= 7.5 Hz, 2H, CHar), 7.95 (s, 1H, triazole-H); 
13
C NMR (CD3OD, 125 MHz): " 22.6 (NHAc), 
22.9 (C-2”), 31.7 (C-3”), 42.6 (C-3), 44.5 (C-9), 50.9 (C-1”), 54.0 (C-5), 56.3 (OCH3), 58.9 
(C-1’), 69.7 (C-4), 71.2 (C-8), 72.5 (C-7), 74.4 (C-6), 101.1 (Ar-H), 102.0 (C-2), 111.4, 
112.6, 112.9, 114.3, 124.1, 125.4, 128.3, 128.8, 129.5, 132.5, 133.4, 135.8, 146.7, 154.9 
(16C, C-Ar), 170.3, 174.1, 175.4 (3 CO); HRMS calcd. for C33H39N6Na2O10 [M+Na]
+
: 
725.2518; Found .725.2522. 
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Sodium [3-(5-trifluoromethyl-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 5-
acetamido -9-benzamido-3,5,9-trideoxy-D-glycero-!-D-galacto-2-nonulopyranosid]onate 
(6). Prepared from 21 (10 mg, 20 !mol) and 25o (7 mg, 30 !mol) according to general 
procedure C to afford 6 (7.7 mg, 67%) after chromatography as white solid. [!]D
20
 –21.38 (c 
0.14, MeOH); 
1
H NMR (CD3OD, 500 MHz): " 1.62 (t, J = 11.5 Hz, 1H, H-3a), 2.0 (s, 3H, 
NHAc), 2.29 (m, 2H, H-2”), 2.79 (t, J = 7.0 Hz, 2H, H-3”), 2.87 (dd, J = 11.5, 3.5 Hz, 1H, H-
3b), 3.44 (dd, J = 9.0, 2.0 Hz, 1H, H-7), 3.50 (dd, 1H, J = 13.5, 8.0 Hz, H-9a), 3.66 (m, 1H, 
H-6), 3.77 - 3.68 (m, 2H, H-4, H-5), 3.80 (dd, J = 13.5, 3.5 Hz, 1H, H-9b), 4.05 (td, J = 8.5, 
3.0 Hz, 1H, H-8), 4.41 (t, J = 7.0 Hz, 2H, H-1’’), 4.69, 4.95 (d, J = 12.0 Hz, 2H, H-1’), 7.21 
(s, 1H, CHar), 7.33 (m, 1H, CHar), 7.50-7.41 (m, 4H, CHar), 7.81 (m, 3H, CHar), 7.97 (s, 1H, 
triazole-H); 
13
C NMR (CD3OD, 125 MHz): " 22.6 (C-2”), 22.6 (NHAc) 31.6 (C-3”), 42.6 (C-
3), 44.5 (C-9), 50.8 (C-1”), 54.1 (C-5), 58.9 (C-1’), 69.7 (C-4), 71.2 (C-8), 72.6 (C-7), 74.4 
(C-6), 102.0 (C-2), 112.7, 115.8, 116.9 (q, J = 4.25 Hz), 118.8 (q, J = 3.5 Hz), 121.9 (q, J = 
31.25 Hz), 125.4, 125.6, 127.9, 128.2, 129.5, 132.5, 135.8, 139.6, 146.8 (16C, C-Ar), 170.3, 
174.2, 175.4 (3 CO); HRMS calcd for C33H36F3N6Na2O9 [M+Na]
+
: 763.2286; Found 
763.2295. 
 
Sodium [3-(6-cyclopropylamide)-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 5-
acetamido -9-benzamido-3,5,9-trideoxy-D-glycero-!-D-galacto-2-nonulopyranosid]onate 
(7). Prepared from 21 (6 mg, 10 !mol) and 25l (4 mg, 20 !mol) according to general 
procedure C to afford 7 (6.1 mg, 65%) after chromatography as a white solid. [!]D
20
 –15.3 (c 
0.17, MeOH); 
1
H NMR (CD3OD, 500 MHz): " 1.15 - 1.07 (m, 4H, CH(CH2)2),
 
1.63 (t, J = 
11.5 Hz, 1H, H-3a), 2.0 (s, 3H, NHAc), 2.30 (m, 2H, H-2”), 2.79 (t, J = 7.0 Hz, 2H, H-3”), 
2.94 - 2.88 (m, 2H, CH(CH2)2, H-3b), 3.44 (dd, J = 9.0, 1.5 Hz, 1H, H-7), 3.51 (dd, 1H, J = 
14.0, 8.0 Hz, H-9a), 3.68 (m, 1H, H-6), 3.78 - 3.72 (m, 2H, H-5, H-4), 3.80 (dd, J = 13.5, 3.5 
Hz, 1H, H-9b), 4.05 (td, J = 8.0, 3.0 Hz, 1H, H-8), 4.42 (t, J = 7.0 Hz, 2H, H-1”), 4.69, 4.96 
(d, J = 12.5 Hz, 2H, H-1’), 7.32 (s, 1H, CHar), 7.42 (t, J = 7.5 Hz, 1H, CHar), 7.50 (t, J = 7.5 
Hz, 2H, CHar), 7.60 (d, J = 8.5 Hz, 1H, CHar), 7.75 (dd, J = 8.5, 1.5 Hz, 1H, CHar), 7.82 (m, 
2H, CHar), 7.98 (s, 1H, CHar), 8.12 (s, 1H, triazole-H); 
13
C NMR (CD3OD, 125 MHz): " 11.9 
(CH(CH2)2), 17.8 (CH(CH2)2), 22.6 (NHAc), 22.7 (C-3”), 31.8 (C-2”), 42.6 (C-3), 44.6 (C-
9), 50.8 (C-1”), 54.1 (C-4), 59.0 (C-1’), 69.7 (C-5), 71.2 (C-8), 72.5 (C-7), 74.4 (C-6), 102.0 
(C-2), 113.5 (16C, C-Ar), 115.3, 119.2, 119.7, 125.4, 128.1, 128.3, 129.5, 132.4, 132.5, 
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135.8, 137.6, 146.9 (C-Ar), 170.3, 174.2, 175.4, 203.5 (4 CO); HRMS calcd. for 
C36H41N6Na2O10 [M+Na]
+
: 763.2674, found 763.2673. 
 
Sodium [3-(4-chlorobenzyl amide) -1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 5-
acetamido -9-benzamido-3,5,9-trideoxy-D-glycero-!-D-galacto-2-nonulopyranosid]onate 
(8). Prepared from 21 (6 mg, mmol) and 25m (6.8 mg, mmol) according to general procedure 
C to afford 8 (4.8 mg, 47%) after chromatography as a pale yellow solid. [!]D
20
 –11.99 (c 
0.21, MeOH); 
1
H NMR (CD3OD, 500 MHz): ! 1.62 (t, J = 11.5 Hz, 1H, H-3a), 2.0 (s, 3H, 
NHAc), 2.31 (m, 2H, H-2”), 2.80 (t, J = 7.0 Hz, 2H, H-3”), 2.89 (dd, J = 12.0, 4.0 Hz, 1H, H-
3b), 3.42 (dd, J = 9.0, 2.0 Hz, 1H, H-7), 3.51 (dd, 1H, J = 13.5, 8.0 Hz, H-9a), 3.66 (m, 1H, 
H-6), 3.75 - 3.71 (m, 2H, H-4, H-5), 3.79 (dd, J = 13.5, 3.0 Hz, 1H, H-9b), 4.04 (td, J = 8.0, 
3.0 Hz, 1H, H-8), 4.42 (t, J = 7.0 Hz, 2H, H-1”), 4.69, 4.96 (d, J = 12.5 Hz, 2H, H-1’), 7.35 
(s, 1H, CHar), 7.41 (m, 2H, CHar), 7.51 - 7.48 (m, 2H, CHar), 7.56 (d, J = 8.5 Hz, 2H, CHar), 
7.64 (d, J = 8.5 Hz, 1H, CHar), 7.84 - 7.75 (m, 5H, CHar), 7.98 (s, 1H, triazole-H); 
13
C NMR 
(CD3OD, 125 MHz): ! 22.6 (NHAc), 22.7 (C-3”), 31.7 (C-2”), 42.6 (C-3), 44.6 (C-9), 50.8 
(C-1”), 54.1 (C-5), 59.0 (C-1’), 69.7 (C-4), 71.2 (C-8), 72.6 (C-7), 74.4 (C-6), 102.1 (C-2), 
115.5, 116.1, 119.3, 121.6, 125.4, 128.3, 129.5, 131.0, 135.6, 137.2, 138.7, 139.1, 147.0 
(22C, C-Ar), 170.4, 174.1, 175.4, 198.2 (4 CO); HRMS calcd. for C39H40ClN6Na2O10 
[M+Na]+: 833.2284; Found 833.2284. 
 
Sodium [3-(5-nitro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-benzamido-3,5,9-
trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-nonulopyranosid]onate (9). 
Prepared from 39a (15 mg, 30 "mol) and 25n (12 mg, 45 "mol) according to general 
procedure C to afford 9 (3.7 mg, 16%) after chromatography as yellow solid. [!]D
20
 –20.58 (c 
1.00, MeOH); 
1
H NMR (500 MHz, D2O): ! 1.64 (t, J = 12.1 Hz, 1H, H-3a), 2.16 – 2.23 (m, 
2H, H-2’’), 2.61 (dd, J = 6.5, 11.9 Hz, 2H, H-3’’), 2.69 (dd, J = 4.8, 12.5 Hz, 1H, H-3b), 3.34 
(dd, J = 8.3, 14.0 Hz, 1H, H-9a), 3.52 (dd, J = 1.3, 8.6 Hz, 1H, H-7), 3.68 – 3.77 (m, 1H, H-
4), 3.77 – 3.91 (m, 3H, H-6, H-8, H-9b), 3.95 (t, J = 10.1 Hz, 1H, H-5), 4.25 – 4.36 (m, 3H, 
H-1’a, H-1’’), 4.55 (B of AB, J = 12.2 Hz, 1H, H-1’b), 4.92 (m, 1H, CH2F), 7.04 (s, 1H, 
CHar), 7.23 (d, J = 9.0 Hz, 1H, CHar), 7.33 (t, J = 7.7 Hz, 2H, CHar), 7.43 (t, J = 7.4 Hz, 1H, 
CHar), 7.58 (s, 1H, CHar), 7.61 (d, J = 7.4 Hz, 2H, CHar), 7.78 (dd, J = 1.9, 8.9 Hz, 1H, CHar), 
8.06 (d, J = 1.8 Hz, 1H, CHar);
13
C NMR (D2O, 125 MHz): " 28.9 (C-3’’), 40.2 (C-2’’), 42.5 
(C-9), 50.0 (C-1’’), 51.1 (C-5), 57.0 (C-1’), 67.8 (C-4), 69.8 (C-7), 70.0 (C-8), 72.0 (C-6), 
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78.9, 80.3 (d, J = 190.2, CH2F), 111.0, 116.8, 125.0, 126.0, 126.7, 128.4, 131.9, 133.3 (15C, 
C-Ar), (3C, CO); HRMS calcd. for C32H35FN7Na2O11 [M+Na]
+
: 758.2174; found m/z 
758.2176.  
 
Sodium [3-(5-nitro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (10). Prepared from 39b (18.3 mg, 0.0364 mmol) and 25n (13.3 mg, 
0.0546 mmol) according to general procedure C to afford 10 (19 mg, 70%). [!]D
20 -21.558 (c 
1.000, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.30 (p, J = 
7.1 Hz, 2H, H-2”), 2.80 (t, J = 7.36 Hz, 2H, H-3”), 2.87 (dd, J = 3.9, 12.1 Hz, 1H, H-3b), 
3.44 – 3.52 (m, 2H, H-9a, H-7), 3.78 – 3.95 (m, 4H, H-9b, H-4, H-5, H-6)), 4.03 (m, 1H, H-
8), 4.43 (t, J = 6.8 Hz, 2H, H-1”), 4.68 (A of AB, J = 12.2 Hz, 1H, H-1’a), 4.80 (m, 1H, 
CH2F), 4.94 (B of AB, J = 12.2 Hz, 1H, H-1’b), 7.27 (s, 1H, CHar), 7.42 (dd, J = 8.8, 11.0 Hz, 
3H, CHar), 7.79 (d, J = 8.5 Hz, 2H, CHar), 7.97 (s, 1H, CHar), 8.01 (dd, J = 2.1, 9.0 Hz, 1H, 
CHar), 8.48 (d, J = 2.1 Hz, 1H, CHar); 13C NMR (126 MHz, MeOD) ! 22.73 (C-3”), 31.71 
(C-2”), 42.60 (C-3), 44.71 (C-9), 50.97 C-1”), 53.78 (C-5), 59.02 (C-1’), 69.57 (C-4), 71.69 
(C-8), 72.44 (C-7), 73.99 (C-6), 81.12 (d, 2JC,F = 183.0 Hz, CH2F), 112.57, 116.75, 117.73, 
117.99, 127.29, 128.03, 129.77, 130.20, 134.51, 138.75, 141.37, 142.37 (15C, C-AR) 169.40, 
172.17, 172.32 (C=O); ESI-MS m/z calcd for C32H35ClFN7NaO11 [M+H]
+: 770.20; found: 
770.37.  
 
Sodium [3-(5-chloro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (11). Prepared from 39b (30 mg, 0.0591 mmol) and 25c (20.8 mg, 
0.0886 mmol) according to general procedure C to afford 11 (27 mg, 60%). [!]D
20 -21.024 (c 
1.080, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.61 (m, 1H, H-3a), 2.23 (p, J = 7.1 Hz, 2H, 
H-2”), 2.69 (t, J = 7.3 Hz, 2H, H-3”), 2.88 (dd, J = 4.6, 12.2 Hz, 1H, H-3b), 3.39 – 3.59 (m, 
2H, H-9a, H-7), 3.74 – 3.97 (m, 4H, H-9b, H-4, H-5, H-6), 4.03 (td, J = 3.0, 8.5 Hz, 1H, H-
8), 4.37 (t, J = 7.0 Hz, 2H, H-1”), 4.68 (A of AB, J = 12.2 Hz, 1H, H-1’a), 4.84 (d, J = 46.7 
Hz, 2H, CH2F), 4.95 (B of AB, J = 12.2 Hz, 1H, H-1’b), 7.02 (dd, J = 2.0, 8.6 Hz, 1H, CHar), 
7.09 (s, 1H, CHar), 7.28 (d, J = 8.6 Hz, 1H, CHar), 7.40 (d, J = 8.6 Hz, 2H, CHar), 7.44 (d, J = 
1.9 Hz, 1H, CHar), 7.79 (d, J = 8.6 Hz, 2H, CHar), 7.91 (s, 1H, CHar); 
13C NMR (126 MHz, 
CD3OD) ! 22.86 (C-3”), 31.79 (C-2”), 42.64 (C-3), 44.64 (C-9), 50.98 (C-1”), 53.72 (C-5), 
58.98 (C-1’), 69.59 (C-4), 71.76 (C-8), 72.38 (C-7), 73.96 (C-6), 81.12 (d, 2JC,F = 183.2 Hz, 
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CH2F), 102.16, 113.63, 114.53, 118.79, 122.56, 125.28, 125.44, 125.47, 129.76, 130.19, 
134.53, 136.70, 138.72, 146.78 (15C, C-Ar), 169.39, 172.14, 172.28 (C=O); ESI-MS m/z 
calcd for C32H35Cl2FN6NaO9 [M+H]
+: 759.17; found: 759.28. 
 
Sodium [3-(6-chloro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (12). Prepared from 39b (16 mg, 0.0327 mmol) and 25f (11.3 mg, 
0.0482 mmol) according to general procedure C to afford 12 (19 mg, 79%). [!]D
20 -24.310 (c 
1.067, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.65 (t, J = 12.0 Hz, 1H, H-3a), 2.28 (p, J = 
7.1 Hz, 2H, H-2”), 2.88 (dd, J = 4.7, 12.3 Hz, 1H, H-3b), 2.95 (t, J = 7.4 Hz, 2H, H-3”), 3.40 
– 3.57 (m, 2H, H-9a, H-7), 3.77 – 3.87 (m, 3H, H-9b, H-4, H-6), 3.92 (m, 1H, H-5), 4.04 (td, 
J = 3.1, 8.4 Hz, 1H, H-8), 4.41 (t, J = 6.9 Hz, 2H, H-1”), 4.67 (A of AB, J = 12.2 Hz, 1H, H-
1’a), 4.84 (d, J = 47.0 Hz, 2H, CH2F), 4.95 (B of AB, J = 12.2 Hz, 1H, H-1’b), 6.92 (d, J = 
7.5 Hz, 1H, CHar), 6.98 (t, J = 7.8 Hz, 1H, CHar), 7.08 (s, 1H, CHar), 7.25 (d, J = 8.0 Hz, 1H, 
CHar), 7.41 (d, J = 8.5 Hz, 2H, CHar), 7.79 (d, J = 8.5 Hz, 2H, CHar), 7.95 (s, 1H, CHar); 
13C 
NMR (126 MHz, CD3OD) ! 24.32 (C-3”), 33.67 (C-2”), 42.71 (C-3), 44.66 (C-9), 50.95 (C-
1”), 53.72 (C-5), 59.01 (C-1’) , 69.66 (C-4), 71.70 (C-8), 72.45 (C-7), 73.95 (C-6) 81.12 (d, 
2
JC,F = 183.3 Hz, CH2F), 102.17, 111.50, 115.07, 120.67, 122.99, 125.15, 125.46, 125.56, 
126.86, 129.77, 130.18, 134.57, 138.72, 140.00, 146.86 (C-Ar), 169.41, 172.15, 172.30, 
(CO); ESI-MS m/z calcd for C32H35Cl2FN6NaO9 [M+H]
+: 759.16; found: 759.22.  
 
Sodium [3-(7-chloro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (13). Prepared from 39b (12 mg, 0.0241 mmol) and 25i (8.5 mg, 
0.0302 mmol) according to general procedure C to afford 13 (15 mg, 83%). [!]D
20 -22.60 (c 
1.00, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.28 (p, J = 
7.2 Hz, 2H, H-2”), 2.74 (t, J = 7.4 Hz, 2H, H-3”), 2.88 (dd, J = 4.7, 12.3 Hz, 1H, H-3b), 3.43 
– 3.53 (m, 2H,  H-9a, H-7), 3.74 – 3.88 (m, 3H, H-9b, H-4, H-6), 3.92 (m, 1H, H-5), 4.03 (td, 
J = 3.1, 8.4 Hz, 1H, H-8), 4.40 (t, J = 7.0 Hz, 2H, H-1”), 4.69 (A of AB, J = 12.3 Hz, 1H, H-
1’a), 4.84 (d, J = 47.0 Hz, 2H, CH2F), 4.96 (B of AB, J = 12.2 Hz, 1H, H-1’b), 6.97 (t, J = 
7.7 Hz, 1H, CHar), 7.09 (d, J = 7.5 Hz, 1H, CHar), 7.14 (s, 1H), 7.38 – 7.47 (m, 3H, CHar), 
7.76 – 7.83 (m, 2H, CHar), 7.96 (s, 1H, CHar); 
13C NMR (126 MHz, CD3OD) ! 23.04 (C-3”), 
31.85 (C-2”), 42.72 (C-3), 44.68 (C-9), 50.96 (C-1”), 53.73 (C-5), 59.05 (C-1’), 69.66 (C-4), 
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71.67 (C-8), 72.47 (C-7), 73.97 (C-6), 81.12 (d, 2JC,F = 183.1 Hz, CH2F), 115.98, 117.84, 
118.37, 120.61, 121.94, 124.69, 125.50, 129.78, 130.19, 130.55, 134.59, 135.23, 138.72 
(15C, C-Ar), 169.39, 172.16, 172.31 (CO); ESI-MS m/z calcd for C32H35Cl2FN6NaO9 
[M+H]+: 759.16; found: 759.30.  
 
Sodium [3-(5-methyl-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (14). Prepared from 39b (16 mg, 0.0327 mmol) and 25e (10.6 mg, 
0.0490 mmol) according to general procedure C to afford 14 (18 mg, 75%). [!]D
20 -23.215 (c 
1.00, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.25 – 2.29 
(m, 2H, H-2”), 2.46 (s, 3H, CH3), 2.74 (t, J = 7.3 Hz, 2H, H-3”), 2.88 (dd, J = 4.7, 12.3 Hz, 
1H, H-3b), 3.44 – 3.53 (m, 2H, H-9a, H-7), 3.76 – 3.87 (m, 3H, H-9b, H-4, H-6), 3.95 (m, 
1H, H-5), 4.03 (td, J = 2.9, 8.5 Hz, 1H, H-8), 4.37 (t, J = 7.0 Hz, 2H, H-1”), 4.67 (A of AB, J 
= 12.2 Hz, 1H, H-1’a), 4.84 (d, J = 46.9 Hz, 2H, CH2F), 4.95 (B of AB, J = 12.2 Hz, 1H, H-
1’b), 6.83 – 6.94 (m, 2H, CHar), 7.05 (s, 1H, CHar), 7.31 (d, J = 7.5 Hz, 1H, CHar), 7.41 (d, J = 
8.5 Hz, 2H, CHar), 7.79 (d, J = 8.5 Hz, 2H, CHar), 7.92 (s, 1H, CHar); 
13C NMR (126 MHz, 
CD3OD) ! 17.04 (CH3), 23.18 (C-3”), 31.95 (C-2”), 42.71 (C-3), 44.65 (C-9), 51.03 (C-1”), 
53.73 (C-5), 59.02 (C-1’), 69.64 (C-4), 71.72 (C-8), 72.44 (C-7), 73.95 (C-6), 81.12 (d, 2JC,F = 
183.0 Hz, CH2F), 114.99, 117.13, 120.00, 121.84, 122.97, 123.33, 125.47, 128.32, 129.77, 
130.19, 134.58, 137.78, 138.71 (15C, C-Ar), 169.41, 172.15, 172.29, (CO); ESI-MS m/z 
calcd for C33H38ClFN6NaO9 [M+H]
+: 739.22; found: 739.26.  
 
Sodium [3-(5-fluoro-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (15). Prepared from 39b (13 mg, 0.0257 mmol) and 25d (8.4 mg, 
0.0385 mmol) according to general procedure C to afford 15 (10 mg, 50%). [!]D
20 -17.624 (c 
0.680, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.65 (t, J = 12.0 Hz, 1H, H-3a), 2.26 (p, J = 
7.2 Hz, 2H, H-2”)), 2.71 (t, J = 7.3 Hz, 2H, H-3”), 2.88 (dd, J = 4.8, 12.3 Hz, 1H, H-3b), 3.42 
– 3.54 (m, 2H, H-9a, H-7), 3.75 – 3.87 (m, 3H, H-9b, H-4, H-6), 3.91 (m, 1H, H-5), 4.04 (td, 
J = 3.1, 8.1 Hz, 1H, H-8), 4.39 (t, J = 7.0 Hz, 2H, H-1”), 4.68 (A of AB, J = 12.2 Hz, 1H, H-
1’a), 4.84 (d, J = 47.0 Hz, 2H, CH2F), 4.95 (B of AB, J = 12.2 Hz, 1H, H-1’b), 6.83 (td, J = 
2.5, 9.1 Hz, 1H, CHar), 7.11 (s, 1H, CHar), 7.14 (dd, J = 2.5, 9.9 Hz, 1H, CHar), 7.27 (dd, J = 
4.4, 8.8 Hz, 1H, CHar), 7.39 – 7.46 (m, 2H, CHar), 7.76 – 7.84 (m, 2H, CHar), 7.94 (s, 1H, 
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CHar); 
13C NMR (126 MHz, CD3OD) ! 23.03 (C-3”), 31.80 (C-2”), 42.77 (C-3), 44.72 (C-9), 
51.03 (C-1”), 53.77 (C-5), 59.08 (C-1’), 69.71 (C-4), 71.71 (C-8), 72.51 (C-7), 74.01 (C-4), 
81.12 (d, 2JC,F = 183.3 Hz, CH2F), 102.22 (C-Ar), 104.02 (d, 
2
JC,F = 23.40 Hz, C-4indole), 110.53 
(d, 2JC,F = 26.48, C-6indole), 113.17 (d, 
3
JC,F = 9.71 Hz, C-7indole), 114.91 (d, 
4
JC,F = 4.78 Hz, C-
8indole), 125.53, 125.63 (C-Ar), 129.00 (d, 
3
JC,F = 9.57 Hz, C-3indole), 129.83, 130.24, 134.65, 
134.97, 138.76, 146.93 (C-Ar), 158.99 (d, 1JC,F = 232.10 Hz, C-5indole), 169.45, 172.20, 172.34, 
(CO); ESI-MS m/z calcd for C32H35ClF2N6NaO9 [M+H]
+: 743.19; found: 743.34.  
 
Sodium [3-(5-methoxy-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (16). Prepared from 39b (10 mg, 0.0200 mmol) and 25b (6.9 mg, 
0.0300 mmol) according to general procedure C to afford 16 (8.6 mg, 61%). [!]D
20 -20.529 (c 
0.667, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.64 (t, J = 11.9 Hz, 1H, H-3a), 2.27 (p, J = 
7.1 Hz, 2H, H-2”), 2.72 (t, J = 7.3 Hz, 2H, H-3”), 2.88 (dd, J = 4.7, 12.2 Hz, 1H, H-3b), 3.43 
– 3.53 (m, 2H, H-9a, H-7), 3.81 (s, 3H, OCH3), 3.77 – 3.87 (m, 3H, H-9b, H-4, H-6), 3.91 
(m, 1H, H-5), 4.04 (td, J = 3.1, 8.4 Hz, 1H, H-8), 4.40 (t, J = 6.9 Hz, 2H, H-1”), 4.68 (A of 
AB, J = 12.2 Hz, 1H, H-1’a), 4.84 (d, J = 47.0 Hz, 2H, CH2F), 4.96 (B of AB, J = 12.2 Hz, 
1H, H-1’b), 6.73 (dd, J = 2.4, 8.8 Hz, 1H, CHar), 6.95 (d, J = 2.3 Hz, 1H, CHar), 7.02 (s, 1H, 
CHar), 7.21 (d, J = 8.8 Hz, 1H, CHar), 7.42 (d, J = 8.5 Hz, 2H, CHar), 7.80 (t, J = 7.1 Hz, 2H, 
CHar), 7.94 (s, 1H, CHar); 
13C NMR (126 MHz, CD3OD) ! 23.03 (C-3”), 31.85 (C-2”), 42.74 
(C-3), 44.70 (C-9), 51.03 (C-1”), 53.73 (C-5), 56.51 (OCH3), 59.05 (C-1’), 69.68 (C-4), 
71.65 (C-8), 72.50 (C-7), 73.97 (C-6), 81.11 (d, 2JC,F = 183.3 Hz, CH2F), 101.34, 112.76, 
113.06, 114.44, 124.27, 125.51, 128.98, 129.79, 130.20, 133.62, 134.61, 138.71, 155.07 
(15C, C-Ar), 169.40, 172.16, 172.30 (CO); ESI-MS m/z calcd for C33H38ClFN6NaO10 
[M+H]+: 755.12; found: 755.27.  
 
Sodium [3-(5-isopropyl-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (17). Prepared from 39b (17.5 mg, 0.0349 mmol) and 25g (12.7 mg, 
0.0524 mmol) according to general procedure C to afford 17 (13 mg, 50%). [!]D
20 -18.50 (c 
0.967, MeOH); 1H NMR (500 MHz, CH3OD) ! 1.28 (d, J = 6.9 Hz, 6H, CH3), 1.65 (t, J = 
11.8 Hz, 1H, H-3a), 2.28 (p, J = 7.1 Hz, 2H, H-2”), 2.74 (t, J = 7.3 Hz, 2H, H-3”), 2.89 (dd, J 
= 3.3, 11.8 Hz, 1H, H-3b), 2.95 (m, 1H, CH), 3.43 – 3.52 (m, 2H, H-9a, H-7), 3.77 – 3.87 (m, 
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3H, H-4, H-6, H-9b), 3.91 (m, 1H, H-5), 4.04 (td, J = 2.3, 8.3 Hz, 1H, H-8), 4.39 (t, J = 6.9 
Hz, 2H, H-1”), 4.68 (A of AB, J = 11.9 Hz, 1H, H-1’a), 4.84 (d, J = 47.0 Hz, 2H, CH2F), 
4.95 (B of AB, J = 11.9 Hz, 1H, H-1’b), 6.98 (dd, J = 1.3, 8.4 Hz, 1H, CHar), 7.01 (s, 1H, 
CHar), 7.24 (d, J = 8.4 Hz, 1H, CHar), 7.29 (s, 1H, CHar), 7.41 (d, J = 8.5 Hz, 2H, CHar), 7.79 
(d, J = 8.5 Hz, 2H, C6H4), 7.95 (s, 1H, CHar); 
13C NMR (126 MHz, CD3OD) ! 23.08 (C-3”), 
25.41 (2C, CH3), 31.92 (C-2”), 35.74 (CH), 42.73 (C-3), 44.70 (C-9), 51.07 (C-1”), 53.73 (C-
5), 59.05 (C-1’), 69.67 (C-4), 71.66 (C-8), 72.49 (C-7), 73.96 (C-6), 81.12 (d, 2JC,F = 183.2 
Hz, CH2F), 112.22, 114.39, 116.21, 121.58, 123.61, 128.75, 129.78, 130.20, 134.60, 137.03, 
138.71, 140.44 (16C, C-Ar), 169.39, 172.15, 172.30 (CO); ESI-MS m/z calcd for 
C35H42ClFN6NaO9 [M+H]
+: 767.25; found: 767.33.  
 
Sodium [3-(5-cyano-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (18). Prepared from 39b (15.3 mg, 0.0305 mmol) and 25j (10.3 mg, 
0.0457 mmol) according to general procedure C to afford 18 (16 mg, 72%). [!]D
20 -22.12 (c 
1.07, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.28 (p, J = 
7.1 Hz, 2H, H-2”), 2.73 – 2.83 (m, 2H, H-3”), 2.88 (dd, J = 4.8, 12.3 Hz, 1H, H-3b), 3.48 
(dd, J = 8.1, 13.9 Hz, 2H, H-9a, H-7), 3.76 – 3.88 (m, 3H, H-4, H-6, H-9b), 3.91 (m, 1H, H-
5), 4.03 (td, J = 3.1, 8.3 Hz, 1H, H-8), 4.41 (t, J = 6.9 Hz, 2H, H-1”), 4.68 (A of AB, J = 12.3 
Hz, 1H, H-1’a), 4.84 (d, J = 47.0 Hz, 2H, CH2F), 4.95 (B of AB, J = 12.3 Hz, 1H, H-1’b), 
7.23 (s, 1H, CHar), 7.35 (dd, J = 1.4, 8.4 Hz, 1H, CHar), 7.42 (d, J = 8.6 Hz, 2H, CHar), 7.46 
(d, J = 8.4 Hz, 1H, CHar), 7.79 (d, J = 8.6 Hz, 2H, CHar), 7.95 (s, 2H, CHar); 
13C NMR (126 
MHz, MeOD) ! 22.72 (C-3”), 31.73 (C-2”), 42.71 (C-3), 44.67 (C-9), 50.94 (C-1”), 53.73 
(C-5), 59.03 (C-1’), 69.65 (C-4), 71.69 (C-8), 72.45 (C-7), 73.96 (C-6), 81.12 (d, 2JC,F = 183.2 
Hz, CH2F), 102.18, 102.27 (C-2, C-Ar), 113.62, 116.08, 122.17, 125.27, 125.40, 125.52, 
126.31, 128.62, 129.78, 130.19, 134.57, 138.72, 140.12, 146.92 (CN, C-Ar), 169.38, 172.17, 
172.31, (CO); ESI-MS m/z calcd for C33H35ClFN7NaO9 [M+H]
+: 750.20; found: 750.25.  
 
Sodium [3-(5-methylsulfonyl  -1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (19). Prepared from 39b (9.6 mg, 0.0192 mmol) and 25k (8 mg, 
0.0287 mmol) according to general procedure C to afford 19 (15 mg, 66%). [!]D
20 -20.41 (c 
0.60, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.64 (t, J = 12.0 Hz, 1H, H-3a), 2.32 (p, J = 
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7.1 Hz, 2H, H-2”), 2.82 (t, J = 7.4 Hz, 2H, H-3”), 2.88 (dd, J = 4.8, 12.3 Hz, 1H, H-3b), 3.12 
(s, 3H, CH3), 3.43 – 3.50 (m, 2H, H-9a, H-7), 3.77 – 3.86 (m, 3H, H-4, H-6, H-9b), 3.90 (m, 
1H, H-5), 4.04 (td, J = 3.1, 8.3 Hz, 1H, H-8), 4.42 (t, J = 6.9 Hz, 2H, H-1”), 4.67 (A of AB, J 
= 12.3 Hz, 1H, H-1’a), 4.84 (d, J = 46.9 Hz, 2H, CH2F), 4.94 (B of AB, J = 12.3 Hz, 1H, H-
1’b), 7.28 (s, 1H, CHar), 7.42 (d, J = 8.5 Hz, 2H, CHar), 7.53 (d, J = 8.6 Hz, 1H, CHar), 7.64 
(dd, J = 1.7, 8.6 Hz, 1H, CHar), 7.80 (d, J = 8.5 Hz, 2H, CHar), 7.94 (s, 1H, CHar), 8.14 (d, J = 
1.4 Hz, 1H, CHar); 
13C NMR (126 MHz, CD3OD) ! 22.78 (C-3”), 31.70 (C-2”), 42.74 (C-3), 
44.71 (C-9), 45.48 (CH3), 50.94 (C-1”), 53.74 (C-5), 59.06 (C-1’), 69.68 (C-4), 71.65 (C-8), 
72.50 (C-7), 73.97 (C-6), 81.12 (d, 2JC,F = 183.3 Hz, CH2F), 102.18, 113.22, 116.75, 120.35, 
120.86, 125.51, 126.67, 128.32, 129.79, 130.20, 131.82, 134.61, 138.71, 140.68, 146.96 (C-
Ar), 169.38, 172.16, 172.31, (CO); ESI-MS m/z calcd for C33H38ClFN6NaO11S [M+H]
+: 
803.18; found: 803.25.  
 
Sodium [3-(5,6-cyclopropyl-1H-indol-3-yl)propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido -D-glycero-!-D-galacto-2-
nonulopyranosid]onate (20). Prepared from 39b (10 mg, 0.0191 mmol) and 25h (6.9 mg, 
0.0287 mmol) according to general procedure C to afford 20 (9 mg, 64%). [!]D
20 -24.540 (c 
0.573, MeOH); 1H NMR (500 MHz, CD3OD) ! 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.07 (p, J = 
7.2 Hz, 2H, CH2
cyc), 2.26 (p, J = 6.9 Hz, 2H, H-2”), 2.71 (t, J = 7.2 Hz, 2H, H-3”), 2.89 (dd, J 
= 4.7, 12.3 Hz, 1H, H-3b), 2.93 (t, J = 7.2 Hz, 4H, CH2
cyc), 3.43 – 3.53 (m, 2H, H-9a, H-7), 
3.76 - 3.86 (m, 3H, H-9b, H-4, H-6), 3.91 – (m, 1H, H-5), 4.03 (td, J = 3.0, 8.4 Hz, 1H, H-8), 
4.38 (t, J = 7.0 Hz, 2H, H-1”), 4.68 (A of AB, J = 12.2 Hz, 1H, H-1’a), 4.84 (d, J = 47.0 Hz, 
2H, CH2F), 4.96 (B of AB, J = 12.2 Hz, 1H, H-1’b), 6.94 (s, 1H, CHar), 7.14 (s, 1H , CHar), 
7.26 (s, 1H, CHar), 7.41 (d, J = 8.5 Hz, 2H, CHar), 7.79 (d, J = 8.5 Hz, 2H, CHar), 7.93 (s, 1H, 
CHar); 
13C NMR (126 MHz, CD3OD) ! 23.21 (C-3”), 27.89 (C
cyc), 31.92 (C-2”), 33.57, 33.89 
(Ccyc), 42.73 (C-3), 44.70 (C-9), 51.06 (C-1”), 53.73 (C-5), 59.04 (C-1’), 69.67 (C-4), 71.66 
(C-8), 72.50 (C-7), 73.97 (C-6), 81.11 (d, 2JC,F = 183.2 Hz, CH2F), 107.62, 114.09, 114.11, 
122.86, 125.53, 127.98, 129.78, 130.19, 134.59, 136.19, 138.12, 138.71, 139.48 (15C, C-Ar), 
169.40, 172.16, 172.31 (CO); ESI-MS m/z calcd for C35H40ClFN6NaO9 [M+H]
+: 765.23; 
found: 765.25. 9494 
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Surface Plasmon Resonance. The SPR measurements were performed on a Biacore 3000 
surface plasmon resonance based optical biosensor (Biacore AB, Sweden). Sensor chips 
(CM5), immobilization kits, maintenance supply and HBS-EP (10 mM HEPES pH 7.4, 150 
mM NaCl, 3 mM EDTA, 0.005% v/v surfactant P20) were purchased from Biacore AB 
(HBS-EP ready-to-use; degassed and filtered). CM5 chips were preconditioned prior to usage 
by injecting a series of conditioning solutions. A flow rate of 50 !L/min was used and 2 " 20 
!L of 50 mM NaOH, 10 mM HCl, 0.1% SDS and 100 mM H3PO4 were injected. The 
carboxy groups on the CM5 chip were activated for 10 min with a 1:1 mixture of 0.1 M N-
hydroxysuccinimide (NHS) and 0.1 M 3-(N,N-dimethylamino)propyl-N-ethylcarbodiimide 
(EDC) at a flow rate of 10 !L/min. Polyclonal goat anti-human IgG (Fc specific) was 
purchased from Sigma (I2136, Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). A 
sample and a reference surface were prepared sequentially or in parallel. For immobilizing, a 
30 !g/mL solution of the polyclonal antibody diluted in acetate buffer (10 mM sodium 
acetate, pH 5.0) was then injected over the activated surface for 10 min at a flow rate of 10 
!L/min. Densities around 13000 to 14000 RU were achieved. Flow cells were blocked with a 
10 min injection of 1 M ethanolamine, pH 8.0. For capturing, MAGd1-3-Fc solution 
(expressed and purified as decribed
[27]
) was diluted to a 30-40 !g/mL concentration using 
HBS-EP. Afterwards, MAGd1-3-Fc was injected at a flow rate of 1 !L/min for 10 min. The 
surface was equilibrated over night at a flow rate of 5 !L/min, achieving densities around 
3500 to 4000 RU. Tenfold dilution series were freshly prepared in eluent buffer immediately 
before use. All binding experiments were conducted at 25 °C at a flow rate of 20 !L/min. 
The samples were injected over 1 min followed by 1 min dissociation. Each sample was 
measured with a duplicate of one concentration, using a randomized concentration order. 
Several buffer samples were injected before the first concentration, and one blank between 
each concentration, which were used for the double blank referencing during data processing. 
Double referencing was applied to correct for bulk effects and other systematic artifacts. Data 
processing and equilibrium binding constant determinations were accomplished with 
Scrubber (BioLogic Software, Version 1.1g or 2.0c). Kinetic data were simultaneously fit 
using the non-linear regression program Clamp or Scrubber 2.0c.  
 
CMC determination. 10 mM stock solutions in DMSO of the samples were prepared. Then, 
a dilution series in DMSO was prepared by a Hamilton Microlab Star robot (Hamilton AG, 
Bonaduz, Switzerland) and 5 !L of each well were transferred into buffer (0.05 M MOPSO, 
pH 6.5) to yield 50 !L of the 12 desired concentrations (between 0 and 1 mM). Before 
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starting the experiment, the Delta-8 instrument (Kibron Inc., Espoo, Finland) was calibrated 
with water. Finally, the 12 dilutions were measured and the results were analyzed with the 
Vector software (Kibron, version 4.02). The assay used for CMC determination was 
performed at F. Hoffmann-La Roche Ldt., Basel. 
 
Isothermal Titration Calorimetry. ITC experiments were performed using a VP-ITC 
instrument from MicroCal, Inc. (Northampton, MA). The measurements were performed at 
25 °C. Injections of 10 !L ligand solutions were added from a computer controlled 300 !L 
microsyringe at an interval of 5 min into the sample cell solution of MAG (cell volume 
1.4512 mL) with stirring at 307 rpm. A control experiment was performed, where the 
identical ligand solutions were injected into buffer without protein. The enthalpogram 
showed negligible heat development, resulting from dilution effects. The assay buffer was 
HBS-E (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, pH 7.4). The concentration of MAG 
was 6.3 !M (determined by HPLC) and 100 !M antagonist was injected. The experimental 
data were fitted to a theoretical titration curve (one site binding model) using Origin version 
7 software (MicroCal), with "H (enthalpy change in kcal/mol), Ka (association constant in M
-
1
), and N (number of binding sites) as adjustable parameters. The quantity c = Ka·Mt(0), 
where Mt(0) is the initial macromolecule concentration, is of importance in titration 
microcalorimetry.
[28]
 The experiment was performed with a c value of 48. Thermodynamic 
parameters were calculated from equation (1), 
"G = "H – T"S = RTlnKA = - RTlnKD (1) 
 
where "G, "H, and "S are the changes in free energy, enthalpy, and entropy of binding, 
respectively, T is the absolute temperature, and R = 1.98 cal/mol/K. For reasons of 
consistency the values were converted to kJ (1 cal = 4.1868 J). 
 
Protein concentration determination by HPLC. The concentration of MAG was 
determined via HPLC against a standard curve of BSA at 210 nm using a Beckmann Gold 
system, with UV detection (180 nm). The column used was Poros R1/10 10 !m (100 ! 2 mm, 
Dr. Maisch HPLC Markensäulen, po10.r1.s1002, Morvay Analytik GmbH). The running 
buffers were A: H2O + 0.1% TFA and B: 90% MeCN + 0.09% TFA. All measurements were 
performed at 75 °C, applying a gradient of 20% to 90% running buffer B within 20 min at a 
flow rate of 0.2 mL/min.
[32]
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Molecular Modeling. Molecular-dynamic simulations (MD) using Desmond,
[24]
 were 
performed to check the stability of the proposed binding modes along with the kinetic aspects 
of the binding. The complexes were simulated during 4.0 ns at 300 K using explicit solvent 
(TIP3P water) and sampled at 1.2 ps intervals.
 
Those frames were then analyzed for 
hydrogen-bond contribution, ! stacking and the 1 –NO2"""Lys 67 interactions to complex 
stabilization. 
FEP was employed to calculate the relative binding free energy (!!G) between 1 and a 
corresponding mutant lacking the 5’-nitro group. The FEP was simulated for a total of 1.0 ns 
and divided in 12 # windows using the SPC water model. In order to obtain more reliable 
affinity estimations, contribution of solvation to !!G is explicitly included for both states. 
The !!G is calculated as follows from the solvated states: 
 
!!G = !G[complex17b–complexmutant] – !G[ligand17b–ligandmutant] 
     = (–2.32 ± 0.10 kcal/mol) – (–5.97 ± 0.16 kcal/mol) 
          = +3.65 ± 0.19 kcal/mol 
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From a Library of MAG Antagonists to Nanomolar CD22
Ligands
Stefanie Mesch,[a] Katrin Lemme,[a] Matthias Wittwer,[a] Hendrik Koliwer-Brandl,[b]
Oliver Schwardt,[a] Sørge Kelm,[b] and Beat Ernst*[a]
Introduction
Patients diagnosed with B-cell lymphomas can be effectively
treated with the anti-CD20 antibody rituximab.[1] However, this
therapy is not a cure, and especially for patients with indolent
lymphoid malignancies novel treatments with alternative
mechanisms of B-cell killing are required.[2] Numerous antibod-
ies for B-cell depletion therapy are therefore under clinical de-
velopment.[3] Two of them, the immunotoxins BL22[4] and CMC-
544,[5] target CD22, a B-lymphocyte-specific receptor. CD22
(Siglec-2) is a member of the sialic acid binding immunoglobu-
lin-like lectin (Siglec) family.[6] It is an inhibitory co-receptor for
the B-cell receptor (BCR) and plays a crucial role in the regula-
tion of activity,[7] homeostasis,[8] and survival of B-cells.[9] Upon
BCR–antigen binding, tyrosine phosphorylation is induced,[10]
which triggers further phosphorylation processes and finally
leads to a dampening of the BCR-induced signal.[6, 11] Apart
from a few exceptions,[12] sialic acid binding sites of CD22 were
shown to be effectively occupied by cis ligands, that is, ligands
located on the same cell surface.[13] This interaction is impor-
tant for the regulation of CD22 activity. Furthermore, it was
shown that CD22 can also interact with ligands in trans,[14] that
is, ligands located on other cells, to enable cell–cell communi-
cation. As an alternative to antibodies, sialosides that were
shown to directly influence CD22 activity[15] initiated an intense
search for high-affinity ligands.
The physiological ligands of Siglecs are gangliosides and sia-
lidated glycoproteins.[16,17] CD22 recognizes sialic acid a2,6-
linked to d-Gal, d-GalNAc (!1), or d-GlcNAc. A decrease in the
structural complexity yielded sialic acid derivatives 2–4[15,18, 19]
(Figure 1), indicating that a biphenyl carboxamide moiety at
the 9-position can improve affinity substantially. When this ex-
tension in the 9-position was applied to the disaccharide epi-
tope, ligands such as 5 and 6 exhibiting sub-micromolar affini-
ties were identified.[20] Finally, benzyl substituents at the reduc-
ing end of the disaccharide epitope led to a further improve-
ment in affinity.[19,21]
When testing in B-cell based assays, a further aspect, the so-
called density-dependent binding, must be considered.[22] In
tests of monomeric sialosides (e.g. , 7[23] or 8,[24] Figure 1) cou-
pled to various supports such as a polyacrylamide backbone,[23]
a glutamate cluster,[18] or a polymer obtained by ring-opening
metathesis,[25] a substantial increase in binding affinity relative
to monovalent sialosides was observed.[18,26] Interestingly, with
a multivalent presentation, cis interactions could be abolished
without precedent treatment with sialidase to remove masking
by cis ligands.[13] Additionally, O’Reilly et al. showed that bifunc-
tional ligands comprising a ligand of CD22 linked to an antigen
can self-assemble by antibody triggering on B-cell surfaces and
are able to overcome cis interactions as well.[24] Based on the
current state of knowledge, an oligovalent presentation of
glycan ligands is required for a successful competition with cis
ligands.[27] However, further investigation is required to clarify
whether an oligomeric display is mandatory to compete with
cis ligands, or if monomeric high-affinity ligands could success-
Siglec-2, also known as CD22, is involved in the regulation and
survival of B-cells and has been successfully targeted in cell de-
pletion therapies with antibody-based approaches. Sialic acid
derivatives, already known to bind with high affinity to myelin-
associated glycoprotein (MAG, Siglec-4), were screened for
their binding affinity for CD22 by surface plasmon resonance.
The best compound identified was further modified with vari-
ous hydrophobic substituents at the 2-, 5-, and 9-positions of
the sialic acid scaffold, leading to nanomolar derivatives, of
which ligand 17b shows the most promising pharmacodynam-
ic and pharmacokinetic profiles. Isothermal titration calorimetry
measurements demonstrate that the binding is enthalpy
driven. Interestingly, the thermodynamic fingerprints reveal an
excellent correlation between gains in enthalpy and compen-
sation by increased entropy costs. Moreover, 17b exhibits a
residence time in the range of a few seconds, clearly pro-
longed relative to residence times typically observed for carbo-
hydrate–lectin interactions. Finally, initial tests regarding drug-
like properties of 17b demonstrate the required high plasma
protein binding yet a lack of oral availability, although its distri-
bution coefficient (logD) is in the required range.
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of the ligand–CD22 interaction, but also the pharmacokinetic
properties of the best representatives.
Starting from sialyl donor 10,[31] test compound 13b was ob-
tained according to published procedures.[28,29] The o-nosyl de-
rivatives were synthesized according to a different approach
(Scheme 1). After cleavage of the N-acetate (!14),[32] the
amine was allowed to react with o-nosyl chloride (!15) fol-
lowed by glycosylation with 2,3-dichlorobenzyl alcohol to yield
intermediate 16. Acylation by modified Staudinger condi-
tions[33] and deprotection yielded the acyl derivatives 17a–c.
The low yields in this particular reaction can be explained by
the formation of side products due to acetate migration. In ad-
dition, because of the small scale, purification, especially re-
moval of PPh3=O, was extremely difficult. Interestingly, lithium
hydroxide in water/tetrahydrofuran had to be used for depro-
tection, because treatment with 10% aqueous sodium hydrox-
ide resulted in loss of the nitro substituent. To avoid acetate
migration, the 9-amino derivative 19 was obtained by depro-
tection of 16 (!18) followed by azide reduction. Upon alkyla-
tion of the amino group by reductive amination, re-
duction of the nitro group could not be avoided.
However, alkylation of the primary amine with 1-(bro-
momethyl)-4-phenylbenzene in the presence of po-
tassium carbonate furnished sialoside 20, although
only in a modest yield.
Surface plasmon resonance (SPR)
The compound library 9a–k (Table 1) and the newly
synthesized CD22 ligands 13a,b, 17a–c, and 20 were
evaluated by SPR (Table 2). Here, hCD22d1–3–Fc
[34] was
immobilized on a protein A surface, which had been
covalently attached to the chip by amino coupling.
In the reference cell, only protein A was immobilized
to compensate for unspecific binding to the matrix.
Dilution series of the compounds were prepared
either in pure HBS-EP buffer (9a–k, 13a,b) or in the
same buffer additionally containing 5% DMSO (17a–
c, 20). Finally, the sensorgrams were fitted according
to a 1:1 binding model.
Ligand 13a showed a binding affinity in the sub-
micromolar range (Entry 13). With the 2,3-dichloro-
benzyl aglycone (!13b), a gain in affinity by a factor
of eight was observed (Entry 14). Modifications at the
9-position caused a gain in affinity for 4-(4-hydroxy-
phenyl)benzamide 17b (Entry 16), equal affinity for
4-(pyridin-4-yl)benzamide 17c (Entry 17), and a loss
in affinity for amine 20 (Entry 18). Surprisingly, 17a
(Entry 15) showed no affinity, neither in the SPR ex-
periments, nor in the isothermal titration calorimetry
(ITC) assay (Table 2), although the best substituents
identified so far for the 2- (2,3-dichlorobenzyl) and
the 5-positions (o-nosyl) were present. Regarding se-
lectivity, 17b exhibits a 50-fold higher affinity for
CD22 than for MAG (KD=3.0 mm). This might be
largely due to the biphenyl moiety at the 9-position,
which has previously been shown to decrease the af-
finity for MAG.[20,28,35]
For the ligands 13b, 17b, and 17c a clear prolongation of
the residence time of the protein–ligand complex was ob-
served (Table 3, Figure 2). Potential advantages of a prolonged
Figure 2. Sensorgram of 17b at 25 8C measured in SPR; RU= response units.
Scheme 1. Reagents and conditions: a) 4-phenylbenzoyl chloride, PPh3, DCE (77%);
b) ROH, NIS, TfOH, CH3CN [12a : 70%, 12b : 50%, 16 : 76%]; c) 10% aq NaOH [13a : 51%,
13b : 25%]; d) o-nosyl-Cl, NEt3, DMAP, CH2Cl2 (78%); e) RCOCl, PPh3, DCE; f) LiOH, H2O,
THF [17a–c : 6–19% for two steps, !18 : 52%]; g) PPh3, H2O, NEt3, 50 8C (13%); h) 1-(bro-
momethyl)-4-phenylbenzene, K2CO3, THF (12%).
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of the ligand–CD22 interaction, but also the pharmacokinetic
properties of the best representatives.
Starting from sialyl donor 10,[31] test compound 13b was ob-
tained according to published procedures.[28,29] The o-nosyl de-
rivatives were synthesized according to a different approach
(Scheme 1). After cleavage of the N-acetate (!14),[32] the
amine was allowed to react with o-nosyl chloride (!15) fol-
lowed by glycosylation with 2,3-dichlorobenzyl alcohol to yield
intermediate 16. Acylation by modified Staudinger condi-
tions[33] and deprotection yielded the acyl derivatives 17a–c.
The low yields in this particular reaction can be explained by
the formation of side products due to acetate migration. In ad-
dition, because of the small scale, purification, especially re-
moval of PPh3=O, was extremely difficult. Interestingly, lithium
hydroxide in water/tetrahydrofuran had to be used for depro-
tection, because treatment with 10% aqueous sodium hydrox-
ide resulted in loss of the nitro substituent. To avoid acetate
migration, the 9-amino derivative 19 was obtained by depro-
tection of 16 (!18) followed by azide reduction. Upon alkyla-
tion of the amino group by reductive amination, re-
duction of the nitro group could not be avoided.
However, alkylation of the primary amine with 1-(bro-
momethyl)-4-phenylbenzene in the presence of po-
tassium carbonate furnished sialoside 20, although
only in a modest yield.
Surface plasmon resonance (SPR)
The compound library 9a–k (Table 1) and the newly
synthesized CD22 ligands 13a,b, 17a–c, and 20 were
evaluated by SPR (Table 2). Here, hCD22d1–3–Fc
[34] was
immobilized on a protein A surface, which had been
covalently attached to the chip by amino coupling.
In the reference cell, only protein A was immobilized
to compensate for unspecific binding to the matrix.
Dilution series of the compounds were prepared
either in pure HBS-EP buffer (9a–k, 13a,b) or in the
same buffer additionally containing 5% DMSO (17a–
c, 20). Finally, the sensorgrams were fitted according
to a 1:1 binding model.
Ligand 13a showed a binding affinity in the sub-
micromolar range (Entry 13). With the 2,3-dichloro-
benzyl aglycone (!13b), a gain in affinity by a factor
of eight was observed (Entry 14). Modifications at the
9-position caused a gain in affinity for 4-(4-hydroxy-
phenyl)benzamide 17b (Entry 16), equal affinity for
4-(pyridin-4-yl)benzamide 17c (Entry 17), and a loss
in affinity for amine 20 (Entry 18). Surprisingly, 17a
(Entry 15) showed no affinity, neither in the SPR ex-
periments, nor in the isothermal titration calorimetry
(ITC) assay (Table 2), although the best substituents
identified so far for the 2- (2,3-dichlorobenzyl) and
the 5-positions (o-nosyl) were present. Regarding se-
lectivity, 17b exhibits a 50-fold higher affinity for
CD22 than for MAG (KD=3.0 mm). This might be
largely due to the biphenyl moiety at the 9-position,
which has previously been shown to decrease the af-
finity for MAG.[20,28,35]
For the ligands 13b, 17b, and 17c a clear prolongation of
the residence time of the protein–ligand complex was ob-
served (Table 3, Figure 2). Potential advantages of a prolonged
Figure 2. Sensorgram of 17b at 25 8C measured in SPR; RU= response units.
Scheme 1. Reagents and conditions: a) 4-phenylbenzoyl chloride, PPh3, DCE (77%);
b) ROH, NIS, TfOH, CH3CN [12a : 70%, 12b : 50%, 16 : 76%]; c) 10% aq NaOH [13a : 51%,
13b : 25%]; d) o-nosyl-Cl, NEt3, DMAP, CH2Cl2 (78%); e) RCOCl, PPh3, DCE; f) LiOH, H2O,
THF [17a–c : 6–19% for two steps, !18 : 52%]; g) PPh3, H2O, NEt3, 50 8C (13%); h) 1-(bro-
momethyl)-4-phenylbenzene, K2CO3, THF (12%).
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residence time are extended duration of the pharmacological
effect and target selectivity.[36] Additionally, a therapeutic effect
can be reached with a lower dose. As the half-life (t1/2) of car-
bohydrate–protein complexes is typically very short (<1 s),[37,38]
this is clearly an improved property of these new CD22 ligands,
although there is still a need for further improvement. The ex-
tended t1/2 of the ligand–CD22
complex[39] might be due to the
improved lipophilicity of the li-
gands (see logD values in
Table 5 below).
Isothermal titration calorimetry
(ITC)
The binding affinities measured
by SPR and ITC experiments
(Table 2) are in good agreement
with each other. The thermody-
namic fingerprint of a ligand de-
scribes enthalpy and entropy
contributions of the interaction
with its target and therefore pro-
vides characteristic insight into
the binding process. ITC meas-
urements for the ligands 9k,
13a,b, and 17a–c were per-
formed at 25 8C using hCD22d1–
3–Fc
[34] (Table 4) and confirmed
the behavior typically observed
for carbohydrate–lectin interac-
tions,[40–43] namely an enthalpy-
driven binding. Less common
are entropy-driven carbohy-
drate–lectin interactions, such as
heparin binding to the agrin-G3
domain[42] or the interaction of
di- and trisaccharides with calre-
ticulin.[43]
The interaction of the parent
compound 9k is dominated by
a large enthalpic contribution,
which is, however, decreased by
substantial entropy costs (Entry
23). The approximate sixfold
drop in affinity observed for 13a
results from a large increase in
entropy costs, which is only partially compensated by an im-
proved enthalpy contribution (Entry 24). A possible explana-
tion for the increased entropy term is a substantial conforma-
tional change caused by the spatial demands of the biphenyl
substituent. Replacement of the benzyl aglycone in 13a with
the 2,3-dichlorobenzyl group (!13b, Entry 25) gives a further
increase in enthalpy, whereas the entropy term remains stable.
Surprisingly, 17a (Entry 26) does not bind to CD22, although
the o-nosyl substituent does not prohibit binding of 9k. As re-
ported by Kiso and colleagues,[19] intramolecular attraction be-
tween benzyl at the 2-position and biphenyl at the 9-position
can lead to a hydrophobic collapse. The introduction of an o-
nosyl group at the 5-position may further support this process,
abolishing the binding of 17a. This hypothesis is also support-
ed by the pharmacokinetic properties of 17a because it is the
only compound that was retained in an artificial membrane
Table 3. Kinetic properties of 9k, 13b, and 17b,c.
Entry Compd KD [nm] kon [10
6 m!1 s!1] koff [s
!1] t1/2 [s]
[a]
19 9k 130 2.1 0.27 2.6
20 13b 100 1.1 0.13 5.3
21 17b 60 1.1 0.08 8.7
22 17c 110 1.3 0.16 4.3
[a] t1/2= ln2/koff.
Table 4. Thermodynamic parameters as determined at 25 8C by ITC.
Entry Compd N KD [nm] DG8 [kJmol
!1] DH8 [kJmol!1] !TDS8 [kJmol!1]
23 9k 0.96 131 !39.3 !54.8 +15.5
24 13a 0.96"0.04 751"224 !35.1"0.8 !73.4"0.8 +38.3"1.6
25 13b 0.94"0.02 82"19 !40.5"0.6 !80.2"3.4 +39.7"3.6
26 17a NB[a] NB[a] NB[a] NB[a] NB[a]
27 17b 1.07"0.01 80"9 !40.6"0.4 !61.6"1.1 +21.0"0.7
28 17c 0.95"0.02 152"43 !39.0"0.7 !83.4"2.8 +44.4"3.5
[a] No binding.
Table 2. Affinity data for CD22 ligands as determined by SPR and ITC experiments.
KD [nm]
Entry Compd R1 R2 R3 SPR ITC
12 9k 110 131
13 13a Bn Ac 800 751"224
14 13b Ac 100 82"19
15 17a NB[a] NB[a]
16 17b 60 80"9
17 17c 110 152"43
18 20 500 ND[b]
[a] No binding. [b] Not determined.
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(PAMPA,[44] see Table 5, Entry 31). Interestingly, compound 20,
in which the amide linker of 17a is replaced by an amine
linker, again exhibited nanomolar binding affinity in SPR
(Table 2, Entry 18).
Introduction of 4-(4-hydroxyphenyl)benzamide (!17b,
Entry 27) resulted in a ligand with an affinity similar to that of
compound 13b, although the DH8 and TDS8 terms substantial-
ly change; they both differ by 19 kJmol!1, but with opposite
signs. Introduction of a para-hydroxy substituent caused a fa-
vorable enthalpy change similar to an observation reported by
Kiso et al.[20] Interestingly, when the terminal phenol (!17b)
was replaced by pyridine (!17c, Entry 28), a substantially im-
proved DH8 value (!22 kJmol!1) was observed, which, howev-
er, is overcompensated by a loss of entropy leading to an over-
all twofold decrease in affinity. Clearly, the o-nosyl substituent
elicits a reorientation of the ligand in the binding site, or leads
to a remarkable change in desolvation energies. As a conse-
quence, a dramatic change in the thermodynamic fingerprint
results. An enthalpy–entropy plot (Figure 3) reveals a linear re-
lationship with a high correlation coefficient (R2=0.97), indicat-
ing enthalpy–entropy compensation, a property often reported
for carbohydrate–lectin interactions.[40,45] The slope of !1 de-
notes that the enthalpic gain is completely compensated by
an entropic penalty.
Pharmacokinetics
As CD22 is found exclusively on
B-cells, oral or intravenous appli-
cations must be considered. To
elucidate the potential for oral
availability, logD values were de-
termined, as they are generally
considered a rough indicator of
a given compound’s membrane
permeation behavior,[46,47] al-
though restrictions apply.[48] The
logD values of compounds
13a,b and 17a–c were determined, and are in the range of
0.91–3.25 (Table 5), which indicates possible membrane perme-
ability. However, determination of logPe with the parallel artifi-
cial membrane permeability assay (PAMPA)[44] showed that 13a
and 17b do not permeate at all, and 13b and 17a,c only to a
very limited extent. Furthermore, retention within the mem-
brane (PAMPA %Mm) could be excluded, except for 17a. Here,
at pH 5, 24% of the total amount of compound was retained
in the membrane. The different results in the PAMPA for other
ligands despite similar logD values might be caused by other
molecular descriptors. For example, the logD values of 17a
and 17b are in the same range, but their nonpolar surface
areas and hydrogen bonding capacity differ. The former are
generally observed to favor partition, whereas the latter seems
to hinder it.[49] Due to these findings, no oral absorption based
on passive diffusion can be expected for the presented CD22
ligands, as logPe values below !6.7 indicate a very poor per-
meation through membranes. Therefore, if no active transport
processes are involved, oral administration seems unrealistic.
Finally, plasma protein binding (PPB) of our CD22 ligands
turned out to be very high. As CD22 is located on the surface
of B-cells which circulate in the blood, high PPB might be ben-
eficial, as suggested by Urien et al. for cetirizine, as an exam-
ple.[50] Moreover, side effects due to distribution in various tis-
sues of the body might be decreased as a consequence of
both the high extent of PPB and the compound’s inability to
cross membranes. An additional positive aspect might be pro-
longation of plasma t1/2, resulting from the fact that only free
ligands can be metabolized and excreted. Nevertheless, the
amount of unbound ligand, and consequently its distribution
and clearance, depends not only on the extent of binding at
equilibrium but also on the rates of association and dissocia-
tion (kon and koff)
[51] as well as tissue distribution and binding.
The latter seems negligible, as PAMPA results do not indicate
membrane permeation. The kinetic behavior of the ligands
with respect to plasma proteins could be assessed by SPR and
could provide valuable additional information.[52]
Conclusions
A series of high-affinity CD22 ligands was synthesized and in-
vestigated with regard to their biological and pharmacokinetic
properties. The best ligand, sialoside 17b, contains a dichloro-
benzyl substituent at the anomeric position, an ortho-nitroben-
Table 5. Pharmacokinetic properties of CD22 ligands.
Entry Compd logD7.4 PAMPA logPe PAMPA [%Mm] PPB [%]
29 13a 0.91 NP[a] NR[b] 97
30 13b 2.24 !9.8 NR[b] 98
31 17a 3.25 !8.7 pH 5.0: 24%
pH 6.2: 14%
pH 7.4: NR[b]
>99
32 17b 3.12 NP[a] NR[b] >99
33 17c 2.08 !8.9 NR[b] >99
[a] No permeation. [b] No retention.
Figure 3. Enthalpy–entropy compensation plot : correlation of the change in
enthalpy (DH8) and the change in entropy (!TDS8) of CD22 ligands interact-
ing with hCD22d1–3–Fc.
[34]
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zylsulfonamide at the 5-position, and a 4’-hydroxy-4-biphenyl-
carboxamide at the 9-position. In addition to nanomolar affini-
ty, ligand 17b exhibits a prolonged residence time of the pro-
tein–ligand complex, which is atypical for carbohydrate–lectin
interactions.[38] With respect to its pharmacokinetic properties,
17b is not expected to be orally available based on PAMPA
data, and therefore intravenous administration would need to
be considered for an in vivo validation. However, the low per-
meation may be improved by a prodrug approach[47] or by re-
placing the carboxylate with a bioisostere.[53] Finally, 17b
shows extended plasma protein binding, which might be ben-
eficial concerning various aspects such as pharmacological
effect, plasma half-life, or side effects.
Experimental Section
Chemistry
NMR spectra were recorded on a Bruker Avance DMX-500 spec-
trometer (500MHz). Assignment of 1H and 13C NMR spectra was
performed by using 2D methods (COSY, HSQC, TOCSY). Chemical
shifts are expressed in ppm using residual CHCl3, CHD2OD and
HDO as references. Optical rotations were measured with Perki-
nElmer Polarimeters 241 and 341. MS analyses were carried out
with a Waters Micromass ZQ Detector system. The spectra were re-
corded in positive or negative ESI mode. HPLC–HRMS analyses
were carried out with an Agilent 1100 instrument equipped with a
photodiode array detector and a Micromass QTOF I equipped with
a 4 GHz digital time converter. All target compounds exhibited a
purity of !95%. Reactions were monitored by TLC using glass
plates coated with silica gel 60 F254 (Merck) and visualized by using
UV light and/or by charring with a molybdate solution (0.02m solu-
tion of ammonium cerium sulfate dihydrate and ammonium mo-
lybdate tetrahydrate in 10% aq H2SO4). Column chromatography
was performed on silica gel (Uetikon, 40–60 mesh). CH3OH was
dried by holding at reflux with NaOMe and distilled immediately
before use. THF was distilled over Na immediately before use.
CH2Cl2, dichloroethane (DCE), CH3CN, toluene, and benzene were
dried by filtration over Al2O3 (Fluka, type 5016 A basic). Molecular
sieves (3 !) were activated under vacuum at 500 8C for 2 h immedi-
ately before use. Synthetic procedures for compounds 10,[31] 12a,
13a,[28] 14, and 15[29] were reported earlier.
Methyl [methyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-
(4-phenylbenzamido)-2-thio-d-glycero-a-d-galacto-2-nonulopyr-
anosid]onate (11): Compound 10 (250 mg, 0.50 mmol, 1.0 equiv)
was dissolved in dry DCE (10 mL). 4-Phenylbenzoyl chloride
(432 mg, 2.00 mmol, 4.0 equiv) and PPh3 (290 mg, 1.10 mmol,
2.2 equiv) were added, and the reaction mixture was stirred at
room temperature for 24 h. After dilution with CH2Cl2 (10 mL), the
organic layer was washed with satd aq NaHCO3 (3"5 mL) and H2O
(5 mL), dried over Na2SO4 and filtered. Afterward, the solvents were
removed under reduced pressure and the crude product was puri-
fied by chromatography on silica gel (0.5% gradient of CH3OH in
CH2Cl2) to yield 11 (251 mg, 77%) as an oil.
1H NMR (500MHz,
CDCl3): d=1.90 (s, 3H, OAc), 1.97 (s, 3H, SMe), 2.03, 2.07 (2 s, 6H, 2
OAc), 2.20 (dd, J=11.8, 13.8 Hz, 1H, H-3a), 2.24 (s, 3H, NHAc), 2.56
(dd, J=4.9, 13.8 Hz, 1H, H-3b), 3.05 (ddd, J=0.5, 3.5, 15.3 Hz, 1H,
H-9a), 3.82 (s, 3H, OMe), 4.16 (q, J=10.3 Hz, 1H, H-5), 4.28 (dd, J=
1.9, 10.6 Hz, 1H, H-6), 4.50 (ddd, J=3.9, 8.6, 15.0 Hz, 1H, H-9b),
5.16 (dt, J=3.5, 7.3 Hz, 1H, H-8), 5.20–5.33 (m, 2H, H-4, H-7), 5.43
(d, J=10.1 Hz, 1H, 5-NH), 7.22 (dd, J=4.3, 8.5 Hz, 1H, 9-NH), 7.36–
7.43 (m, 1H, CHar), 7.47 (dd, J=4.8, 10.3 Hz, 2H, CHar), 7.54–7.63 (m,
2H, CHar), 7.64–7.72 (m, 2H, CHar), 7.90 ppm (d, J=8.5 Hz, 2H,
CHar) ;
13C NMR (125MHz, CDCl3): d=11.4 (SMe), 21.0, 21.3 (3C, 3
OAc), 23.3 (NHAc), 37.3 (C3), 38.1 (C9), 49.9 (C5), 53.1 (OMe), 68.4
(C7), 69.4 (C4), 70.7 (C8), 71.0 (C6), 84.9 (C2), 127.3, 127.4, 127.7,
128.2, 129.1, 133.0, 140.1, 144.5 (12C, Car), 167.3, 168.2, 170.4, 170.5,
171.2, 172.2 ppm (6 CO); MS (ESI) m/z calcd for C32H38N2O11S [M+
Na]+ : 681.20, found: 681.28.
Methyl [2,3-dichlorobenzyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-
trideoxy-9-(4-phenylbenzamido)-d-glycero-a-d-galacto-2-nonu-
lopyranosid]onate (12b): Compound 11 (50 mg, 7.5 mmol,
1.0 equiv) was dissolved in dry CH3CN (2.0 mL). 2,3-Dichlorobenzyl
alcohol (40 mg, 23 mmol, 3.0 equiv) and powdered MS (3 !) were
added. The mixture was stirred at room temperature for 1.5 h. The
suspension was then cooled to "40 8C and subsequently treated
with N-iodosuccinimide (NIS; 27 mg, 12 mmol, 1.6 equiv) and triflic
acid (5.3 mL, 6 mmol in 0.2 mL CH3CN, 0.8 equiv). After 30 min, the
reaction mixture was warmed to "30 8C and stirring was continued
for 16 h. The mixture was allowed to warm to room temperature,
stirred for another 2 h and filtered through a pad of Celite. The
Celite was washed with CH2Cl2 (5 mL) and the filtrate was subse-
quently washed with 20% aq Na2S2O3 (1 mL) and satd aq NaHCO3
(3"2 mL). The organic phase was dried over Na2SO4, filtered and
concentrated under reduced pressure. The crude product was puri-
fied by chromatography on silica gel (0.5% gradient of iPrOH in
petroleum ether (PE)/CH2Cl2 8:4) to yield 12b (30 mg, 50%) as an
oil. 1H NMR (500MHz, CDCl3): d=1.89 (s, 6H, NHAc, OAc), 2.01–
2.06 (m, 4H, H-3a, OAc), 2.15 (s, 3H, OAc), 2.57 (dd, J=4.1, 13.4 Hz,
1H, H-3b), 3.49 (dd, J=5.6, 12.2 Hz, 1H, H-9a), 3.79 (s, 3H, OMe),
3.83 (d, J=12.4 Hz, 1H, H-9b), 4.09 (t, J=10.5 Hz, 1H, H-5), 4.15 (m,
1H, H-6), 4.58 (A of AB, J=13.7 Hz, 1H, CH2Ar), 4.83–4.98 (m, 2H,
H-4, CH2Ar), 5.33–5.40 (m, 2H, H-7, H-8), 7.21 (t, J=7.5 Hz, 1H,
CHar), 7.23–7.31 (m, 4H, CHar), 7.34–7.50 (m, 6H, CHar), 7.56–
7.69 ppm (m, 1H, CHar) ;
13C NMR (125MHz, CDCl3): d=20.8, 20.9,
21.1 (3 OAc), 23.3 (NHAc), 37.8 (C3), 43.2 (C9), 49.5 (C5), 53.0 (OMe),
64.3 (CH2Ar), 68.3 (C7), 68.9 (C4), 70.7 (C8), 73.0 (C6), 98.8 (C2),
126.2, 127.2, 127.3, 127.5, 129.4, 129.6, 137.3 (18C, Car), 168.1, 170.2,
170.4, 170.7, 171.0, 171.2 ppm (6 CO); MS (ESI) m/z calcd for
C38H40Cl2N2O12 [M+Na]
+ : 809.18, found: 809.28.
Sodium [2,3-dichlorobenzyl 5-acetamido-3,5,9-trideoxy-9-(4-phe-
nylbenzamido)-d-glycero-a-d-galacto-2-nonulopyranosid]onate
(13b): Compound 12b (30 mg, 38 mmol) was treated with 10% aq
NaOH (0.4 mL) in CH3OH (2 mL). The crude product was purified by
LC–MS to yield 13b as a white solid (6.3 mg, 25%). [a]D
20 "21.8
(c=0.33, CH3OH);
1H NMR (500MHz, CD3OD): d=1.73 (t, J=
11.0 Hz, 1H, H-3a), 2.00 (s, 3H, NHAc), 2.93 (d, J=11.4 Hz, 1H, H-
3b), 3.46 (d, J=9.0 Hz, 1H, H-7), 3.53 (m, 1H, H-9a), 3.68 (d, J=
9.0 Hz, 1H, H-6), 3.71–3.85 (m, 3H, H-4, H-5, H-9b), 4.04 (t, J=
7.7 Hz, 1H, H-8), 4.73 (A, B of AB, J=13.4 Hz, 2H, CH2Ar), 7.26 (t,
J=7.9 Hz, 1H, CHar), 7.39 (t, J=6.6 Hz, 2H, CHar), 7.46 (t, J=7.4 Hz,
2H, CHar), 7.57 (d, J=7.7 Hz, 1H, CHar), 7.67 (d, J=7.4 Hz, 2H, CHar),
7.72 (d, J=7.8 Hz, 2H, CHar), 7.91 (d, J=7.9 Hz, 2H, CHar), 8.22 (d,
J=6.5 Hz, 1H, 5-NH), 8.30 ppm (s, 1H, 9-NH); 13C NMR (125MHz,
CD3OD): d=22.6 (NHAc), 42.5 (C3), 44.5 (C9), 54.1 (C5), 64.6
(CH2Ar), 69.6 (C4), 71.2 (C8), 72.5 (C7), 74.5 (C6), 101.4 (C2), 127.9,
128.0, 128.2, 128.5, 128.6, 129.0, 129.1, 130.0, 130.1, 140.3, 145.6
(18C, Car), 175.5 ppm (3C, 3 CO); HRMS (ESI) m/z calcd for
C31H32Cl2N2O9 [M+Na]
+ : 669.1384, found: 669.1384.
Methyl [methyl 4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-5-(2-ni-
trophenylsulfonamido)-2-thio-d-glycero-a-d-galacto-2-nonulo-
pyranosid]onate (15): Nosyl chloride (105 mg, 0.47 mmol), NEt3
(34.0 mL, 48.0 mg, 0.47 mmol), and DMAP (10.0 mg, 0.08 mmol)
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were added successively to a solution of 14 (73.0 mg, 0.16 mmol)
in dry CH2Cl2 (3 mL) at 0 8C. The reaction mixture was stirred at
room temperature overnight and then washed with satd aq
NaHCO3 (2!5 mL) and H2O (5 mL). The organic phase was dried
over Na2SO4, filtered and concentrated under reduced pressure.
The residue was purified by chromatography on silica gel (PE/
EtOAc 1:1!1:2) to yield 15 (81 mg, 78%) as an oil. 1H NMR
(500MHz, CDCl3): d=1.85 (m, 1H, H-3a), 2.02 (s, 3H, SMe), 2.10,
2.13, 2.21 (3 s, 9H, 3 OAc), 2.80 (m, 1H, H-3b), 3.32 (dd, J=6.2,
13.4 Hz, 1H, H-9a), 3.57 (dd, J=3.2, 13.4 Hz, 1H, H-9b), 3.80 (m, 1H,
H-5), 3.82 (s, 3H, OMe), 3.91 (d, J=10.5 Hz, 1H, H-6), 4.97 (td, J=
4.7, 11.4 Hz, 1H, H-4), 5.30 (m, 2H, H-7, H-8), 5.75 (d, J=9.4 Hz, 1H,
NH), 7.70 (m, 2H, CHar), 7.90 (d, J=7.9, 1H, CHar), 8.10 ppm (d, J=
6.5, 1H, CHar) ;
13C NMR (125MHz, CDCl3): d=12.1 (SMe), 20.5, 21.1,
21.1 (3 OAc), 38.1 (C3), 50.8 (C9), 53.2, 53.5 (C5, OMe), 68.8 (C7),
69.7 (C4), 70.4 (C8), 74.7 (C6), 82.8 (C2), 125.5, 130.4, 133.5, 135.5,
147.5 (6C, Car), 167.8, 170.4 ppm (4C, 4 CO); MS (ESI) m/z calcd for
C23H29N5O13S2 [M!H]! : 646.12, found: 646.56.
Methyl [2,3-dichlorobenzyl 4,7,8-tri-O-acetyl-9-azido-3,5,9-tri-
deoxy-5-(2-nitrophenylsulfonamido)-d-glycero-a-d-galacto-2-
nonulopyranosid]onate (16): Compound 15 (370 mg, 0.57 mmol,
1.0 equiv) was dissolved in dry CH3CN (10 mL). Then, 2,3-dichloro-
benzyl alcohol (302 mg, 1.71 mmol, 3.0 equiv) and powdered MS
(3 ") were added. The mixture was stirred at room temperature for
1.5 h. Afterward, the suspension was cooled to !40 8C and subse-
quently treated with NIS (205 mg, 0.92 mmol, 1.6 equiv) and triflic
acid (40 mL, 0.4 mmol, 0.8 equiv). After 30 min, the reaction mixture
was warmed to !30 8C, and stirring was continued for 16 h. The
mixture was then warmed to room temperature, stirred for another
2 h and filtered through a pad of Celite. The Celite was washed
with CH2Cl2 (15 mL), and the filtrate was subsequently washed with
20% aq Na2S2O3 (5 mL), satd aq NaHCO3 (3!5 mL), and H2O (5 mL).
The organic phase was dried over Na2SO4, filtered and concentrat-
ed under reduced pressure. The crude product was purified by
chromatography on silica gel (0.5% gradient of iPrOH in PE/CH2Cl2
2:1) to yield 16 as a yellow solid (337 mg, 76%). [a]D
20 !43.7 (c=
0.46, CH3OH);
1H NMR (500MHz, CDCl3): d=1.96 (m, 1H, H-3a),
2.02, 2.14, 2.22 (3 s, 9H, 3 OAc), 2.75 (m, 1H, H-3b), 3.31 (m, 1H, H-
9a), 3.50 (m, 1H, H-9b), 3.78 (s, 3H, OMe), 3.88 (m, 1H, H-5), 4.15
(d, J=10.6 Hz, 1H, H-6), 4.58, 4.66 (A, B of AB, J=12.7, 2H, CH2Ar),
4.96 (m, 1H, H-4), 5.24–5.32 (m, 2H, H-7, H-8), 5.60 (d, J=9.3 Hz,
1H, 5-NH), 7.25 (m, 1H, CHar), 7.35–7.48 (m, 2H, CHar), 7.74 (dd, J=
4.5, 10.7 Hz, 1H, CHar), 7.77–7.86 (m, 2H, CHar), 8.19 ppm (m, 1H,
CHar) ;
13C NMR (125MHz, CDCl3): d=20.5, 20.7, 21.0 (3 OAc), 38.2
(C3), 50.5 (C9), 51.0 (OMe), 52.9 (C5), 64.4 (CH2Ar), 68.6 (C4), 69.7
(C7), 71.1 (C8), 76.7 (C6), 98.1 (C2), 123.7, 125.4, 126.4, 127.5, 127.7,
129.4, 132.4, 132.7, 134.1, 135.4, 149.5 (12C, Car), 168.6, 170.7,
170.9 ppm (4C, 4 CO); MS (ESI) m/z calcd for C29H31Cl2N5O14S [M+
Na]+ : 798.08, found: 797.95.
General procedure A for the preparation of acid chlorides : The
acid (0.15 mmol) was suspended in dry CH2Cl2 (1–2 mL) and cooled
to 0 8C. Chloroenamine (0.17 mmol) was added dropwise, and the
reaction was allowed to warm to room temperature. After 2 h, the
initial precipitate was dissolved, and the acid chlorides were direct-
ly used without work-up and purification.
General procedure B for the synthesis of compounds 17a–c :
Compound 16 (75 mmol) was added to the corresponding acid
chloride (0.15 mmol), dissolved in dry CH2Cl2 (1 mL). PPh3
(0.18 mmol) in dry CH2Cl2 (1.5 mL) was added after 5 min, and the
solution was stirred at room temperature for 24 h. Then, the reac-
tion mixture was diluted with CH2Cl2 (5 mL) and washed with satd
aq NaHCO3 (3!3 mL) and H2O (3 mL). The organic phase was dried
over Na2SO4, filtered, and concentrated under reduced pressure.
The residue was purified by chromatography on silica gel. After-
ward, the acetylated intermediate was dissolved in THF/H2O
(2.5 mL, 4:1) and treated with LiOH (0.28 mmol) at room tempera-
ture for 4 h. After completion of the reaction, the crude product
was purified by LC–MS to yield the final compound.
Sodium [2,3-dichlorobenzyl 3,5,9-trideoxy-5-(2-nitrophenylsulfo-
namido)-9-(4-phenylbenzamido)-d-glycero-a-d-galacto-2-nonulo-
pyranosid]onate (17a): Prepared from 16 (50 mg, 0.06 mmol) and
4-phenyl benzoic acid according to general procedures A and B.
Yield: 10 mg (19%) as a white solid. [a]D
20 !1.8 (c=0.04, CH3OH);
1H NMR (500MHz, CD3OD): d=1.64 (t, J=12.1 Hz, 1H, H-3a), 2.40
(dd, J=3.7, 13.0 Hz, 1H, H-3b), 3.51 (m, 1H, H-9a), 3.59 (t, J=
10.0 Hz, 1H, H-5), 3.69–3.80 (m, 2H, H-7, H-9b), 3.98 (m, 1H, H-8),
4.05 (m, 1H, H-4), 4.12 (d, J=10.5 Hz, 1H, H-6), 4.53, 4.85 (A, B of
AB, J=12.3 Hz, 2H, CH2Ar), 7.29 (t, J=8.3 Hz, 1H, CHar), 7.38 (t, J=
7.2 Hz, 1H, CHar), 7.42–7.49 (m, 3H, CHar), 7.64 (d, J=7.7 Hz, 1H,
CHar), 7.68 (d, J=7.1 Hz, 3H, CHar), 7.73 (d, J=7.6 Hz, 4H, CHar),
7.91 (d, J=7.6 Hz, 2H, CHar), 8.18 (d, J=7.6 Hz, 1H, CHar), 8.35 ppm
(s, 1H, NH); 13C NMR (125MHz, CD3OD): d=42.3 (C3), 45.7 (C9),
58.1 (C5), 63.9 (CH2Ar), 68.4 (C4), 71.0 (C7), 71.2 (C8), 72.6 (C6), 99.3
(C2), 125.6, 125.9, 128.1, 128.2, 128.7, 129.0, 129.1, 129.2, 130.0,
130.3, 132.4, 133.5, 134.3, 136.5, 139.6, 141.3, 145.7, 149.0 (24C, Car),
171.0 ppm (2C, 2 CO); HRMS (ESI) m/z calcd for C35H32Cl2N3NaO12S
[M+Na]+ : 834.0880, found: 834.0893.
Sodium [2,3-dichlorobenzyl 3,5,9-trideoxy-9-[4-(4-hydroxyphe-
nyl)benzamido]-5-(2-nitrophenylsulfonamido)-d-glycero-a-d-gal-
acto-2-nonulopyranosid]onate (17b): Prepared from 16 (30 mg,
40 mmol) and 4-(4-hydroxyphenyl)benzoic acid according to gener-
al procedures A and B. Yield: 2.0 mg (6%) as a pale-yellow solid.
[a]D
20 !88.0 (c=0.01, CH3OH); 1H NMR (500MHz, CD3OD): d=1.65
(t, J=12.0 Hz, 1H, H-3a), 2.78 (dd, J=3.6, 12.0 Hz, 1H, H-3b), 3.41–
3.58 (m, 2H, H-5, H-9a), 3.67 (m, 1H, H-4), 3.70–3.79 (m, 2H, H-7, H-
9b), 3.88 (d, J=10.3 Hz, 1H, H-6), 3.97 (m, 1H, H-8), 4.64, 4.87 (A, B
of AB, J=12.6 Hz, 2H, CH2Ar), 6.91 (d, J=7.8 Hz, 2H, CHar), 7.26 (t,
J=7.7 Hz, 1H, CHar), 7.39 (d, J=8.0 Hz, 1H, CHar), 7.47–7.60 (m, 3H,
CHar), 7.67 (d, J=7.8 Hz, 2H, CHar), 7.70–7.80 (m, 4H, CHar), 7.85 (d,
J=7.8 Hz, 2H, CHar), 8.16 (d, J=7.3 Hz, 1H, NH), 8.23 ppm (m, 1H,
NH); 13C NMR (125MHz, CD3OD): d=42.6 (C3), 43.8 (C9), 49.5 (C5),
64.7 (CH2Ar), 70.2, 71.2, 71.9 (C4, C7, C8), 74.0 (C6), 116.8, 125.8,
127.3, 128.6, 128.7, 128.9, 129.2, 130.1, 132.1, 132.5, 133.3, 133.7,
134.6, 135.8 (24C, Car), 170.5 ppm (2C, 2 CO); HRMS (ESI) m/z calcd
for C35H33Cl2N3O13S [M+Na]
+ : 828.1009, found: 828.1009.
Sodium [2,3-dichlorobenzyl 3,5,9-trideoxy-5-(2-nitrophenylsulfo-
namido)-9-[4-(pyridin-4-yl)benzamido]-d-glycero-a-d-galacto-2-
nonulopyranosid]onate (17c): Prepared from 16 (58 mg, 70 mmol)
and 4-(pyridin-4-yl)benzoic acid according to general procedures A
and B. Yield: 8.0 mg (13%) as a pale-yellow solid. [a]D
20 !45.0 (c=
0.32, CH3OH);
1H NMR (500MHz, CD3OD): d=1.71 (t, J=12.1 Hz,
1H, H-3a), 2.72 (dd, J=4.3, 12.3 Hz, 1H, H-3b), 3.51 (t, J=10.0 Hz,
1H, H-5), 3.57 (dd, J=6.3, 13.7 Hz, 1H, H-9a), 3.69 (td, J=4.3,
11.3 Hz, 1H, H-4), 3.76–3.86 (m, 2H, H-7, H-9b), 3.91 (d, J=10.3 Hz,
1H, H-6), 4.02 (t, J=7.4 Hz, 1H, H-8), 4.69, 4.92 (A, B of AB, J=
13.2 Hz, 2H, CH2Ar), 7.26 (t, J=7.8 Hz, 1H, CHar), 7.40 (d, J=8.0 Hz,
1H, CHar), 7.49 (d, J=7.7 Hz, 1H, CHar), 7.76 (t, J=6.2 Hz, 2H, CHar),
7.81 (m, 1H, CHar), 7.86–7.93 (m, 5H, CHar), 7.99 (d, J=7.8 Hz, 2H,
CHar), 8.17 (d, J=7.0 Hz, 1H, NH), 8.67 ppm (d, J=5.1 Hz, 2H, CHar) ;
13C NMR (125MHz, CD3OD): d=42.3 (C3), 44.4 (C9), 57.9 (C5), 64.7
(CH2Ar), 69.8 (C4), 71.2 (C7), 71.7 (C8), 74.5 (C6), 100.9 (C2), 123.9,
125.9, 128.5, 128.6, 128.7, 129.5, 130.4, 132.3, 133.5, 133.7, 134.6,
136.2, 136.9, 139.6, 141.2, 148.9, 151.4 (23C, Car), 170.0, 172.6 ppm
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(2 CO); HRMS (ESI) m/z calcd for C34H32Cl2N4O12S [M+H]
+ :
791.1193, found: 791.1194.
Sodium [2,3-dichlorobenzyl 9-azido-3,5,9-trideoxy-5-(2-nitrophe-
nylsulfonamido)-d-glycero-a-d-galacto-2-nonulopyranosid]onate
(18): A solution of 16 (310 mg, 0.4 mmol) in THF/H2O (6 mL:2.5 mL)
was allowed to react with LiOH (78 mg, 3.2 mmol) at room temper-
ature for 4 h. The crude product was purified by LC–MS to yield 18
(107 mg, 52%) as an oil. 1H NMR (500MHz, CD3OD): d=1.68 (t, J=
12.2 Hz, 1H, H-3a), 2.71 (dd, J=4.8, 12.5 Hz, 1H, H-3b), 3.31 (m, 1H,
H-9a), 3.45 (m, 1H, H-5), 3.53 (dd, J=2.4, 12.8 Hz, 1H, H-9b), 3.67
(ddd, J=4.8, 9.9, 11.8 Hz, 1H, H-4), 3.81 (dd, J=1.5, 8.9 Hz, 1H, H-
7), 3.86 (dd, J=1.5, 10.5 Hz, 1H, H-6), 3.95 (ddd, J=2.4, 6.6, 8.9 Hz,
1H, H-8), 4.70, 4.92 (A, B of AB, J=13.3 Hz, 2H, CH2Ar), 7.27 (t, J=
7.9 Hz, 1H, CHar), 7.44 (dd, J=1.4, 8.0 Hz, 1H, CHar), 7.50 (d, J=
7.7 Hz, 1H, CHar), 7.70–7.81 (m, 2H, CHar), 7.88 (m, 1H, CHar),
8.16 ppm (dd, J=3.3, 6.0 Hz, 1H, CHar) ;
13C NMR (125MHz,
CD3OD): d=42.4 (C3), 55.0 (C9), 57.9 (C5), 64.6 (CH2Ar), 69.6 (C4),
70.5 (C7), 72.4 (C8), 74.5 (C6), 125.8, 128.5, 128.7, 130.3, 132.3,
133.5, 134.4 (12C, Car), 172.5 ppm (CO); MS (ESI) m/z calcd for
C22H23Cl2N5O11S [M!H]! : 634.04, found: 634.16.
Sodium [2,3-dichlorobenzyl 9-amino-3,5,9-trideoxy-5-(2-nitro-
phenylsulfonamido)-d-glycero-a-d-galacto-2-nonulopyranosid]o-
nate (19): PPh3 (33 mg, 0.13 mmol, 1.6 equiv) and NEt3 (1.2 mL, 12
mmol, 1.5 equiv) were successively added to a solution of 18
(50 mg, 8.0 mmol, 1.0 equiv) in dry THF (5 mL) at 0 8C. After 1 h,
PPh3 (66 mg, 0.26 mmol, 3.2 equiv) and H2O (1.5 mL) were added,
and stirring was continued at 50 8C for 4 h. After cooling to room
temperature, the solvent was removed under reduced pressure,
and the residue was purified by LC–MS to yield 19 (6.3 mg, 13%)
as an oil. [a]D
20 !43.7 (c=0.46, CH3OH); 1H NMR (500MHz,
CD3OD): d=1.60 (t, J=12.0 Hz, 1H, H-3a), 2.79 (dd, J=4.9, 12.3 Hz,
1H, H-3b), 2.93 (dd, J=9.3, 12.7 Hz, 1H, H-9a), 3.34 (m, 1H, H-9b),
3.38 (t, J=10.1 Hz, 1H, H-5), 3.66 (m, 1H, H-4), 3.80–3.89 (m, 2H, H-
6, H-7), 4.05 (m, 1H, H-8), 4.69, 4.91 (A, B of AB, J=13.6 Hz, 2H,
CH2Ar), 7.27 (t, J=7.9 Hz, 1H, CHar), 7.42 (d, J=8.0 Hz, 1H, CHar),
7.54 (d, J=7.8 Hz, 1H, CHar), 7.71–7.81 (m, 2H, CHar), 7.89 (dd, J=
3.3, 6.0 Hz, 1H, CHar), 8.17 ppm (dt, J=3.7, 7.5 Hz, 1H, CHar) ;
13C NMR (125MHz, CD3OD): d=43.0 (C3), 43.9 (C9), 57.9 (C5), 64.5
(CH2Ar), 69.5 (C8), 70.0 (C4), 72.0 (C7), 74.1 (C6), 125.9, 128.3, 128.6,
130.0, 132.3, 133.4, 133.6, 134.5, 136.0, 140.2, 149.1 (12C, Car),
173.9 ppm (CO); MS (ESI) m/z calcd for C22H25Cl2N3O11S [M+H]
+ :
610.07, found: 610.12.
Sodium [2,3-dichlorobenzyl 3,5,9-trideoxy-5-(2-nitrophenylsulfo-
namido)-9-(4-phenylbenzylamine)-d-glycero-a-d-galacto-2-nonu-
lopyranosid]onate (20): Compound 19 (2.0 mg, 3.3 mmol,
1.0 equiv) was dissolved in THF (0.6 mL). 1-(Bromomethyl)-4-phe-
nylbenzene (1.1 mg, 6.6 mmol, 2.0 equiv) and K2CO3 (1.1 mg,
8.0 mmol, 2.4 equiv) were added in portions. The reaction mixture
was stirred at room temperature for 4 days. The crude product was
purified by LC–MS to yield 20 as an oil (0.3 mg, 12%). [a]D
20
!102.3 (c=0.01, CH3OH); 1H NMR (500MHz, CD3OD): d=1.60 (t,
J=11.8 Hz, 1H, H-3a), 2.77 (m, 1H, H-3b), 2.98 (t, J=10.9 Hz, 1H,
H-9a), 3.39–3.41 (m, 2H, H-5, H-9b), 3.66 (m, 1H, H-4), 3.76–3.90 (m,
2H, H-6, H-7), 4.10 (t, J=8.7 Hz, 1H, H-8), 4.19 (s, 2H, NCH2), 4.72,
4.95 (A, B of AB, 2H, CH2Ar), 7.26 (t, J=7.5 Hz, 1H, CHar), 7.36 (m,
1H, CHar), 7.38–7.48 (m, 3H, CHar), 7.54 (d, J=7.4 Hz, 2H, CHar), 7.63
(d, J=7.3 Hz, 2H, CHar), 7.69 (d, J=7.3 Hz, 2H, CHar), 7.76 (s, 2H,
CHar), 7.87 (s, 1H, CHar), 8.17 (s, 1H, CHar), 8.55 ppm (s, 1H, CHar) ;
13C NMR (125MHz, CD3OD): d=41.6 (C3), 47.3 (C9), 51.2 (NCH2),
57.0 (C5), 63.6 (CH2Ar), 68.5 (C8), 69.1 (C4), 70.5 (C7), 72.3 (C6),
123.9, 126.6, 126.7, 127.1, 127.5, 127.6, 128.3, 128.4, 129.7, 130.6,
132.3 ppm (24C, Car) ; HRMS (ESI) m/z calcd for C35H35Cl2N3O11S [M+
Na]+ : 798.1267, found: 798.1262.
Biological assays
Siglec–Fc proteins: Human CD22d1–3–Fc from CHO-Lec1 and murine
MAGd1–3–Fc from CHO-Lec3.2.8.1 cell culture supernatants were af-
finity purified as described previously,[34] dialyzed against 10 mm
phosphate buffer (pH 7.4), sterile filtered, and stored at 4 8C. The
proteins were analyzed by an ELISA and binding assay with immo-
bilized fetuin.[34]
Surface plasmon resonance (SPR): The SPR measurements were per-
formed on a Biacore 3000 SPR-based optical biosensor (Biacore, GE
Healthcare, Uppsala, Sweden). Sensor chips (CM5), immobilization
kits, maintenance supply, and HBS-EP buffer (10 mm HEPES pH 7.4,
150 mm NaCl, 3 mm EDTA, 0.005% v/v surfactant P20) were pur-
chased from GE Healthcare. The carboxy groups on the CM5 chip
were activated for 10 min with a 1:1 mixture of 0.1m N-hydroxy-
succinimide (NHS) and 0.1m 3-(N,N-dimethylamino)propyl-N-ethyl-
carbodiimide (EDC) at a flow rate of 10 mLmin!1. For immobilizing
protein A (P6031, Sigma), a solution of 30 mgmL!1 in acetate buffer
was injected over the activated surface for 10 min at a flow rate of
10 mLmin!1. Protein A densities of ~4000 RU were achieved. Flow
cells were blocked with a 10 min injection of 1m ethanolamine,
pH 8.0. For capturing, hCD22d1–3–Fc or mMAGd1–3–Fc solutions of
30–40 mgmL!1 concentration in NaOAc (pH 5.0) were injected at a
flow rate of 5 mLmin!1 for 3 min. The surface was equilibrated with
HBS-EP buffer overnight at a flow rate of 5 mLmin!1, achieving den-
sities of ~3000–4000 RU. Tenfold dilution series of antagonists
were freshly prepared in HBS-EP. All binding experiments were con-
ducted at 25 8C at a flow rate of 20 mLmin!1. The samples were in-
jected for 1 min followed by 1 min dissociation. Each sample con-
centration was measured in duplicate. Double referencing was ap-
plied to correct for bulk effects and other systematic artifacts (sub-
traction of reference surface and blank injections). Data processing
and equilibrium binding constant determinations were accom-
plished with Scrubber (BioLogic Software, Version 1.1g or 2.0c). Ki-
netic data were simultaneously fit using Scrubber 2.0c. For com-
pounds with low solubility (!17a–c, 20), 5% DMSO (for molecular
biology, >99.9%, Fluka) was used in the buffer. The running buffer
was 5% DMSO in HBS-EP. The surface was equilibrated at a flow of
5 mLmin!1 until the baseline was stable. To eliminate the influence
of DMSO on the signals, a calibration curve was recorded with
DMSO concentrations of 4.7–5.1%. The DMSO calibration was ac-
complished directly in Scrubber 2.0c.
Isothermal titration calorimetry (ITC): ITC experiments were per-
formed using a VP-ITC instrument from MicroCal Inc. (GE Health-
care, Northampton, UK). The measurements were performed at
25 8C. Injections of 5–10 mL ligand solutions were added from a
computer-controlled syringe at an interval of 5 min into the
sample cell solution containing hCD22d1–3–Fc
[34] (cell volume:
1.4523 mL) with stirring (307 rpm). For control experiments, identi-
cal ligand solutions were injected into buffer without protein. The
heat released in this control experiment was subtracted from the
experimental data. The assay buffer was HBS-E (10 mm HEPES
pH 7.4, 150 mm NaCl, 3 mm EDTA, 5% DMSO). The concentration
of hCD22d1–3–Fc was 1.8–11.1 mm, calculated in terms of monomer,
determined by HPLC–UV,[54] and the ligand concentration was 60–
200 mm. The experimental data were fitted to a theoretical titration
curve (one-site binding model) using Origin version 7 (GE Health-
care, Northampton, UK), with DH8 (enthalpy change in kJmol!1), KA
(association constant in m!1), and N (number of binding sites). The
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quantity c=KA·Mt0, where Mt0 is the initial macromolecule concen-
tration, is important in titration microcalorimetry. The experiment
was performed at c values between 2 and 85. Thermodynamic pa-
rameters were calculated from Equation (1):
DG! ¼ DH!#TDS! ¼ RT lnKA ¼ #RT lnKD ð1Þ
for which DG8, DH8, and DS8 are the changes in free energy, en-
thalpy, and entropy of binding, respectively. T is the absolute tem-
perature, and R=8.314 Jmol#1K#1.[55]
logD7.4 determination: Triplicate measurements were performed for
every compound at two ratios of octanol to buffer according to
the expected logD7.4 value. Equal amounts of phosphate buffer
(0.1m, pH 7.4) and octanol were mixed and shaken vigorously for
5 min. Upon separation of the two phases, the buffer phase was
withdrawn and analytes were dissolved therein (10#5m). Predefined
volumes of octanol and analyte solutions were transferred to a
PCR plate, which was thermo-sealed with aluminum foil and
shaken (2 h, 1350 rpm, 25 8C on a Heidolph Titramax 100 plate
shaker (Heidolph, Schwabach, Germany). The plate was then centri-
fuged at 2000 rpm (657 g) and 25 8C for 5 min, and buffer samples
were withdrawn from each well. The analyte concentrations were
determined by LC–MS, and logD7.4 values were calculated. Values
were accepted if the mean values of the two ratios did not differ
by >0.1 units.
Parallel artificial membrane permeation assay (PAMPA): logPe was
determined in a 96-well format. For each compound, measure-
ments were performed in quadruplicate at three pH values: 5.0,
6.2, and 7.4. Each well of a deep-well plate was filled with 650 mL
System Solution (pIon, Woburn MA, USA, P/N 110151) at the ac-
cording pH value. Samples (150 mL) were withdrawn from each
well to determine the blank spectra by UV/Vis spectroscopy. Ana-
lyte was then added to the remaining System Solution to yield
50 mm solutions. To exclude precipitation, the optical density was
measured at l 650 nm, with 0.01 being the threshold value. Again,
samples of 150 mL were withdrawn to determine the reference
spectra. A further 200 mL were transferred to each well of the
donor plate of the PAMPA sandwich. The filter membranes at the
bottom of the acceptor plate were impregnated with 5 mL GIT-0
Lipid Solution (pIon, P/N 110669), and 200 mL Acceptor Sink Buffer
(pIon, P/N 110139) were filled into each acceptor well. The sand-
wich was assembled, then placed in the GutBox, left undisturbed
for 16 h, and then disassembled again followed by the transfer of
150 mL from each donor and acceptor well to UV plates. Quantifica-
tion was performed by both UV/Vis spectroscopy (SpectraMax 190,
Molecular Devices, Sunnyvale, CA, USA) and LC–MS; logPe values
were calculated based on the LC–MS results and with the aid of
the PAMPA Explorer Software (pIon, version 3.5).
Plasma protein binding (PPB): The dialysis membranes (HTDialysis
LCC, Gales Ferry, USA; MWCO 12–14 kDa) were prepared according
to the manufacturer’s instructions. Human plasma (Biopredic,
Rennes, France) was centrifuged (5800 rpm (4325 g), 25 8C, 10 min),
the centrifugate (without floating plasma lipids) was adjusted to
pH 7.5, and analyte was added to yield 10 mm solutions. Equal vol-
umes (150 mL each) of phosphate buffer (0.1m, pH 7.5) and ana-
lyte-containing plasma were transferred to the separated compart-
ments of the assembled 96-well high-throughput dialysis block
(HTDialysis). Measurements were performed in triplicate. The plate
was covered with a sealing film and incubated (5 h, 37 8C). Buffer
and plasma compartment were processed separately: 90 mL were
withdrawn from the buffer compartment and 10 mL blank plasma
were added, while 10 mL were withdrawn from the plasma com-
partment and 90 mL of blank buffer were added. After protein pre-
cipitation with 300 mL CH3CN (4 8C) the solutions were mixed, cen-
trifuged (3600 rpm (1666 g), 4 8C, 11 min) and 50 mL of the superna-
tant were withdrawn. Analyte concentrations were determined by
LC–MS. The fraction unbound was calculated by dividing the con-
centration in the buffer compartment by the concentration in the
plasma compartment (both concentrations adjusted for dilutions
prior to analysis). The fraction bound was calculated by subtracting
the fraction bound from 1. Values were accepted if the recovery of
analyte was between 80 and 120%.
LC–MS measurements: Separation was performed on an Agilent
1100 Series HPLC instrument with a 1200 series autosampler, con-
nected to an Agilent 6400 Series Triple Quadrupole mass spec-
trometer for quantification (Agilent Technologies, Santa Clara, CA,
USA). Double-distilled H2O with 0.1% formic acid (A) and CH3CN
with 0.1% formic acid (B) were used as solvents. The gradient was
a follows: 0.1 min 95% A to 5% B; 1 min 5% A to 95% B; 1.2 min
95% A to 5% B. The total method duration was 4 min. For the sep-
aration, a Waters Atlantis T3 column (3 mm, 2.1!50 mm) was used
(Waters, Milford, MA, USA). The column was heated at 608C, and
the flow rate was set to 0.6 mLmin#1; 5 mL of analyte were injected
per run. Quantification was performed with the MassHunter soft-
ware (Agilent Technologies, Version B.01.04).
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What does it need to achieve selectivity for Sialoadhesin, CD22 and MAG? 
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Introduction. The process of drug development demands to selectively address the target of 
interest and is of major importance in order to avoid side effects. Unfortunately, proteins of 
the same family often show highly conserved binding sites, e.g. Siglecs, making selectivity to 
a challenge for medicinal chemists. Sialoadhesin and CD22 are members of the Siglec-
family
[1]
 and are expressed on the surface of macrophages
[2]
 and B-cells,
[3]
 respectively. 
Consequently there might be a need for selectivity, as they are both in the same physiological 
compartment. In contrast, MAG is found on the surface of neurite cells,
[4]
 but as it shows 
similar binding behavior as Sialoadhesin,
[5]
 it was also considered. 
Siglecs are a subset of the immunoglobuline superfamily, binding to sialic acid by 
definition.
[6]
 As a consequence, their binding sites are well conserved and selectivity of their 
physiological ligands originates from different linkages of residual carbohydrates to the 
terminal sialic acid.
[6]
 Hence, Sialoadhesin and MAG prefer !2,6-linked sialic acid, whereas 
CD22 shows a clear preference for !2,3-linkages.
[7]
  
However, oligosaccharides are not considered as good drug candidates due to their low 
binding affinities and high structural complexity, their high polarity and fast excretion.
[8]
 
Consequently, introducing modifications at the sialic acid core, being only tolerated by one 
specific Siglec or combination of several substituents, might be a valuable approach for the 
achievement of selectivity. It has been suggested, that substitution in 5-position could be used 
to induce selectivity between the Siglec-members.
[9]
 Hence, Kelm et al. showed that Gc5Ac 
is binding to CD22 but not to Sialoadhesin and MAG.
[5]
 Furthermore, halogenated acetates in 
5-position resulted in an increased binding affinity of MAG but not of Sialoadhesin.
[5]
 
 
Results and Discussion. We were interested in finding further possibilities to trigger 
selectivity among the Siglecs Sialoadhesin, CD22 and MAG. Therefore we determined and 
compared the affinity of a small series of ligands using a surface plasmon resonance (SPR) 
based approach (Biacore).  
 
Biacore assay. As reported previously, a Biacore assay for MAG
[10]
 and CD22 (see chapter 
2.2.) was performed by capturing the Siglec of interest on a protein A surface. For the reason 
of comparability, the assay set-up was maintained for Sialoadhesin. A pH scouting was 
performed in order to elucidate the appropriate pH for Sialoadhesin-capturing prior to protein 
A immobilization. After capturing and equilibration overnight around 4000 RU of Fc-Snd1-3 
were achieved. The reference cell provided only protein A to compensate for non-specific 
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binding to the matrix. The obtained sensorgrams were all negatives, as it was also observed 
for MAG, and therefore mirrored prior fitting.
[10]
 
 Compounds 1-3
[9,11]
 (Figure 1) were reported as ligands for Sialoadhesin, binding with 100-
200 !M affinity. Furthermore, antagonists 1 and 2 were also tested for binding to CD22 and 
MAG, respectively. 
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Figure 1. Overview on Sialoadhesin antagonists 
 
Affinity determination. A small series of MAG and CD22 antagonists was evaluated. 
Firstly, the affinity of antagonist 4, having the aglycon and the modification in 9-position of 1 
and 2 combined, was determined. It bound with a KD of 90 !M.  
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Figure 2. Antagonists, binding to CD22 and MAG 4, 5a
[12]
 and 5b-e.
[10]
 
 
 
Afterwards, sialosides with the general formula 5 (Figure 2) were measured. Here, 
Sialoadhesin showed a clear preference for pentafluorobenzyl and 2,3-dichlorobenzyl as 
aglycon. Although 5c and 5d have 4-chlorobenzoyl instead of the preferred 
biphenylcarboxamide in 9-position, binding affinity was improved by a factor of 2. 
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Table 2. Affinities towards Sialoadhesin (Siglec-1), CD22 (Siglec-2) and MAG (Sigelc-4) were determined by 
Biacore (KD) and hapten inhibition assay (rIC50) 
a. KD was extrapolated without reaching saturation.  
 
With respect to the 5-position Zaccai et al.
[9]
 suggested based on X-ray and modeling data 
that small hydrophobic substituents in 5-position might increase binding affinity towards 
Sialoadhesin. This suggestion is in good agreement with our observations of a 4-fold 
improvement by replacing NHAc with cyclopropylacetamide (!6a). In contrast, a mesyl-
substitutent (6c) abolished binding almost completely. 
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Figure 3. Ligands modified in 5-position.
[10]
 
 
 Sn-1 Sn-2 Sn-4 
Compound KD [!M] KD [!M] rIC50 KD [!M] rIC50 
1 -- -- 0.034 -- -- 
4 90; 97 0.8 -- -- -- 
5a -- -- 1 25 1 
5b 204 3.9 -- 2.4 0.2 
5c 56 0.4 -- 4.3 0.3 
5d 49 2.7 0.03 6.11 0.17 
5e 71 2.8 -- 11.6 0.5 
6a 63 0.5 -- 4.1 0.06 
6b  -- 1.4 -- -- 0.09 
6c  “ 1000”
a 
1.2 0.03 17 0.4 
6d -- 0.1 0.04 1.4 0.03 
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Antagonists 4, 5c-e and 6a showed increased affinity towards Sialoadhesin, however binding 
is decreased by a factor of 10 -100 compared to CD22 and by a factor of 10 compared to 
MAG.  
 
Achieving Selectivity - Trends. 
9-position. Whereas biphenylcarboxamide in 9-position is tolerated by Sialoadhesin and 
CD22, affinity towards MAG drops significantly.
[11,12]
 This might be due to a binding site, 
being spatially limited or due to a steric clash.
[11]
 In Sialoadhesin, Zaccai et al. observed a 
rearrangement of Val109 upon binding of 1 compared to the unligated protein crystal 
structure.
[11]
 
5-position. Sialoadhesin exhibits a preference for cyclopropylacetamide, improving binding 
by a factor of 3, whereas halogenated acetates were shown not to improve binding.
[5]
 In the 
case of sialoside 6c, having a mesyl-substituent in 5-position, binding affinity was almost 
lost. In contrast, sulfonamides were well tolerated by CD22 and MAG (6c,d, Table 1).
[10]
 
These findings are in good agreement with earlier findings, suggesting that the 5-position is 
suited for the achievement of selectivity. However, the differences between CD22 and MAG 
are not pronounced (e.g. antagonist 6d binds with very similar affinity). 
2-position. In all cases, the aglycon is clearly contributing to the binding affinity. However, 
the three Siglecs display similar preferences within the ligand-series and consequently, rather 
small substituents, such as benzyls, are not suited for the achievement of selectivity.  
However, modifications in 2-position are readily introduced and a valuable approach was 
first presented by Shelke at el.
[13]
 Based on a second site screening approach, selectivity was 
thought to rise from the different protein surfaces and shapes. When antagonist 7, reported by 
Shelke et al.
[13]
 was tested for binding to Sialoadhesin, no binding was observed.  
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Figure 4. Second site ligand designed for MAG displayed high selectivity 
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Conclusions. 
Different approaches for the achievement of selectivity were discussed. Substituents in 5- but 
also in 9-position were observed to induce selectivity among Siglecs-1, -2 and -4. However, 
these effects depend on the substituent and not in all cases a clear preference for a specific 
Siglec was obtained. Therefore, the conduction of a second site screening for Sn and CD22 
might a valuable approach for selective and high affinity ligands.  
 
Experimental Part. 
SPR analysis. The SPR measurements were performed on a Biacore 3000 surface plasmon 
resonance based optical biosensor (Biacore AB, Sweden). Sensor chips (CM5 and CM4), 
immobilization kits, maintenance supply and HBS-EP (10 mM HEPES pH 7.4, 150 mM 
NaCl, 3 mM EDTA, 0.005% v/v surfactant P20) were purchased from Biacore AB (HBS-EP 
ready-to-use; degassed and filtered). CM5 (CM4 respectively) chips were preconditioned 
prior to usage by injecting a series of conditioning solutions. A flow rate of 50 !l/min was 
used and 2 " 20 !l of 50 mM NaOH, 10 mM HCl, 0.1% SDS and 100 mM H3PO4 were 
injected.  The carboxy groups on the CM5 (CM4) chip were activated for 10 min with a 1:1 
mixture of 0.1 M N-hydroxysuccinimide (NHS) and 0.1 M 3-(N,N-dimethylamino)propyl-N-
ethylcarbodiimide (EDC) at a flow rate of 10 !l/min. Protein A (P6031) was purchased from 
Sigma. A sample and a reference surface were prepared sequentially or in parallel. For 
immobilizing protein A, a stock solution (1 mg/ml in 50 mM phosphate buffer, pH 7.0) was 
diluted in 10 mM sodium acetate, pH 5.0 to obtain a concentration of 30 !g/ml. This solution 
was then injected over the activated surface for 10 min at a flow rate of 10 !l/min. Protein A 
densities around 4’000 RU and 5’000 RU were achieved. Flow cells were blocked with a 10 
min injection of 1 M ethanolamine, pH 8.0.  
For capturing, Sialoadhesin, CD22 and MAGd1-3-Fc solution (expressed and purified as 
decribed)
14
 were diluted to a 30-40 !g/ml concentration using NaOAc (pH 5). Afterwards, 
Siglecd1-3-Fc (Siglec-1, -4) was injected at a flow rate of 1 !L/min for 10 min. CD22d1-3-Fc 
was injected at a flow rate of 3 !L/min for 5 min. The surface was equilibrated over night at a 
flow rate of 5 !l/min, achieving densities around 2000 to 4000 RU.  
Tenfold dilution series were freshly prepared in eluent buffer immediately before use. All 
binding experiments were conducted at 25 °C (except thermodynamic measurements) at a 
flow rate of 20 !l/min. The samples were injected over 1 min followed by 1 min dissociation. 
Each sample was measured with a duplicate of one concentration, using a randomized 
concentration order. Several buffer samples were injected before the first concentration, and 
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one blank between each concentration, which were used for the double blank referencing 
during data processing. Double referencing was applied to correct for bulk effects and other 
systematic artifacts. Data processing and equilibrium binding constant determinations were 
accomplished with Scrubber (BioLogic Software, Version 1.1g or 2.0a). Kinetic data were 
simultaneously fit using the non-linear regression program Clamp or Scrubber 2.0a. 
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Second-site screening with CD22 
 
A NMR-based second-site screening was performed and the ligands were evaluated with 
respect to their affinity.  
 
Stefanie Mesch, Brian Cutting, Hendrik Koliwer-Brandl, Katrin Lemme, Oliver Schwardt, 
Soerge Kelm, Beat Ernst. 
 
 
Work performed by Stefanie Mesch: 
NMR-screening, synthesis of CD22 antagonists and performance and evaltuation of Biacore 
assay. 
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Second site screening CD22 
 
Stefanie Mesch, Brian Cutting, Hendrik Koliwer-Brandl, Katrin Lemme, Oliver Schwardt, 
Soerge Kelm, Beat Ernst 
 
Introduction. 
CD22 is a member of the Siglec-family and is expressed on the surface of B-cells.
1
 There, it 
regulates the activity of the B-cell receptor and is involved in regulation of B-cell survival
2
 
and homeostasis.
3
 In most cases, CD22 is masked by cis-ligands, however trans-interactions 
are still possible.
4
 
Multivalent synthetic sialosides have been reported to bind with enhanced affinity and 
therefore are able to overcome cis-interactions.
5
 The approach of O’Reilly et al. showed that 
multivalent assembly of a bifunctional ligand could be triggered by an antibody.
6
 
Interestingly, they also showed that a dimer could overcome cis-interactions and therefore, 
we speculated that a sufficient potent monovalent antagonists may be also able to surmount 
cis-interactions. Furthermore, we wanted to develop an antagonist with two independent 
binding sites on CD22, what might be an interesting approach with respect for activity as 
well as for selectivity. 
In recent years the concept of fragment assembly has gained increased importance in drug 
development. Here, fragments binding in close proximity are linked and the resulting hit is 
further refined. Consequently, various screening methods have been developed. A NMR-
based approach
7
 of second site screening has been successfully applied in the case of MAG.
8
 
Therefore we decided to apply this approach also to CD22.  
 
Results and Discussion. 
Structural interesting fragments were divided into sub-libraries, which were screened 
successively. Subsequent, verification of the identified hits was performed. The most 
promising fragment was then linked to the first site ligand, using different linker lengths 
resulting in antagonists 16a-h. 
 
The screening approach is based on differences in the relaxation rates of T1rho of the free 
and bound fragment. As the longitudinal relaxation (T1rho) of molecules depends on their 
size, after addition of protein, the fragments binding to the protein adopt the slower 
relaxation. However, for the identification of only those fragments, which are binding close 
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to the binding site, first-site ligand 6 with a TEMPO-substituent in 2-position was added. Due 
to the unpaired electron, t1rho relaxation rates of compounds binding in close proximity (ca 
10 Å) are changed. Upon addition of L-ascorbic acid the tempo is reduced and relaxation 
returns to “normal”. This procedure was applied to all sub-libraries. 
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Figure 1. Exemplary sub-library and the corresponding 1H-spectra. 
 
Synthesis of TEMPO-ligand. 
For our attempt to identify small molecules binding close to the first site ligand, TEMPO 
(free radical) was attached to the first site ligand at the reducing end (Scheme 1). 
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Scheme 1. a) 4-Biphenylcarbonyl chloride, PPh3, DCE, rt (77%); b) 3-Z-amino-propan-1-ol, NIS, TfOH, MeCN 
(39%); c) 10% aq. NaOH, MeOH; d) Pd(OH)2/C, H2, MeOH, 1 bar, rt, 2 h (73% two steps); e) 4-Carboxy-
TEMPO (free radical), HBTU, HOBt, DMF, rt, 2 h (28%). 1 was prepared according to Mesch et al., 2010.
9
 
 
NMR screening. 
In a first step we verified that 6 is binding to CD22. Hence, selective T1 inversion recovery 
was measured for the reduced form of 6 in absence and presence of the protein. As the 
relaxation behavior differs for big and small molecules, binding of the ligand to the protein 
induced an acceleration of the relaxation rate. We observed a distinct different relaxation 
behavior upon addition of CD22 to the ligand (Figure 2), indicating binding. 
 
 
6 (500 !M) + AA (5 mM) 
 
selective T1
1 2 3 4
-1.5
-0.5
0.5
1.5
SMC-9-8 (500 uM) +
asc acid (5 mM)
CD22 (2.5 uM) +
SMC-9-8 (100 uM)
+ asc acid (3 mM)
time [s]
 
CD22 (2.5 !M) + 6 (100 !M) + 
AA (3 mM) 
Figure 2. Selective T1 inversion recovery measurement shows binding of 6 (reduced form); AA: L-ascorbic 
acid. 
 
Afterwards, T1rho of all components of the different sub-libraries were measured in the 
absence and then in the presence of the TEMPO first-site ligand (6). As a control, L-ascorbic 
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acid is added and the T1rho of the fragments in the presence of the reduced form of the 
TEMPO-ligand is measured.  
 
The experiments were conducted using 300 !M of the second site fragment, 100 !M SMC-9-
8 (TEMPO-ligand) and 2.5 !M CD22 (80.1 !l of 1mg/ml protein solution in PBS) in 
PBS/D2O (1/1, Vt 250 ul). For the reduction L-ascorbic acid sodium salt (6 mM) was added. 
In order to get a reasonable signal to noise ratio, 256 scans per experiment were applied. 
 
Finally, 4 compounds were identified as possible hits (Figure 3) and were subjected to further 
investigations for the purpose of verification. Furthermore, a qualitative ranking between the 
compounds was established based on the “in-proximity of the tempo binding effect”. 
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52 SH-105-15  FB-65 SH-104-6 
Figure 3. Fragments were identified as preliminary hits after screening the library 
 
The transverse relaxation (T1rho) of fragment 52 was re-measured at 10 time points. 
Although the decay was faster in the presence of the active TEMPO-compound and 
consequently bound in close proximity to the first binding site, the decay was slightly slower 
than with the protein alone.  
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Figure 4. Decay of transverse magnetization (T1rho); For evaluation the methyl groups were chosen. 
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Based on this observation, we suspected that 52 is competing to a certain extend with the 
TEMPO-ligand for the binding site. Therefore, we measured the decay of T1rho of 52 in the 
presence of CD22 as a control and added afterwards 6 (Figure 5). Upon addition of the 
reduced TEMPO-ligand, again, we observed that the relaxation rate of 52 was slowed down. 
These results show that 52, being a weaker binder than 6, is replaced. However, there seems 
to be a second binding site for 52, as there is a visible difference between the rate of the free 
ligand and after addition of the competitor (this would not be the case if it was only binding 
in the “first-binding site”). 
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Figure 5. a. Influence on the T1rho by addition of SMC-9-4. b. decay of free A and A with CD22 and SMC-9-
4. 
 
Beside 52, naphtalene-1-sulfonamide (FB-65) and 4-fluorobenzophenone (SH-104-6) have 
been identified as possible hits and were therefore re-measured one by one.  
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Figure 6. Decay of T1rho in the presence of 6 (red) and 6-reduced (black) at 10, 20, 30, 40, 50, 80, 100 !s. 
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The measurement showed an influence of compound 6 on the relaxation of FB 65 although 
only one of three (analyzed) protons shows a distinct difference. In the case of 4-
Fluorobenzophenone (SH-104-6) all three protons investigated showed a clear influence 
(Figure 7). We considered SH-104-6, that showed the most promising “in-proximity of the 
tempo binding effect”, to be further investigated. 
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Figure 7. Decay of T1rho in the presence of 6 (red) and 6-reduced (black) at 10, 20, 30, 40, 50, 80, 100 !s. 
 
We were interested in the orientation of the second site fragment with respect to the TEMPO-
ligand. In order to figure the directionality out, equation (1) was used. Here, high values of x 
indicate a closer proximity towards the free radical. 
 
! 
x =
T1rho
red
"T1rho
rad
T1rho
red
                    (1) 
 
When this concept was applied to SH-104-6 it turned out that the fluorine points towards the 
TEMPO. 
O
F
0.47
0.25
0.27
 
Figure 8. Fluorine seems to point towards the TEMPO-ligand as the influence on neighboured proton is distinct 
higher compared to the others. 
 
With respect to facile chemical linking, 4-hydroxybenzophenone, 3-hydroxybenzophenone 
and 2-hydroxy-9-fuorenone were investigated. Unfortunately, the latter compound was 
completely insoluble in the buffer and therefore not further considered. 
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Figure 9. Decay of T1rho in the presence of 6 (red) and 6-reduced (black) at 10, 20, 30, 40, 50, 80, 100 !s. 
Evaluation of several protons hints on the orientation of the fragment with respect to the TEMPO-ligand. 
 
4-hydroxybenzophenone as well as 3-hydroxybenzophenone showed a clear effect of the 
TEMPO-radical on the T1rho rates. Finally, 3-Hydroxybenzophenone was chosen due to 
good binding and synthetic reasons. 
 
Synthesis of second site fragments was performed by alkylating 3-Hydroxybenzophenone 
with the corresponding bromides (12a,b, Scheme 3). Due to stability reasons of 1,2-
dibromoethane, the 2C-linker was obtained starting from commercially available 2-
chloroethanol by nucleophilic substitution of the chloride by azide
10
 followed by tosylation.
11
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Scheme 2. a) NaN3, H2O (quant);
10
 b) pTsCl, DCM (91%);
11
 c) 3-Hydroxybenzophenone (11), NaH, DMF 
(85%). 
a)
O
OH
O
O Br
11
12a: n = 3
12b: n = 4
n
b)
O
O N3
n
13a: n = 3
13b: n = 4  
Scheme 3. a) 1,4-Dibromobutane (!12a) or 1,5-Dibromopentane (!12b), K2CO3, MeOH (12a: 74%, 12b: 
78%); b) NaN3, DMF (13a: 70%, 13b: 95%). 
 
Synthesis of first-site ligands. Antagonists 15a-c with alkyne linkers (1C to 3C) were 
synthesized by glycosidation of donor 2 with the corresponding alcohols using the promotor 
system NIS and triflic acid. 
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Scheme 4. a) alcohol, NIS, TfOH, MeCN (45-73%); b) 10% aq. NaOH, MeOH (50-80%); c) 10 (or i. 13a; or ii. 
13b), CuSO4·5H2O, L-ascorbic acid sodium salt, 
t
BuOH/ H2O/ THF (1/1/1), rt, (12-54%); n=1,2,3.  
 
Afterwards, the sialosides were reacted under Cu(I)- catalyzed click-conditions with the 
azides 15a-c to afford the anti-configurated final compounds 16a-h. 
Surface plasmon resonance (SPR). The final compounds 16a-h as well as sialosides 15a-c 
were evaluated by a surface plasmon resonance based assay (Biacore). Here, Fc-CD22d1-3 was 
captured on a protein A surface and the ligands were injected over the surface. 
Unfortunately, the binding affinity of the second-site compounds compared to the first site 
ligands with the acetylene linker was decreased by a factor of 3 to 8. Moreover, some 
compounds abolished completely binding (16b,c and 16h, Table 1).  
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Table 1. Overview on second site library, KD determined using CD22@31.10.09 
Compound Structure n 
KD 
[!M] 
15a 
O O
COOH
HO
AcHN
H
N
OH
OH
O
 
1 2.3 
16a 
O O
COOH
HO
AcHN
H
N
OH
OH
O
N
N
N O O
 
1 “28” 
16b 
O O
COOH
HO
AcHN
H
N
OH
OH
O
N
N
N
O
O  
1 n.b.
a 
16c O O
COOH
HO
AcHN
H
N
OH
OH
O
N
N
N
O
O
 
1 n.b.
a 
15b 
O O
COOH
HO
AcHN
H
N
OH
OH
O
 
2 0.33 
16d 
O O
COOH
HO
AcHN
H
N
OH
OH
O
N
N
N
O
O
 
2 3.1 
16e 
O O
COOH
HO
AcHN
H
N
OH
OH
O
N
N
N
O
O
 
2 2.6 
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16f 
O O
COOH
HO
AcHN
H
N
OH
OH
O
N
N
N
O
O
 
2 4.1 
15c 
O O
COOH
HO
AcHN
H
N
OH
OH
O
 
3 0.46 
16g 
O O
COOH
HO
AcHN
H
N
OH
OH
O
N
N
N
O
O
 
3 1.4 
16h 
O O
COOH
HO
AcHN
H
N
OH
OH
O
N
N
N
O
O
 
3 n.b.
a 
BP: biphenyl; 
a
n.b. not binding. 
 
These results were suspicious, as the protein batch used in the screening was not the same as 
used for the Biacore assay. Consequently, we hypothesized, that the screening was performed 
using a partially unfolded protein, leading to a false positive hit identification. This was 
confirmed by MS measurements of the two proteins. Batch 1 (NMR) of CD22 could hardly 
be ionized, indicating that is was unfolded, whereas in contrast, CD22-batch 2 (Biacore) was 
readily ionized and yielded the expected molecular weight. 
 
As a consequence, we repeated the screening, using the intact protein. Unfortunately, 
repetition of the T1rho experiments using the “identified” hit 3-Hydroxybenzophenone 
revealed, that it was not binding to the CD22 at all, as no difference in the relaxation rates 
after 20 and 200 msec was observed. 
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Figure 10. Overlay of T1rho spectra with a delay of 20 and 200 msec; NMR sample: 3-HBP (300 !M), CD22 
(2.5 !M). 
 
In a next step, we repeated T1rho experiments using a mix screened before, containing hits 
identified earlier. Also here, only a marginal difference in the relaxation after 20 and 200 
msec was observed and consequently the fragments were binding to the protein in a 
negligible extend. 
 
 
Figure 11. Overlay of T1rho spectra of mix 4; NMR sample: Mix 4 (300 !M each compound) + CD22 (2.5 
!M). 
 
Finally, selective T1 experiments, using the reduced TEMPO-ligand, were repeated. The 
selective T1 inversion recovery did not show a distinct discrimination of the relaxation 
behaviour in absence or presence of the protein. 
O O
COOH
HO
AcHN
H
N
OH
OH
N
H
N
OH
O
 
 
6 (500 !M) + AA (5 mM) 
 
selective T1
1 2 3 4
-1
0
1
SMC-9-8 500uM +
ascorbic acid 5 mM
SMC-9-8 100 uM +
ascorbic acid 3mM +
CD22 2.5 uM
time [s]
 
6 (100!M) + AA (3 mM) + CD22 (2.5 
!M) 
Figure 12. Selective T1 inversion recovery of TEMPO-ligand 
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Hereupon, we verified by MS that the ligand 6 in the NMR-sample was not decomposed and 
by SDS page that the protein in NMR tube was not degraded.  
 
Afterwards, STD NMR was performed with CD22 (2.5 !M) and 6 (1.5 mM). No signal was 
obtained, suggesting that the ligand is not binding. 
However, binding of ligand 6 was determined in the Biacore assay to be 800 nM. In order to 
clarify these conflicting results, we additionally performed an ITC measurement of antagonist 
23. As the ITC and Biacore assay gave similar KD values, we speculated that the ligand 
bound too tightly to the protein and therefore the NMR approach was not suited for this 
“affinity” range. 
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Figure 13. ITC measurements confirm the results obtained by SPR-assay.  
 
Conclusion. 
A second-site screening was performed and antagonists were subsequently synthesized and 
evaluated. As the binding affinity was decreased, in contrast to our expectations, further 
investigations revealed that the used CD22 was unfolded (at least partially). All NMR 
experiments were repeated, however we could not identify new hits an even the first site 
ligand could not be investigated with the above described approaches. 
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Biacore and ITC measurements revealed a low !M affinity for the TEMPO-ligand and 
therefore we concluded that the “negative” results in the NMR assay might be explained by 
the high affinity of the ligand, being beyond the range suited for this method. 
 
Experimental Part. 
Chemistry. NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, TOCSY, ROESY, NOESY). Chemical shifts are expressed in ppm using 
residual CHCl3, CHD2OD, CHD2CN and HDO as references. Optical rotations were 
measured using Perkin-Elmer Polarimeters 241 and 341. MS analyses were carried out using 
a Waters Micromass ZQ Detector system. The spectra were recorded in positive or negative 
ESI mode. Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 
(Merck) and visualized by using UV light and/or by charring with a molybdate solution (a 
0.02 M solution of ammonium cerium sulfate dihydrate and ammonium molybdate 
tetrahydrate in aq 10% H2SO4). Column chromatography was performed on silica gel (Fluka, 
40-60 mesh). Methanol was dried by refluxing with sodium methoxide and distilled 
immediately before use. Pyridine was freshly distilled under argon over CaH2. 
Dichloromethane (DCM), dichloroethane (DCE), acetonitrile (MeCN), toluene, and benzene 
were dried by filtration over Al2O3 (Fluka, type 5016 A basic). Molecular sieves (3 or 4 Å) 
were activated in vacuo at 500 °C for 2 h immediately before use. Synthesis of compound 1 
was done according to a published procedure.12 Compound 2 was obtained as described in 
Chapter 2.2. 2-Azidoethanol10 and subsequently 1-[(2-azidoethoxy)sulfonyl]-4-
methylbenzene11 were prepared according to published procedures. Compound 11 was 
purchased from Sigma-Aldrich. 
 
Methyl [3-benzoxycarbonylaminopropyl 5-acetamido-4,7,8-tri-O-acetyl -3,5,9-trideoxy -
9- (4-phenyl)benzamido) -D -glycero-!-D -galacto-2-nonulopyranosid]onate (3). 
Compound 2 (150 mg, 0.23 mmol, 1.0 eq) was reacted with benzyl N-(3-
hydroxypropyl)carbamate (145 mg, 0.68 mmol, 3.0 eq), NIS (82 mg, 0.37 mmol, 1.6 eq) and 
triflic acid (16 !L, 0.18 mmol, 0.8 eq) according to general procedure A to yield 3 after 
chromatography on silica gel (5% gradient of MeOH in DCM) as white solid (72 mg, 38%). 
[!]20D -2.4 (c 0.35, CH2Cl2). 
1H NMR (500 MHz, CDCl3) " 1.69 (m, 2H, CH2), 1.78 (s, 3H, 
NHAc), 1.87 (t, J = 12.6 Hz, 1H, H-3a), 1.91, 1.93, 2.16 (3 s, 9H, 3 OAc), 2.40 (dd, J = 4.9, 
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12.8 Hz, 1H, H-3b), 3.01 (td, J = 4.0, 11.0 Hz, 1H, H-9a), 3.24 – 3.37 (m, 2H, CH2), 3.39 – 
3.53 (m, 2H, CH2), 3.69 (s, 3H, OMe), 3.92 (d, J = 10.5, 1H, H-6), 4.12 (m, 1H, H-5), 4.43 
(m, 1H, H-9b), 4.91 – 5.11 (m, 2H, OCH2Ar), 5.11 – 5.30 (m, 3H, H-4, H-7, H-8), 6.10 (d, J 
= 10.0 Hz, 1H, NHAc), 7.12 (d, J = 5.9 Hz, 3H, 9-NH, CHar), 7.25 (m, 3H, CHar), 7.30 (t, J = 
7.3 Hz, 1H, CHar), 7.37 (t, J = 7.5 Hz, 2H, CHar), 7.44 – 7.54 (m, 4H, CHar), 7.79 (AA’BB’ of 
AA’BB’, J = 8.2 Hz, 2H, CHar). 
13
C NMR (CDCl3) ! 20.9, 21.0, 21.1 (3 OAc), 23.1 (NHAc), 
29.3 (CH2), 38.0 (C-3), 38.3 (C-9), 48.9 (C-5), 52.8 (OMe), 60.4 (CH2), 62.3 (CH2), 66.6 
(OCH2Ar), 68.3, 68.7 (C-7, C-8), 69.0 (C-4), 71.0 (C-6), 98.5 (C-2), 127.2, 127.3, 127.5, 
127.8, 128.0, 128.5, 128.6, 128.9, 132.8, 136.3, 136.6, 139.9, 144.4 (18C, C-Ar), 156.9 
(CONH), 167.3, 167.8, 168.3, 170.4, 170.8, 171.9 (6 CO). HRMS calcd. for C42H49N3O14 
[M+Na]
+
: 842.3112; found m/z 842.3114. 
 
Sodium [3-benzoxycarbonylaminopropyl 5-acetamido -3,5,9-trideoxy-9-(4-phenyl) 
benzamido)-D -glycero-"-D -galacto-2-nonulopyranosid]onate (4). Compound 3 (72 mg, 
89 !mol, 1.0 eq) in MeOH (3 mL) was treated with 10% aq. NaOH (0.2 mL) as described in 
procedure B to yield 4, which was directly reacted further. ["]
20
D -12.8 (c 0.5, MeOH). 
1
H 
NMR (500 MHz, D2O) ! 1.62 (m, 3H, H-3a, CH2), 1.96 (s, 3H, NHAc), 2.66 (dd, J = 4.7, 
12.3 Hz, 1H, H-3b), 3.07 (m, 2H, CH2), 3.41 (m, 2H, CH2), 3.50 (d, J = 8.9 Hz, 1H, H-7), 
3.62 (m, 1H, H-4), 3.65 – 3.83 (m, 4H, H-5, H-6, H-9a, H-9b), 3.98 (m, 1H, H-8), 7.11 (d, J 
= 7.2 Hz, 2H, CHar), 7.19 (m, 3H, CHar), 7.39 (t, J = 7.3 Hz, 1H, CHar), 7.45 (t, J = 7.5 Hz, 
2H, CHar), 7.58 (d, J = 7.8 Hz, 4H, CHar), 7.69 (d, J = 8.3 Hz, 2H, CHar). 
13
C NMR (D2O) ! 
22.0 (NHAc), 37.3 (CH2), 40.4 (C-3), 43.0 (C-9), 51.9 (C-5), 62.1 (CH2), 66.5 (CH2), 68.3, 
70.2, 71.0 (C-4, C-7, C-8), 72.5 (C-6), 92.0 (C-2), 127.0, 127.1, 127.7, 128.0, 128.3, 128.6, 
129.1, 139.4 (18C, C-Ar), 150.0 (CONH), 175.0, 175.3 (3C, CO). HRMS calcd. for 
C35H40N3NaO11 [M+Na]
+
: 724.2451; found m/z 724.2458. 
 
Sodium [3-aminopropyl 5-acetamido -3,5,9-trideoxy-9-(4-phenyl)benzamido-D -glycero-
"-D -galacto-2-nonulopyranosid]onate (5). Compound 4 was dissolved in dry MeOH (4 
mL) and Pd(OH)2/C (Degussa, 40 mg) was added under argon. Afterwards the mixture was 
stirred under H2 (1bar) for 2 h. After completion of the reaction, the catalyst was removed by 
filtration over a pad of celite and the pure product was obtained after chromatography on RP-
18 (5% gradient of MeOH in water) to yield 5 (35 mg, 73% 2 steps). ["]
20
D -13.1 (c 0.33, 
MeOH). 
1
H NMR (500 MHz, CD3OD/H2O) ! 1.74 (m, 1H, H-3a), 1.92 (m, 2H, CH2), 2.00 
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(m, 3H, NHAc), 2.34 (dd, J = 4.7, 12.9 Hz, 1H, H-3b), 3.06 (m, 2H, CH2), 3.51 (d, J = 9.2 
Hz, 1H, H-7), 3.54 – 3.69 (m, 1H, H-9a), 3.84 – 3.97 (m, 5H, H-5, H-6, H-9b, OCH2), 4.08 
(m, 2H, H-4, H-8), 7.40 (m, 2H, CHar), 7.47 (m, 2H, CHar), 7.65 (m, 2H, CHar), 7.72 (m, 2H, 
CHar), 7.96 (m, 2H, CHar). 
13C NMR (CD3OD/H2O) ! 23.0 (NHAc), 27.6 (CH2), 40.0 (CH2), 
42.2 (C-3), 44.2 (C-9), 53.6 (C-5), 63.1 (OCH2), 67.9 (C-4), 70.4 (C-8), 71.8 (C-7), 74.1 (C-
6), 101.9 (C-2), 128.0, 129.1, 130.0, 133.7, 140.9, 145.5 (12C, C-Ar), 174.7, 176.5, 180.9 (3 
CO). ESI-MS calcd. for C27H35N3O9 [M+Na]
+: 568.57; found m/z 568.30. 
 
Sodium [3-(2,2,6,6-tetramethylpiperidine-1-oxyl-4-carboxamido)propyl 5-acetamido -
3,5,9-trideoxy-9-(4-phenyl)benzamido)-D-glycero-"-D-galacto-2-nonulopyranosid]onate 
(6). Compound 5 (25 mg, 45 !mol, 1.0 eq) was added to the reaction mixture of 4-Carboxy-
2,2,6,6-tetramethylpiperidine 1-oxyl (15 mg, 73 !mol, 1.6 eq), HOBt (11 mg, 81 !mol, 1.8 
eq), HBTU (17 mg, 45 !mol, 1.0 eq) and DIPEA (0.3 mL) in dry DMF (1 mL). After 2 h, the 
solvent was removed under high vacuum and the pure product was obtained after LC-MS 
purification as reddish solid (9 mg, 28%). 
 
General procedure of glycosidation (A). 
Compound 2 (0.33 mmol) was dissolved in dry acetonitrile (2.0 ml) under argon. The alcohol 
(0.99 mmol) and powdered MS 3Å were added. The mixture was stirred at r.t. for 1.5 h. Then 
the suspension was cooled to -40 °C and subsequently treated with N-iodosuccinimide (0.53 
mmol) and triflic acid (0.26 mmol). After 30 min the reaction mixture was warmed to -30 °C 
and stirring continued for 24 h. The mixture was then warmed to r.t., stirred for another 2 h 
and filtered through a pad of celite. The celite was washed with DCM (10 ml) and the filtrate 
was subsequently washed with 20% aq. Na2S2O3 (1 ml) and saturated aqueous NaHCO3 (3 " 
5 ml). The organic phase was dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude product was purified by chromatography on silica gel. 
 
General procedure of deprotection (B). 
Compound 3 (15, 17, 19) (0.13 mmol) was dissolved in MeOH (5.0 ml) and treated with 10% 
aq. NaOH (0.4 ml). The reaction mixture was stirred at r.t. for 3 h. Then the reaction mixture 
was neutralized with 7% aq. HCl. The solvent was evaporated and the crude product was 
purified LCMS. 
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General procedure Cu(I)-catalyzed click-reaction (C). 
To a mixture of acetylene (13 !mol) in degassed 
t
BuOH:H2O (v/v, 1:1), the corresponding 
azide (21 !mol), cupric sulfate pentahydrate (3.3 !mol) and sodium ascorbate (7.5 !mol) 
were added under argon atmosphere. The reaction mixture was stirred at r.t. overnight. 
Afterwards, the solvent was removed under reduced pressure and the residue was purified 
LCMS. 
 
[3-(2-azidoethoxy)phenyl](phenyl)methanone (10). 3-Hydroxybenzophenone (11, 150 mg, 
0.76 mmol, 1.0 eq) was dissolved in DMF (2 mL). After cooling to 0 °C, NaH (52 mg, 1.52 
mmol, 2.0 eq) was added and stirring was continued for 30 min. 1-[(2-azidoethoxy)sulfonyl]-
4-methylbenzene (274 mg, 1.14 mmol, 1.5 eq) in DMF (1mL) was added dropwise and the 
reaction was allowed to come to r.t. After 24 h, ethyl acetate 4 mL) was added and the 
organic layer was washed with brine (2 ! 1 mL) and water (1 ! 1 mL), dried over Na2SO4, 
filtered and the solvent was removed under reduced pressure. The pure product was obtained 
after chromatography on silica gel (petrol ether/ ethyl acetate 3:1) as colorless oil (172 mg, 
85%). IR (NaCl) " 2109 (N3), 1658 (CO) cm
-1
.
 1
H NMR (500 MHz, CDCl3) # 3.57 – 3.65 (m, 
2H, CH2N3), 4.17 – 4.22 (m, 2H, OCH2), 7.14 – 7.19 (m, 1H, CHar), 7.34 – 7.43 (m, 3H, 
CHar), 7.47 – 7.50 (m, 2H, CHar), 7.55 – 7.62 (m, 1H, CHar), 7.80 – 7.81 (m, 2H, CHar). 
13
C 
NMR (CDCl3) # 50.1 (CH2N3), 67.2 (OCH2), 114.8, 119.6, 123.6, 128.3, 129.4, 130.0, 132.5, 
137.5, 139.0, 158.3 (12C, C-Ar), 196.3 (CO). ESI-MS calcd. for C15H13N3O2 [M+Na]
+
: 
290.08; found m/z 290.05. Analysis calcd. For C15H13N3O2·" H2O, C 66.29, H 5.01, N 
15.46; found C 66.40, H 5.25, N 14.97. 
 
(3-(3-bromopropoxy)phenyl)(phenyl)methanone (12a). 3-Hydroxybenzophenone (11, 100 
mg, 0.5 mmol, 1.0 eq) was dissolved in MeOH (2 ml) and 1,3-dibromopropane (253 !l, 503 
mg, 2.5 mmol, 5.0 eq) and potassium carbonate (138 mg, 1.0 mmol, 2.0 eq) were added 
successively. The reaction mixture was stirred at 50 °C for 5 h. After cooling to r.t., the 
solvent was evaporated and ethyl acetate was added. Then, the organic layer was washed 
with brine and water, dried over Na2SO4, filtered and the solvents were removed under 
reduced pressure. The crude product was purified by chromatography on silica gel (petrol 
ether/ ethyl acetate 4/1) to afford 12a (119 mg, 74%). 
1
H NMR (500 MHz, CDCl3) # 2.32 (p, 
J = 6.0 Hz, 2H, CH2), 3.60 (t, J = 6.4 Hz, 2H, CH2Br), 4.15 (t, J = 5.8 Hz, 2H, OCH2), 7.04 – 
7.20 (m, 1H, CHar), 7.31 – 7.41 (m, 3H, CHar), 7.47 (t, J = 7.7 Hz, 3H, CHar), 7.58 (dd, J = 
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6.0, 7.6 Hz, 1H, CHar), 7.76 – 7.88 (m, 3H, CHar). 
13
C NMR (CDCl3) ! 29.9 (CH2Br), 32.3 
(CH2), 65.6 (OCH2), 115.2, 119.2, 123.1, 128.3, 129.4, 130.1, 132.5, 137.6, 139.0, 158.7 
(12C, C-Ar), 196.4 (CO). ESI-MS calcd. for C16H15BrO2 [M+Na]
+
: 341.02; found 341.00 /z. 
Anal. Calcd: C 60.21, H 4.74; found C 60.02, H 4.89. 
 
(3-(4-bromobutoxy)phenyl)(phenyl)methanone (12b). 3-Hydroxybenzophenone (11, 100 
mg, 0.5 mmol, 1.0 eq) was dissolved in MeOH (2 ml) and 1,4-dibromobutane (295 !l, 540 
mg, 2.5 mmol, 5.0 eq) and potassium carbonate (138 mg, 1.0 mmol, 2.0 eq) were added 
successively. The reaction mixture was stirred at 50 °C for 5 h. After cooling to r.t., the 
solvent was evaporated and ethyl acetate was added. Then, the organic layer was washed 
with brine and water, dried over Na2SO4, filtered and the solvents were removed under 
reduced pressure. The crude product was purified by chromatography on silica gel (petrol 
ether/ ethyl acetate 4:1) to afford 12b (132 mg, 78%). 
1
H NMR (500 MHz, CDCl3) ! 1.96 
(dq, J = 6.2, 10.2 Hz, 2H, CH2), 2.02 – 2.12 (m, 2H, CH2), 3.48 (t, J = 6.6 Hz, 2H, CH2Br), 
4.04 (t, J = 6.1 Hz, 2H, OCH2), 7.11 (ddd, J = 1.3, 2.4, 7.8 Hz, 1H, CHar), 7.30 – 7.39 (m, 
3H, CHar), 7.47 (t, J = 7.7 Hz, 2H, CHar), 7.58 (t, J = 7.4 Hz, 1H, CHar), 7.75 – 7.84 (m, 2H, 
CHar). 
13
C NMR (CDCl3) ! 27.9 (CH2), 29.5 (CH2), 33.4 (CH2Br), 67.2 (OCH2), 115.0, 
119.3, 123.0, 128.3, 129.3, 130.1, 132.5, 137.7, 139.0, 158.9 (12C, C-Ar), 196.5 (CO). ESI-
MS calcd. for C17H17BrO2 [M+Na]
+
: 355.09; found m/z 354.97. Anal. Calcd: C 61.28, H 
5.14; found: C 61.34, H 5.21.  
 
(3-(3-azidopropoxy)phenyl)(phenyl)methanone (13a). Compound 12a (119 mg, 0.37 
mmol, 1.0 eq) was dissolved in DMF (1 mL) and sodium azide (30 mg, 0.46 mmol, 1.2 eq) 
was added. The reaction mixture was stirred for 24 h at 65 °C. After removal of the solvent 
under high vacuum, the pure product 13a (74 mg, 70%) was obtained after chromatography 
on silica gel (petrol ether/ ethyl acetate 5:1) as colorless oil. IR (NaCl) " 2097 (N3), 1656 
(CO) cm
-1
.
 1
H NMR (500 MHz, CDCl3) ! 1.96 – 2.20 (m, 2H, CH2), 3.53 (t, J = 6.6 Hz, 2H, 
CH2N3), 4.11 (t, J = 5.9 Hz, 2H, OCH2), 7.10 – 7.15 (m, 1H, CHar), 7.30 – 7.40 (m, 3H, 
CHar), 7.49 (t, J = 7.7 Hz, 2H, CHar), 7.59 (t, J = 7.4 Hz, 1H, CHar), 7.75 – 7.88 (m, 2H, 
CHar). 
13
C NMR (CDCl3) ! 28.7 (CH2), 48.2 (CH2N3), 64.8 (OCH2), 115.0, 119.2, 123.1, 
128.3, 129.3, 130.0, 132.5, 137.6, 139.0, 158.7 (12C, C-Ar), 196.4 (CO). ESI-MS calcd. for 
C16H15N3O2 [M+Na]
+
: 304.11; found m/z 304.11. Analysis calcd. C 69.14, H 5.80, N 14.23; 
found C 69.10, H 6.07, N 13.98. 
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[3-(4-azidobutoxy)phenyl](phenyl)methanone (13b). Compound 12b (130 mg, 0.39 mmol, 
1.0 eq) was dissolved in DMF (1 mL) and sodium azide (30 mg, 0.46 mmol, 1.2 eq) was 
added. The reaction mixture was stirred for 24 h at 65 °C. Afterwards, the solvent was 
removed under high vacuum and the crude product was purified by chromatography on silica 
gel (petrol ether/ ethyl acetate 5:1) to yield 13b as colorless oil (112 mg, 97%). IR (NaCl) ! 
2096 (N3), 1655 (CO) cm
-1
.
 1
H NMR (500 MHz, CDCl3) " 1.76 – 1.85 (m, 2H, CH2), 1.85 – 
1.94 (m, 2H), 3.37 (t, J = 6.7 Hz, 2H, CH2N3), 4.04 (t, J = 6.0 Hz, 2H, OCH2), 7.09 – 7.17 
(m, 1H, CHar), 7.32 - 7.39 (m, 3H, CHar), 7.48 (t, J = 7.6 Hz, 2H, CHar), 7.59 (t, J = 7.4 Hz, 
1H, CHar), 7.80 (d, J = 7.2 Hz, 2H, CHar). 
13
C NMR (CDCl3) " 25.7 (CH2), 26.5 (CH2), 51.2 
(CH2N3), 67.4 (OCH2), 114.9, 119.3, 122.9, 128.3, 129.3, 130.0, 132.4, 137.6, 138.9, 158.9 
(12C, C-Ar), 196.5 (CO). ESI-MS calcd. for C17H17N3O2 [M+Na]
+
: 318.11; found m/z 
317.92. Analysis caldc. C 69.14, H 5.80, N 14.23; found C 69.10, H 6.07, N 13.98. 
 
Methyl [2-propynyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-(4-phenyl) 
benzamido -D -glycero-#-D -galacto-2-nonulopyranosid]onate (14a). Compound 2 (206 
mg, 0.31 mmol, 1.0 eq) was reacted with propargyl alcohol (54 !L, 51 mg, 0.9 mmol, 3.0 eq) 
according to procedure A, to yield 14a (142 mg, 68%) after chromatography on silica gel 
(5% gradient of iPrOH in PE/DCM 2/1). [#]
20
D 2.9 (c 0.1, CH2Cl2).
 1
H NMR (500 MHz, 
CDCl3) " 1.89 (s, 3H, NHAc), 1.96 – 2.04 (m, 4H, OAc, H-3a), 2.11, 2.26 (2s, 6H, OAc), 
2.38 – 2.52 (m, 2H, H-3b, C$CH), 2.98 (ddd, J = 4.4, 7.4, 15.2 Hz, 1H, H-9a), 3.81 (s, 3H, 
OMe), 3.96 (dd, J = 1.3, 10.6 Hz, 1H, H-6), 4.17 (dd, J = 2.4, 13.5 Hz, 2H, OCH2C$CH), 
4.19 – 4.27 (m, 1H, H-5), 4.54 (ddd, J = 3.2, 8.9, 15.2 Hz, 1H, H-9b), 5.20 – 5.33 (m, 3H, H-
4, H-7, H-8), 5.44 (d, J = 10.2 Hz, 1H, NHAc), 7.15 (dd, J = 4.0, 8.8 Hz, 1H, NH), 7.39 (t, J 
= 7.3 Hz, 1H, CHar), 7.46 (t, J = 7.6 Hz, 2H, CHar), 7.61 (d, J = 7.5 Hz, 2H, CHar), 7.66 (d, J 
= 8.1 Hz, 2H, CHar), 7.90 (d, J = 8.2 Hz, 2H, CHar). 
13
C NMR (CDCl3) " 21.1, 21.2, 21.3 (3 
OAc), 23.2 (NHAc), 37.2 (C-3), 37.8 (C-9), 49.5 (C-5), 51.8 (OCH2C$CH), 53.0 (OMe), 
68.0, 68.7, 70.0 (C-4, C-7, C-8), 71.1 (C-6), 72.4 (C$CH), 78.8 (C$CH), 98.4 (C-2), 127.2, 
127.3, 127.5, 127.6, 128.9, 132.9, 140.0, 144.4 (12C, C-Ar), 166.9, 167.1, 170.4, 170.5, 
171.1, 172.3 (6 CO). ESI-MS calcd. for C34H38N2O12 [M+Na]
+
: 689.23; found m/z 689.39. 
 
Methyl [3-butynyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9- (4-phenyl) 
benzamido-D -glycero-#-D -galacto-2-nonulopyranosid]onate (14b). Compound 2 (217 
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mg, 0.33 mmol, 1.0 eq) was reacted with but-3-yn-1-ol (75 !l, 69 mg, 0.99 mmol, 3.0 eq) 
according to procedure A, to yield 14b (193 mg, 81%) after chromatography on silica gel 
(5% gradient of iPrOH in PE/DCM 2/1). [!]
20
D -12.5 (c 0.9, CH2Cl2). 
1
H NMR (500 MHz, 
CDCl3) " 1.89 (s, 3H, NHAc), 1.97 (m, 1H, H-3a), 2.03 (s, 3H, OAc), 2.05 (t, J = 2.7 Hz, 1H, 
C#CH), 2.10, 2.27 (2s, 6H, 2 OAc), 2.39 – 2.49 (m, 2H, CH2), 2.62 (dd, J = 4.6, 12.8 Hz, 1H, 
H-3b), 2.98 (ddd, J = 4.4, 7.3, 15.1 Hz, 1H, H-9a), 3.39 – 3.52 (m, 2H, OCH2), 3.81 (s, 3H, 
OMe), 4.01 – 4.07 (m, 1H, H-6), 4.16 – 4.26 (m, 1H, H-5), 4.54 (ddd, J = 3.4, 8.9, 15.1 Hz, 
1H, H-9b), 4.84 (ddd, J = 4.7, 10.4, 12.3 Hz, 1H, H-4), 5.20 – 5.25 (m, 1H, H-7), 5.26 – 5.33 
(m, 1H, H-8), 5.36 (d, J = 10.1 Hz, 1H, NHAc), 7.17 (dd, J = 4.0, 8.8 Hz, 1H, NH), 7.36 – 
7.42 (m, 1H, CHar), 7.46 (t, J = 7.6 Hz, 2H, CHar), 7.59 – 7.64 (m, 2H, CHar), 7.66 (d, J = 8.4 
Hz, 2H, CHar), 7.90 (d, J = 8.4 Hz, 2H, CHar). 
13
C NMR (CDCl3) " 19.6 (CH2), 20.9, 21.2, 
21.3 (3 OAc), 23.2 (NHAc), 37.5 (C-3), 37.8 (C-9), 49.6 (C-5), 52.9 (OMe), 61.6 (OCH2), 
68.1, 68.8, 69.4 (C-4, C-7, C-8), 70.1 (C-6), 70.2 (C#CH), 80.9 (C#CH), 98.4 (C-2), 127.2, 
127.3, 127.6, 128.0, 128.9, 132.9, 140.0, 144.3 (12C, C-Ar), 167.1, 167.4, 170.3, 170.4, 
171.2, 172.3 (6 CO). HRMS calcd. for C35H40N2O12 [M+Na]
+
: 703.2479; found m/z 
703.2474. 
 
Methyl [4-pentynyl 5-acetamido-4,7,8-tri-O-acetyl-3,5,9-trideoxy-9-(4-phenyl) 
benzamido-D -glycero-!-D -galacto-2-nonulopyranosid]onate (14c). Compound 2 (193 
mg, 0.29 mmol, 1.0 eq) was reacted with pent-4-yn-1-ol (90 !l, 82 mg, 1.0 mmol, 3.4 eq) 
according to procedure A, to yield 14c 140 mg, 70%) after chromatography on silica gel (5% 
gradient of iPrOH in PE/DCM 2/1).
1
H NMR (500 MHz, CDCl3) " 1.62 – 1.82 (m, 2H, CH2), 
1.88 (s, 3H, NHAc), 1.90 – 1.94 (m, 1H, H-3a), 1.93 – 1.97 (m, 1H, C#CH), 2.02, 2.12, 2.21 
(3s, 9H, 3 OAc), 2.25 – 2.31 (m, 2H, CH2), 2.58 (dd, J = 4.6, 12.7 Hz, 1H, H-3b), 3.09 – 3.16 
(m, 1H, H-9a), 3.25 – 3.42 (m, 2H, OCH2), 3.76 (s, 3H, OMe), 3.90 – 3.99 (m, 1H, H-6), 4.09 
– 4.24 (m, 1H, H-5), 4.44 (d, J = 12.1 Hz, 1H, H-9b), 4.77 – 4.85 (m, 1H, H-4), 5.18 – 5.23 
(m, 1H, H-8), 5.24 – 5.29 (m, 1H, H-7), 5.38 – 5.46 (m, 1H, NHAc), 7.24 (dd, J = 4.3, 7.6 
Hz, 1H, NH), 7.37 (t, J = 7.3 Hz, 1H, CHar), 7.45 (t, J = 7.6 Hz, 2H, CHar), 7.59 (d, J = 7.7 
Hz, 2H, CHar), 7.64 (dd, J = 2.4, 8.3 Hz, 2H, CHar), 7.88 (dd, J = 3.4, 8.2 Hz, 2H, CHar). 
13
C 
NMR (CDCl3) " 15.0 (CH2), 20.8, 20.9, 21.1 (3 OAc), 23.1 (NHAc), 28.6 (CH2), 37.5 (C-3), 
38.4 (C-9), 49.4 (C-5), 52.8 (OMe), 62.1 (OCH2), 68.0 (C#CH), 68.5, 68.9, 69.4 (C-4, C-7, 
C-8), 70.9 (C-6), 83.8 (C#CH), 98.6 (C-2), 127.1, 127.2, 127.5, 127.6, 128.0, 128.9, 133.0, 
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140.0, 144.3 (12C, C-Ar), 167.2, 167.7, 168.3, 170.4, 171.1, 171.9 (6 CO). ESI-MS calcd. for 
C36H42N2O12 [M+Na]
+
: 717.26; found m/z 717.38. 
 
Sodium [2-propynyl 5-acetamido -3,5,9-trideoxy-9-(4-phenyl)benzamido-D-glycero-!-D 
-galacto-2-nonulopyranosid]onate (15a). Compound 15a was obtained from 14a (142 mg, 
0.21 mmol) according to procedure B as white solid after LC-MS purification (94 mg, 80%). 
[!]
20
D -6.3 (c 0.83, MeOH). 
1
H NMR (500 MHz, CD3OD) " 1.69 (dd, J = 11.3, 12.9 Hz, 1H, 
H-3a), 1.98 (s, 3H, NHAc), 2.39 (dd, J = 4.9, 13.0 Hz, 1H, H-3b), 2.79 (dd, J = 2.3, 3.7 Hz, 
1H, C#CH), 3.47 – 3.51 (m, 1H, H-7), 3.52 – 3.63 (m, 1H, H-9a), 3.77 – 3.86 (m, 1H, H-9b), 
3.88 – 3.94 (m, 2H, H-5, H-6), 3.96 (ddd, J = 4.1, 7.5, 14.5 Hz, 1H, H-8), 4.00 – 4.07 (m, 1H, 
H-4), 4.09, 4.41 (dd, J = 3.3, 15.7 Hz, 2H, OCH2), 7.38 (td, J = 1.2, 7.3 Hz, 1H, CHar), 7.46 
(t, J = 7.6 Hz, 2H, CHar), 7.66 (d, J = 7.8 Hz, 2H, CHar), 7.69 – 7.76 (m, 2H, CHar), 7.89 – 
7.96 (m, 2H, CHar). 
13
C NMR (CD3OD) " 22.7 (NHAc), 41.5 (C-3), 45.9 (C-9), 52.7 (OCH2), 
53.6 (C-5), 67.6 (C-4), 70.6 (C-8), 71.7 (C-7), 72.8 (C-6), 75.6 (C#CH), 80.2 (C#CH), 98.1 
(C-2), 128.0, 128.1, 128.9, 129.0, 129.1, 130.0, 134.3, 141.3, 145.8 (12C, C-Ar), 170.9, 174.9 
(2 CO). ESI-MS calcd. for C27H29N2NaO9 [M+H]
+
: 549.18; found m/z 549.19. 
 
Sodium [3-butynyl 5-acetamido -3,5,9-trideoxy-9-(4-phenyl)benzamido -D-glycero-!-D -
galacto-2-nonulopyranosid]onate (15b). Compound 15b was obtained from 14b (183 mg, 
0.27 mmol) according to procedure B as white solid after LC-MS purification (62 mg, 40%). 
[!]
20
D -8.1(c 0.9, MeOH). 
1
H NMR (500 MHz, CD3OD) " 1.68 (dd, J = 11.5, 12.6 Hz, 1H, H-
3a), 1.98 (s, 3H, NHAc), 2.24 (t, J = 2.6 Hz, 1H, C#CH), 2.38 (dd, J = 4.9, 12.9 Hz, 1H, H-
3b), 2.46 (t, J = 7.0 Hz, 2H, CH2), 3.41 – 3.51 (m, 2H, H-6, OCH2), 3.58 (dd, J = 6.8, 13.9 
Hz, 1H, H-9a), 3.79 – 3.86 (m, 2H, H-9b, OCH2), 3.90 (d, J = 9.9 Hz, 1H, H-5), 3.97 (m, 2H, 
H-7, H-8), 4.01 – 4.09 (m, 1H, H-4), 7.38 (t, J = 7.4 Hz, 1H, CHar), 7.46 (t, J = 7.6 Hz, 2H, 
CHar), 7.65 (d, J = 7.8 Hz, 2H, CHar), 7.72, 7.92 (d, J = 8.3 Hz, 4H, CHar). 
13
C NMR 
(CD3OD) " 20.3 (CH2), 22.7 (NHAc), 41.7 (C-3), 45.8 (C-9), 53.8 (C-5), 62.9 (OCH2), 67.6 
(C-4), 70.6, 70.7 (2C, C-7, C-8), 71.7 (C-6), 72.5 (C#CH), 81.7 (C#CH), 100.3 (C-2), 128.0, 
128.1, 129.0, 130.0, 134.2, 141.2, 145.7 (12C, C-Ar), 170.9, 174.8 (2 CO). HRMS-MS calcd. 
for C28H32N2O9 [M+Na]
+
: 563.2007; found 563.2001 m/z. 
 
Sodium [5-pentynyl 5-acetamido -3,5,9-trideoxy-9-(4-phenyl)benzamido -D-glycero-!-D 
-galacto-2-nonulopyranosid]onate (15c). Compound 15c was obtained from 14c (130 mg, 
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0.19 mmol) according to procedure B as white solid after LC-MS purification (34 mg, 28%). 
[!]
20
D -6.1 (c 0.85, MeOH). 
1
H NMR (500 MHz, CD3OD) " 1.64 – 1.79 (m, 3H, CH2, H-3a), 
1.99 (s, 3H, NHAc), 2.15 (t, J = 2.6 Hz, 1H, C#CH), 2.24 (tt, J = 2.4, 7.0 Hz, 2H, CH2), 2.74 
(dd, J = 4.5, 12.6 Hz, 1H, H-3b), 3.46 (dd, J = 1.3, 8.8 Hz, 1H, H-7), 3.50 – 3.61 (m, 2H, 
OCH2, H-9a), 3.63 – 3.80 (m, 3H, H-4, H-5, H-6), 3.83 (dd, J = 3.4, 13.7 Hz, 1H, H-9b), 3.88 
(dt, J = 6.1, 9.3 Hz, 1H, OCH2), 4.02 – 4.11 (m, 1H, H-8), 7.38 (t, J = 7.4 Hz, 1H, CHar), 7.46 
(t, J = 7.6 Hz, 2H, CHar), 7.63 – 7.69 (m, 2H, CHar), 7.72, 7.92 (d, J = 8.4 Hz, 4H, CHar). 
13
C 
NMR (CD3OD) " 15.8 (CH2), 22.6 (NHAc), 30.1 (CH2), 42.0 (C-3), 44.7 (C-9), 54.0 (C-5), 
63.8 (OCH2), 69.0 (C-4), 69.7 (C#CH), 71.2 (C-8), 72.3 (C-7), 74.6 (C-6), 84.6 (C#CH), 
100.9 (C-2), 128.0, 128.1, 128.9, 129.1, 130.0, 134.4, 141.3, 145.6 (12C, C-Ar), 170.2, 175.3 
(2 CO). HRMS calcd. for C29H33N2NaO9 [M+Na]
+
: 599.1982; found m/z 599.1984. 
 
Sodium [(1-(2-(3-benzoylphenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl) 5-acetamido -
3,5,9-trideoxy-9-(4-phenyl)benzamido-D-glycero-!-D-galacto-2-nonulopyranosid] onate 
(16a). Compound 15a (7 mg, 13 !mol, 1.0 eq) was reacted with 10 (5 mg, 20 !mol, 1.5 eq) 
according to procedure C to yield 16a (1.3 mg, 12%) after LC-MS purification. [!]
20
D 11.9 (c 
0.13, MeOH).
 1
H NMR (500 MHz, CD3OD) " 1.69 (t, J = 11.3 Hz, 1H, H-3a), 1.94 (s, 3H, 
NHAc), 2.39 – 2.41 (m, 1H, H-3b), 3.46 (d, J = 9.5 Hz, 1H, H-7), 3.50 – 3.62 (m, 1H, H-9a), 
3.82 – 3.91 (m, 1H, H-9b), 3.91 – 4.02 (m, 2H, H-4, H-5), 4.06 – 4.08 (m, 2H, H-6, H-8), 
4.47 (t, J = 4.8 Hz, 2H, H-2’’), 4.54, 4.75 (A, B of AB, J = 11.2 Hz, 2H, H-1’), 4.83 (t, J = 
4.8 Hz, 2H, H-1’’) 7.22 (dd, J = 2.2, 8.1 Hz, 1H, CHar), 7.26 – 7.34 (m, 2H, CHar), 7.34 – 
7.55 (m, 7H, CHar), 7.63 (dd, J = 7.5, 16.7 Hz, 3H, CHar), 7.69 (d, J = 8.3 Hz, 2H, CHar), 7.74 
(d, J = 7.4 Hz, 2H, CHar), 7.91 (d, J = 8.3 Hz, 2H, CHar), 7.97 (d, J = 7.9, 1H, 5-NH), 8.16 (s, 
1H, CHar), 8.40 (t, J = 5.3 Hz, 1H, 9-NH). 
13
C NMR (CD3OD) " 22.9 (NHAc), 43.5 (C-3), 
45.6 (C-9), 50.6 (C-1’’), 53.7 (C-5), 57.9 (C-1’), 67.8 (C-2’’), 68.3 (C-4), 70.6, 72.0, 72.3 (C-
6, C-7, C-8), 116.4, 120.4, 124.4, 128.0, 128.1, 129.0, 129.1, 129.5, 130.0, 130.7, 131.0, 
133.9 (26C, C-Ar). ESI-MS calcd. for C42H43N5O11 [M-H]
-
: 792.28; found m/z 792.39. 
 
Sodium [(1-(3-(3-benzoylphenoxy)propyl)-1H-1,2,3-triazol-4-yl)methyl) 5-acetamido -
3,5,9-trideoxy-9-(4-phenyl)benzamido-D-glycero-!-D-galacto-2-nonulopyranosid] onate 
(16b). Compound 15a (6 mg, 11 !mol, 1.0 eq) was reacted with 13a (10 mg, 36 !mol, 3.2 
eq) according to procedure C to yield 16b (4.9 mg, 54%) after LC-MS purification. [!]
20
D 9.4 
(c 0.2, MeOH).
 1
H NMR (500 MHz, CD3OD) " 1.70 (t, J = 11.3 Hz, 1H, H-3a), 1.96 (s, 3H, 
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NHAc), 2.34 – 2.46 (m, 3H, H-3b, H-2’’), 3.47 (d, J = 9.3 Hz, 1H, H-7), 3.56 (dd, J = 6.9, 
13.6 Hz, 1H, H-9a), 3.87 (dd, J = 2.8, 13.8 Hz, 1H, H-9b), 3.92 – 4.02 (m, 2H, H-4, H-5), 
4.04 – 4.13 (m, 4H, H-3’’, H-6, H-8), 4.52 (A of AB, J = 11.0 Hz, 1H, H-1’a), 4.63 (t, J = 6.8 
Hz, 2H, H-1’’), 4.78 (B, of AB, J = 11.0 Hz, 1H, H-1’b), 7.19 (d, J = 8.4 Hz, 1H, CHar), 7.28 
(m, 2H, CHar), 7.39 (m, 2H, CHar), 7.45 (t, J = 7.6 Hz, 2H, CHar), 7.51 (t, J = 7.7 Hz, 2H, 
CHar), 7.63 (m, 3H, CHar), 7.70 (d, J = 8.3 Hz, 2H, CHar), 7.75 (d, J = 7.3 Hz, 2H, CHar), 7.92 
(d, J = 8.3 Hz, 2H, CHar), 8.05 (s, 2H, 5-NH, CHar), 8.44 (t, J = 5.6 Hz, 1H, 9-NH). 
13
C NMR 
(CD3OD) ! 22.8 (NHAc), 31.0 (C-2’’), 41.7 (C-3), 45.6 (C-9), 48.4 (C-1’’), 53.8 (C-5), 57.5 
(C-1’), 65.9 (C-3’’), 68.0 (C-4), 70.5 (C-8), 72.1 (C-7), 72.3 (C-6), 98.0 (C-2), 116.2, 120.4, 
124.0, 128.0, 128.1, 129.0, 129.1, 129.5, 130.0, 130.6, 131.0, 133.9, 134.3, 138.8, 140.1, 
141.3, 145.7, 160.1 (19C, C-Ar), 170.3, 170.7, 174.4, 198.3 (4 CO). ESI-MS calcd. for 
C43H45N5O11 [M-H]
-
: 806.30; found m/z 806.27. 
 
Sodium [(1-(4-(3-benzoylphenoxy)butyl)-1H-1,2,3-triazol-4-yl)methyl) 5-acetamido -9-
(4-phenyl)-3,5,9-trideoxy-D-glycero-"-D -galacto-2-nonulopyranosid] onate (16c). 
Compound 15a (7 mg, 13 !mol, 1.0 eq) was reacted with 13b (10 mg, 34 !mol, 2.6 eq) 
according to procedure C to yield 16c (2.7 mg, 25%) after LC-MS purification. ["]
20
D 11.8 (c 
0.3,MeOH).
 1
H NMR (500 MHz, CD3OD) ! 1.70 (t, J = 11.0 Hz, 1H, H-3a), 1.81 (dt, J = 6.2, 
12.9 Hz, 2H, H-3’’), 1.96 (s, 3H, NHAc), 2.06 – 2.15 (m, 2H, H-2’’), 2.39 (d, J = 11.2 Hz, 
1H, H-3b), 3.48 (d, J = 9.3 Hz, 1H, H-7), 3.52 – 3.60 (m, 1H, H-9a), 3.81 – 3.91 (m, 1H, H-
9b), 3.96 (m, 2H, H-4, H-5), 4.05 (m, 4H, H-4’’, H-6, H-8), 4.45 – 4.58 (m, 3H, H-1’a, H-
1’’), 4.78 (B of AB, J = 11.0 Hz, 1H, H-1’b), 7.16 – 7.22 (m, 1H, CHar), 7.27 (d, J = 7.8 Hz, 
2H, CHar), 7.32 – 7.42 (m, 2H, CHar), 7.45 (t, J = 7.5 Hz, 2H, CHar), 7.51 (t, J = 7.6 Hz, 2H, 
CHar), 7.59 – 7.67 (m, 3H, CHar), 7.70 (d, J = 8.2 Hz, 2H, CHar), 7.75 (d, J = 7.6 Hz, 2H, 
CHar), 7.92 (d, J = 8.2 Hz, 2H, CHar), 8.04 (s, 2H, 5-NH, CHar), 8.45 (t, J = 5.5 Hz, 1H, 9-
NH). 
13
C NMR (CD3OD) ! 22.8 (NHAc), 27.3 (C-3’’), 28.1 (C-2’’), 41.6 (C-3), 45.6 (C-9), 
51.0 (C-1’’), 53.8 (C-5), 57.6 (C-1’), 67.9 (C-4), 68.4 (C-4’’), 70.6 (C-8), 72.1 (C-7), 72.3 
(C-6), 116.1, 120.3, 123.7, 128.0, 128.1, 129.0, 129.1, 129.5, 130.0, 130.6, 131.0, 133.9, 
140.1, 141.3, 145.7, 160.4 (19C, C-Ar), 174.4, 176.1, 198.4 (4C, CO). ESI-MS calcd. for 
C44H47N5O11 [M-H]
-
: 820.32; found m/z 820.42. 
 
Sodium [(2-(1-(2-(3-benzoylphenoxy)ethyl)-1H-1,2,3-triazol-4-yl)ethyl) 5-acetamido -9-
(4- phenyl)benzamido-3,5,9-trideoxy-D-glycero-"-D -galacto-2-nonulopyranosid] onate 
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(16d). Compound 15b (5 mg, 9 !mol, 1.0 eq) was reacted with 10 (3.5 mg, 13 !mol, 1.5 eq) 
according to procedure C to yield 16d (3.2 mg, 43%) after LC-MS purification. [!]
20
D – 6.4 
(c 0.12, MeOH). 
1
H NMR (500 MHz, CD3OD) " 1.65 (t, J = 12.1 Hz, 1H, H-3a), 1.99 (s, 3H, 
NHAc), 2.77 (dd, J = 2.2, 12.8 Hz, 1H, H-3b), 2.94 (s, 2H, H-2’), 3.45 (d, J = 7.9 Hz, 1H, H-
7), 3.50 (dd, J = 7.6, 13.5 Hz, 1H, H-9a), 3.62 – 3.90 (m, 5H, H-4, H-5, H-6, H-9b, H-1’a), 
3.96 – 4.18 (m, 2H, H-8, H-1’b), 4.44, 4.76 (2t, J = 4.3 Hz, 4H, H-1’’, H-2’’), 7.18 (d, J = 8.3 
Hz, 1H, CHar), 7.27 (d, J = 7.3 Hz, 2H, CHar), 7.33 – 7.41 (m, 2H, CHar), 7.45 (t, J = 7.6 Hz, 
2H, CHar), 7.50 (t, J = 7.6 Hz, 2H, CHar), 7.63 (d, J = 7.6 Hz, 3H, CHar), 7.67 (d, J = 8.1 Hz, 
2H, CHar), 7.73 (d, J = 7.8 Hz, 2H, CHar), 7.88 (d, J = 8.1 Hz, 2H, CHar), 8.06 (s, 1H, CHar). 
13
C NMR (CD3OD) " 22.3 (NHAc), 28.0 (C-2’), 42.0 (C-3), 44.6 (C-9), 50.6 (C-1’’), 53.7 
(C-5), 63.6 (C-1’), 67.5 (C-2’’), 68.9 (C-4), 70.9 (C-8), 72.2 (C-7), 74.3 (C-6), 102.7, 109.9, 
116.0, 120.3, 124.0, 127.7, 127.8, 128.7, 128.8, 129.2, 129.7, 130.5, 130.8, 133.6 (26C, C-
Ar), 173.7, 198.0 (3C, CO). ESI-MS calcd. for C43H45N5O11 [M-H]
-
: 806.30; found m/z 
806.34. 
 
Sodium [(2-(1-(3-(3-benzoylphenoxy)propyl])-1H-1,2,3-triazol-4-yl)ethyl) 5-acetamido -
9-(4-phenyl)benzamido-3,5,9-trideoxy-D-glycero-!-D-galacto-2-nonulopyranosid] onate 
(16e). Compound 15b (5 mg, 9 !mol, 1.0 eq) was reacted with 13a (3.6 mg, 13 !mol, 1.5 eq) 
according to procedure C to yield 16e (3.4 mg, 47%) after LC-MS purification. [!]
20
D – 8.3 (c 
0.3, MeOH).
 1
H NMR (500 MHz, CD3OD) " 1.59 (t, J = 11.4 Hz, 1H, H-3a), 2.01 (s, 3H, 
NHAc), 2.26 – 2.43 (m, 2H, H-2’’), 2.76 – 2.87 (m, 1H, H-3b), 2.92 (d, J = 2.5 Hz, 2H, H-
2’), 3.41 – 3.53 (m, 2H, H-7, H-9a), 3.61 – 3.79 (m, 4H, H-4, H-5, H-6, H-1’a), 3.84 (dd, J = 
2.6, 13.4 Hz, 1H, H-9b), 3.97 – 4.11 (m, 4H, H-8, H-1’b, H-3’’), 4.55 (t, J = 6.8 Hz, 2H, H-
1’’), 7.15 (dd, J = 2.0, 8.1 Hz, 1H, CHar), 7.23 (s, 1H, CHar), 7.27 (d, J = 7.6 Hz, 1H, CHar), 
7.32 – 7.41 (m, 2H, CHar), 7.43 (t, J = 7.6 Hz, 2H, CHar), 7.51 (t, J = 7.7 Hz, 2H, CHar), 7.63 
(t, J = 6.9 Hz, 3H, CHar), 7.67 (d, J = 8.2 Hz, 2H, CHar), 7.74 (d, J = 7.6 Hz, 2H, CHar), 7.88 
(d, J = 8.2 Hz, 2H, CHar), 8.04 (s, 1H, CHar), 8.21 (s, 1H, 5-NH), 8.27 (t, J = 4.9 Hz, 1H, 9-
NH). 
13
C NMR (CD3OD) " 22.6 (NHAc), 27.4 (C-2’), 31.0 (C-2’’), 42.7 (C-3), 44.7 (C-9), 
48.4 (C-1’’), 54.1 (C-5), 63.8 (C-1’), 66.1 (C-3’’), 69.5 (C-4), 71.3 (C-8), 72.7 (C-7), 74.4 
(C-6), 116.5, 120.2, 123.8, 124.6, 128.0, 128.1, 129.0, 129.1, 129.5, 130.0, 130.7, 131.0, 
133.8, 140.1, 141.3, 145.5 (26C, C-Ar), 160.1, 169.9, 175.5, 198.3 (4 CO). ESI-MS calcd. for 
C44H47N5O11 [M-H]
-
: 820.32; found m/z 820.41. 
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Sodium [(2-(1-(4-(3-benzoylphenoxy)butyl)-1H-1,2,3-triazol-4-yl)ethyl) 5-acetamido -9-
(4-phenyl)benzamido-3,5,9-trideoxy-D-glycero-!-D -galacto-2-nonulopyranosid] onate 
(16f). Compound 15b (5 mg, 9 !mol, 1.0 eq) was reacted with 13b (3.8 mg, 13 !mol, 1.5 eq) 
according to procedure C to yield 16f (3.1 mg, 42%) after LC-MS purification. [!]
20
D – 8.9 (c 
0.25, MeOH). 
1
H NMR (500 MHz, CD3CN) " 1.58 (t, J = 11.9 Hz, 1H, H-3a), 1.65 – 1.77 
(m, 2H, H-3’’), 1.88 – 2.02 (m, 5H, H-2’’, NHAc), 2.45 – 2.79 (m, 1H, H-3b), 2.81 – 2.91 
(m, 2H, H-2’), 3.39 – 3.54 (m, 3H, H-6, H-7, H-9a), 3.59 (t, J = 8.8 Hz, 1H, H-5), 3.62 – 3.82 
(m, 3H,H-4, H-9a, H-1’a), 3.84 – 3.91 (m, 1H, H-8), 3.97 (t, J = 5.9 Hz, 3H, H-1’b, H-4’’), 
4.33 (t, J = 6.7 Hz, 2H, H-1’’), 7.13 (d, J = 8.2 Hz, 1H, CHar), 7.23 (s, 1H, CHar), 7.26 (d, J = 
7.5 Hz, 1H, CHar), 7.35 – 7.41 (m, 2H, CHar), 7.45 (t, J = 7.5 Hz, 2H, CHar), 7.50 (t, J = 7.6 
Hz, 2H, CHar), 7.60 – 7.66 (m, 3H, CHar), 7.68 (d, J = 7.9 Hz, 2H, CHar), 7.74 (d, J = 7.5 Hz, 
3H, CHar), 7.85 (d, J = 7.8 Hz, 2H, CHar). 
13
C NMR (CD3CN) " 22.9 (NHAc), 26.0 (C-3’’), 
26.9 (2C, C-2’, C-2’’), 41.4 (C-3), 44.5 (C-9), 50.5 (C-1’’), 53.5 (C-5), 63.3 (C-1’), 67.8 (C-
4’’), 68.3 (C-4), 71.7 (2C, C-7, C-8), 74.1 (C-6), 116.0, 120.0, 123.3, 127.9, 128.0, 128.7, 
129.0, 129.4, 130.0, 130.5, 130.8, 133.6 (26C, CO), 173 (4C, CO). ESI-MS calcd. for 
C45H49N5O11 [M-H]
-
: 835.34; found m/z 834.49. 
 
Sodium [(2-(1-(2-(3-benzoylphenoxy)ethyl)-1H-1,2,3-triazol-4-yl)ethoxy) 5-acetamido -9-
(4-phenyl)benzamido-3,5,9-trideoxy-D-glycero-!-D -galacto-2-nonulopyranosid] onate 
(16g). Compound 15c (xx mg, xx !mol, 1.0 eq) was reacted with 10 (xx mg, xx !mol, 1.5 eq) 
according to procedure C to yield 16g (1.4 mg, --%) after LC-MS purification. [!]
20
D – 5.9 (c 
0.13, MeOH).
 1
H NMR (500 MHz, CD3OD) " 1.64 (t, J = 11.6 Hz, 1H, H-3a), 1.76 – 1.91 
(m, 2H, H-2’), 2.01 (s, 3H, NHAc), 2.71 – 2.87 (m, 3H, H-3b, H-3’), 3.46 (dd, J = 6.2, 15.8 
Hz, 3H, H-7, H-9a, H-1’a), 3.64 (d, J = 9.1 Hz, 1H, H-6), 3.68 – 3.75 (m, 2H, H-4, H-5), 3.80 
(dt, J = 6.7, 8.9 Hz, 1H, H-1’b), 3.87 (dt, J = 3.9, 13.6 Hz, 1H, H-9b), 4.01 (td, J = 3.2, 8.4 
Hz, 1H, H-8), 4.42 (t, J = 5.1 Hz, 2H, H-2’’), 4.77 (dd, J = 4.6, 7.9 Hz, 2H, H-1’’), 7.17 (dd, 
J = 2.2, 8.2 Hz, 1H, CHar), 7.24 (s, 1H), 7.27 (d, J = 7.6 Hz, 1H, CHar), 7.37 (q, J = 8.0 Hz, 
2H, CHar), 7.44 (t, J = 7.6 Hz, 2H, CHar), 7.50 (t, J = 7.7 Hz, 2H, CHar), 7.62 (t, J = 7.3 Hz, 
3H, CHar), 7.68 (d, J = 8.3 Hz, 2H, CHar), 7.72 (d, J = 7.5 Hz, 2H, CHar), 7.88 (d, J = 8.3 Hz, 
2H, CHar), 7.97 (s, 1H, CHar), 8.19 (d, J = 7.6 Hz, 1H, 5-NH), 8.25 (t, J = 5.2 Hz, 1H, 9-NH). 
13
C NMR (CD3OD) " 22.3 (C-3’), 22.6 (NHAc), 30.4 (C-2’), 42.7 (C-3), 44.8 (C-9), 50.8 (C-
1’’), 54.2 (C-5), 63.3 (C-1’), 67.9 (C-2’’), 69.5 (C-4), 71.2 (C-8), 72.7 (C-7), 74.4 (C-6), 
103.0 (C-2), 116.4, 120.5, 124.2, 128.0, 128.1, 129.0, 129.1, 129.5, 130.0, 130.7, 131.0, 
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133.9, 134.4, 138.7, 140.1, 141.3, 145.5 (26C, C-Ar), 175.5 (4C, CO). ESI-MS calcd. for 
C44H47N5O11 [M-H]
-
: 820.32; found m/z 820.57 
 
Sodium [(2-(1-(4-(3-benzoylphenoxy)butyl)-1H-1,2,3-triazol-4-yl)ethyl) 5-acetamido -9-
(4-phenyl)benzamido-3,5,9-trideoxy-D-glycero-!-D -galacto-2-nonulopyranosid] onate 
(16h). Compound 15c (xx mg, xx !mol, 1.0 eq) was reacted with 13b (xx mg, xx !mol, 1.5 
eq) according to procedure C to yield 16h (3.4 mg, --%) after LC-MS purification. [!]
20
D – 
7.2 (c 0.23, MeOH). 
1
H NMR (500 MHz, CD3OD) " 1.69 (t, J = 11.7 Hz, 1H, H-3a), 1.75 – 
1.82 (m, 2H, H-3’’), 1.83 – 1.97 (m, 2H, H-2’), 1.96 (s, 3H, NHAc), 2.04 – 2.14 (m, 2H, H-
2’’), 2.71 – 2.88 (m, 3H, H-3b, H-3’), 3.43 – 3.56 (m, 3H, H-7, H-9a, H-1’a), 3.66 (d, J = 9.9 
Hz, 1H, H-6), 3.69 – 3.92 (m, 4H, H-4, H-5, H-9b, H-1’b), 4.01 (t, J = 6.1 Hz, 3H, H-8, H-
4’’), 4.38 – 4.51 (m, 2H, H-1’’), 7.18 (dd, J = 1.9, 8.1 Hz, 1H, CHar), 7.25 – 7.32 (m, 2H, 
CHar), 7.35 – 7.43 (m, 2H, CHar), 7.46 (t, J = 7.6 Hz, 2H, CHar), 7.53 (t, J = 7.7 Hz, 2H, 
CHar), 7.66 (d, J = 7.4 Hz, 3H, CHar), 7.70 (d, J = 8.3 Hz, 2H, CHar), 7.77 (d, J = 7.4 Hz, 2H, 
CHar), 7.92 (d, J = 8.2 Hz, 3H, CHar), 8.20 (d, J = 7.9 Hz, 1H, CHar), 8.31 (t, J = 4.9 Hz, 1H, 
CHar). 
13
C NMR (CD3OD) " 22.6 (C-3’), 22.7 (NHAc), 27.3 (C-3’’), 28.1 (C-2’’), 30.3 (C-
2’), 42.1 (C-3), 44.8 (C-9), 51.0 (C-1’’), 54.1 (C-5), 63.4 (C-1’), 68.4 (C-4’’), 69.3 (C-4), 
71.2 (C-8), 72.5 (C-7), 74.5 (C-6), 100.3 (C-2), 116.2, 120.4, 123.6, 128.0, 128.1, 129.0, 
129.1, 129.5, 130.0, 130.6, 131.0, 133.8, 134.4, 138.8, 140.1, 141.3, 145.6 (26C, C-Ar), 
160.4, 175.4, 198.4 (4C, CO). ESI-MS calcd. for C46H54N5O11 [M-H]
-
: 848.35; found m/z 
848.46. 
 
NMR. Shigemi NMR tubes were used to reduce the sample volume needed for measurement 
to 250 !l. CD22d1-3-Fc protein was diluted from a stock solution of 0.5 mg/ml by a factor of 2 
using 99.8% D2O (Armar Chemicals). Following dilution, the 0.25 mg/ml CD22d1-3-Fc was 
in a solvent of 50% D2O and 50% H2O, with 0.01% NaN3 with a buffer of 5 mM PBS. For all 
experiments, CD22 was further diluted with PBS to a protein concentration of 5 !mol. For 
the T1rho experiemts, stock solutions of all mixes were prepared in DMSO at 25 mM and 
added to the NMR samples containing CD22d1-3-Fc, yielding a 300 !M concentration. For the 
T1rho experiments the pulse sequence was adapted from Hajduk et al.
13
 
All NMR experiments were carried out at 300 K on a Bruker DRX500 spectrometer, 
equipped with Z-gradient SEI probe. The pulse sequence used for the selective inversion 
recovery experiments began with a selective 25 ms I-Burp-1
14
 180-degree pulse applied to 
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NHAc of compound 6. The resonance frequency was sufficiently different from the water 
resonance, thus avoiding complications due to radiation damping.
15
 Following the selective 
inversion pulse, a 1 ms gradient pulse was applied to dephase any residual transverse 
magnetization. The gradient pulse was followed by a variable delay to allow for the recovery 
of longitudinal magnetization. The delay was followed by a DPFGSE water suppression 
sequence to suppress the magnetization from the 50% H2O.
15
 
For each selective inversion recovery time measurement (sT1), 10 experiments were 
performed. These experiments consisted of increasing delays following the selective 
inversion pulse and gradient of 0.1 s, 0.25 s, 0.5 s, 0.75 s, 1 s, 1.25 s, 1.5 s, 2.0 s, 2.5 s and 3 
s. 64 scans, preceded by 8 dummy scans, were measured for compound 6 (500 !M, reduced 
by ascorbic acid 5 mM). The NMR data were analyzed using XWINNMR version 3.5 
operating on a PC running under Linux OS. The spectra were apodized with an exponential 
decay function with 2 Hz line broadening. The inversion recovery data, as well as the one-site 
binding model, were fit using Prism 4 (GraphPad Software Inc., San Diego, USA). 
 
Surface plasmon resonance (SPR) analysis. 
The SPR measurements were performed on a Biacore 3000 surface plasmon resonance based 
optical biosensor (Biacore AB, Sweden). Sensor chips (CM5), immobilization kits, 
maintenance supply and HBS-EP (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 
0.005% v/v surfactant P20) were purchased from Biacore AB (HBS-EP ready-to-use; 
degassed and filtered). CM5 chips were preconditioned prior to usage by injecting a series of 
conditioning solutions. A flow rate of 50 !L/min was used and 2 " 20 !L of 50 mM NaOH, 
10 mM HCl, 0.1% SDS and 100 mM H3PO4 were injected. The carboxy groups on the CM5 
chip were activated for 10 min with a 1:1 mixture of 0.1 M N-hydroxysuccinimide (NHS) 
and 0.1 M 3-(N,N-dimethylamino)propyl-N-ethylcarbodiimide (EDC) at a flow rate of 10 
!L/min. Protein A (P6031) was purchased from Sigma. A sample and a reference surface 
were prepared sequentially or in parallel. For immobilizing protein A, a stock solution (1 
mg/mL in 50 mM phosphate buffer, pH 7.0) was diluted in 10 mM sodium acetate, pH 5.0 to 
obtain a concentration of 30 !g/mL. This solution was then injected over the activated 
surface for 10 min at a flow rate of 10 !L/min. Protein A densities around 4’000 RU were 
achieved. Flow cells were blocked with a 10 min injection of 1 M ethanolamine, pH 8.0. For 
capturing, Fc-CD22d1-3 solution (expressed and purified as described
16
) was diluted to a 30-
40 !g/mL concentration in NaOAc (pH 5.0). Afterwards, Fc-CD22d1-3 was injected at a flow 
rate of 5 !L/min for 3 min. Using HBS-EP, the surface was equilibrated over night at a flow 
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rate of 5 !L/min, achieving densities around 3000 to 4000 RU. Tenfold dilution series were 
freshly prepared in eluent buffer immediately before use (! 6, 15a-c). All binding 
experiments were conducted at 25 °C at a flow rate of 20 !L/min. The samples were injected 
over 1 min followed by 1 min dissociation. Each sample was measured with a duplicate of 
one concentration, using a randomized concentration order. Several buffer samples were 
injected before the first concentration, and one blank between each concentration, which was 
used for the double blank referencing during data processing. Double referencing was applied 
to correct for bulk effects and other systematic artifacts. Data processing and equilibrium 
binding constant determinations were accomplished with Scrubber (BioLogic Software, 
Version 1.1g or 2.0c). Kinetic data were simultaneously fit using Scrubber 2.0c.  
For the DMSO assay, DMSO (for molecular biology, >99.9%) was purchased from Fluka. 
The stock solution of the test compounds (!16a-h) was prepared in DMSO and was kept in 
glass vials to eliminate contaminations by e.g. softeners. The running buffer was 5% DMSO 
in HBS-EP. The surface was equilibrated at a flow of 5 !L/min until the baseline was stable. 
In order to eliminate the influence of DMSO on the signals, a calibration curve was done. 
Therefore, two solutions were prepared (A = 1 mL running buffer + 50 µL HBS-EP; B = 1 
mL running buffer + 1 µL DMSO). Solutions A and B were mixed as indicated in Table 2 
and used for calibration. DMSO calibration solutions were injected after 5 blank injections 
and before the sample solutions. The test compounds were diluted before measuring with 
HBS-EP to achieve a content of 5% DMSO. The DMSO calibration was accomplished 
directly in Scrubber"
 
(version 2.0c).  
 
Table 2. Calibration solutions 
 
Calibration 1 2 3 4 5 
A (µL) 400 300 200 100 0 
B (µL) 0 100 200 300 400 
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3. Summary and Outlook. 
Siglecs play an important role in carbohydrate-mediated signaling processes and cell-cell 
interactions. With the exception of MAG, which is expressed on oligodentrocytes in the 
CNS, they are expressed and involved in the innate immune system. In the recent years, sialic 
acid mimetics, displaying up to nM affinities, have been intensively investigated by our 
group and others. 
 
The ganglioside GQ1b! served as starting point for the development of synthetic sialosides 
for MAG. Intensive SAR studies led to the identification of antagonists with reduced 
structural complexity and improved binding affinity. 
Here, further improvement was achieved by elucidation of iteratively introduced 
modifications and finally combination in one molecule. The influence of the electron density 
of the aglycon on the affinity as well as the contribution of modifications in 5-position were 
determined. Finally, the thermodynamic properties as well as pharmacokinetics were 
measured in order to gain additional information about the different contributions to binding. 
Additionally, a homology model of MAG was used to perform molecular modeling studies 
for a more profound understanding of the binding at the molecular level. 
As carbohydrates suffer in general from short half-life times of the protein-ligand complex, 
we turned our focus on the amelioration of the kinetic profile of our antagonists. On the basis 
of a small library of 4-modified antagonists, we investigated the influence of various 
substituents on the half-life times. 
Finally, the most promising antagonist was synthesized in larger amounts compounds as it 
fulfills all pre-requirements for investigation in nerve-outgrowth assays. 
 
Recently, second-site compounds for MAG were reported to bind with enhanced affinity. 
Hence, the lead was further optimized by incorporation of substituents based on the 
knowledge gained about the contributions to binding of the sialic acid moiety in precedent 
studies. As only little is known about the 5’-nitro indole moiety, additionally, antagonists 
with modifications at the 5’-nitro indole were synthesized and investigated. Thermodynamic 
measurements revealed further insights beside the binding affinity, and with the help of 
modeling we could illustrate the specific role of the 5’-nitro substituent. 
Furthermore, a combination of the findings obtained during the optimization of the second-
site ligands might be of interest to further improve the binding affinity. 
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CD22 is currently the most important Siglec with respect to therapeutic applications and 
many efforts have been undertaken to develop high affinity ligands. Combination of findings 
reported in literature with in-house screening results yielded nM-binding antagonists. The 
kinetic properties were found to be improved, what could be due to the increased 
lipophilicity. Furthermore, pharmacokinetic parameters as pKa, log D and logPe values were 
measured. Additionally the plasma protein binding was determined, rising potential risks of 
the antagonists.  
With respect to the metabolic stability, nitro-groups are in general not desired. Consequently 
it remains to elucidate the impact on the binding affinity and replacement by more stable 
substituents is desirable.  
 
Sialoadhesin and CD22 are expressed in the same physiological compartment and therefore 
selective targeting might be of interest. As the binding site is conserved in all Siglecs, we 
discussed different approaches for the achievement of selectivity. 
For Sialoadhesin, it might be interesting to apply the second site screening approach, as the 
modifications in the sialic acid in general did not lead to drastic differences in the binding 
affinity.  
 
Finally, the library of synthetic sialosides might serve as a starting point for the development 
of antagonists for other therapeutic important Siglecs such as CD33.  
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4. Formula index. 
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f:  R1 = H, R2 = Cl, R3 = H
g: R1 = isopropyl, R2, R3 = H
h: R1, R2 = -(CH2)3-, R
3 = H
i:  R1, R2 = H, R3 = Cl
j: R1 = CN, R2, R3 = H
k: R1 = SO2Me, R
2, R3 = H
N
H
R1
R2
R3
N3
25a - k
 
N
H
N3
R
O
25l: R = cyclopropyl
25m: R = 4-chlorobenzyl  
 
O
COOMe
O
AcO
RHN
OAc
OAc
N3
34: R = Boc
35: R = H
36: R = FAc  
 
 
38a: R1 = Ac, R2 = Me, R3 = H
38b: R1 = Ac, R2 = Me, R3 = Cl
39a: R1 = H,  R2 = Li, R3 =H
39b: R1 = H, R2 = Li, R3 = Cl
O
COOR2
O
R1O
FAcHN
OR1
OR1
H
N
R3
O
 
 
 
 
 
O
COONa
O
HO
R5HN
OH
OHH
N
O
N
N
N
N
R1
R4
R3
R
2
R6
 
Compound R
1 
R
2
 R
3 
R
4 
R
5
 R
6
 
1 H H H NO2 Ac H 
2 Me H H NO2 Ac H 
3 Et H H NO2 Ac H 
4 H H H H Ac H 
5 H H H OMe Ac H 
9 H H H CF3 Ac H 
7 H 
H 
 
H Ac 
H 
8 H H 
 
H Ac H 
O
O
Cl
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9 H H H NO2 FAc H 
10 H H H NO2 FAc Cl 
11 H H H Cl FAc Cl 
12 H H Cl H FAc Cl 
13 H Cl H H FAc Cl 
14 H CH3 H H FAc Cl 
15 H H H F FAc Cl 
16 H H H OCH3 FAc Cl 
17 H H H CH(CH3)2 FAc Cl 
18 H H H CN FAc Cl 
19 H H H SO2Me FAc Cl 
20 H H cyclopentane FAc Cl 
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O O
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O O
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OH
O
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5  
O O
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N
OH
OH
O
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O
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O
O N3
n
a10: n = 2
13a: n = 3
13b: n = 4  
O O
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HO
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H
N
OH
OH
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15a: n = 1
15b: n = 2
15c: n = 3
n
 
O O
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N
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O
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N
N O O
16a, n = 1
16b, n = 2
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n
 
O O
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H
N
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16d, n = 1
16e, n = 2
16f,  n = 3  
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